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ABSTRACT 
ln Canada, prostate cancer is the most frequently diagnosed cancer in 
man and the third leading cause of cancer related death. In order to identify 
genes implicated in prostate cancer progression, we used microcell-mediated 
chromosome transfer to introduce chromosomes 10, 12, 17 and 18 into human 
PC-3-derived cells lines called PC-3M-Pro4GP1 and PC-3M-LN4GP2. The 
properties of the hybrids were determined by invasion assay, growth in soft agar 
and injection into nude mice (either subcutaneously or orthotopically). After the 
transfer of chromosome 18 in our cell lines, we have identified two sets of 
hybrids that show opposite phenotypes. Genotyping studies indicated that one 
locus on chromosome 18 (018851) contains an additional allele in the less 
tumorigenic hybrids. This allele is absent in the highly tumorigenic hybrids as 
weil as in tumors derived from the injection of less tumorigenic cells into nude 
mice. Preliminary microarray data analysis showed that two genes located in 
the 018851 region (ERK4 and BCL2) were differentially expressed in the less 
tumorigenic hybrids compared to the tumorigenic hybrids. We examined publicly 
available microarray data sets and found that ERK4 was down regulated in 
prostate, adrenal and lung cancers. We have also examined the possibility that 
the metastasis suppressor gene MA8PIN (also located in the 018851 region) 
could be responsible for the less tumorigenic phenotype seen in our hybrids. 
Real-time PCR studies showed that ERK4 and MA8PIN were up regulated in 
the less tumorigenic hybrids and that BCL2 was down regulated in these sa me 
cells. However, Western immunoblot experiments did not show any difference in 
the MASPIN or the BCL2 protein levels. Thus, MA8PIN or a BCL2 repressor are 
most likely not responsible for the less tumorigenic phenotype of our hybrids. 
Interestingly, re-introduction of ERK4 in our tumorigenic hybrids completely 
abolished their ability to form colonies in soft agar and to invade through 
Matrigel. However, there is no difference in tumor growth rate upon injection of 
ERK4-over-expressing cells compared to mock-transfected controls. We also 
found a non-synonymous polymorphism in the coding sequence of the ERK4 
gene. This polymorphism is present at the same frequency in Asian, European 
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and Ashkenazi Jewish populations but less frequently in the Africal"l (Yoruba) 
population. This is the tirst report of a non-synonymous polymorphism in the 
coding sequence of the ERK4 gene. However, based on a limited number of 
prostate cancer cases, the presence of this poylmorphism is not associated with 
the disease. Taken together, these results demonstrate that ERK4 is a good 
candidate for a tumor suppressor gene implicated in prostate cancer 
progression. 
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RÉSUMÉ 
Au Canada, le cancer de la prostate est le cancer le plus diagnostiqué chez 
l'homme et est la troisième cause de mortalité tumorale. Afin d'identifier les 
gènes impliqués dans la progression du cancer de la prostate, nous avons 
utilisé la technique de transfert de chromosome par microcellules pour introduire 
les chromosomes 10, 12 17 et 18 dans deux lignées cellulaires humaines 
dérivées de PC-3 (PC-3M-Pro4GP1 et PC-3M-LN4GP2). Les propriétés des 
différents hybrides ont été déterminées par invasion, croissance en agar mou et 
par injection dans des souris nues (sous-cutanée ou orthotopique). Suite au 
transfert du chromosome 18 dans nos lignées cellulaires, nous avons identifié 
deux groupes d'hybrides qui démontraient des phénotypes opposés. Des 
études de génotypage ont montré qu'un locus sur le chromosome 18 (018S51) 
contient un allèle supplémentaire dans les hybrides moins tu morigènes. Cet 
allèle est absent dans les hybrides très tumorigènes ainsi que dans les tumeurs 
dérivées de l'injection des hybrides moins tu morigènes dans des souris nues. 
Des données préliminaires de micropuces ont démontré que deux gènes situés 
dans la région 018S51 (ERK4 et BCL2) étaient différentiellement exprimés 
dans les hybrides moins tumorigènes comparativement aux hybrides très 
tu morigènes. Nous avons examiné les bases de données publiques de 
résultats de micropuces et avons observé que l'expression de ERK4 est 
diminuée dans le cancer de la prostate, des glandes surrénales ainsi que dans 
le cancer du poumon. Nous avons également examiné la possibilité que le 
gène de suppression métastatique MASPIN (également situé dans la région 
018S51) soit responsable du phénotype moins tumorigène de nos hybrides. 
Nos expériences de PCR en temps réel ont démontré que l'expression de ERK4 
et de MASPIN est augmentée dans les hybrides moins tumorigènes et que celle 
de BCL2 est diminuée. Par contre, des expériences d'immunobuvardage ont 
révélé qu'il n'y pas de différence dans l'expression de la protéine MASPIN ou 
BCL2 dans nos hybrides tumorigènes et moins tumorigènes. Donc, le gène 
MASPIN ou un répresseur de BCL2 ne sont probablement pas responsable du 
phénotype moins tumorigène de nos hybrides. De façon intéressante, la ré-
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introduction du gène ERK4 dans les hybrides tu morigènes a -complètement 
aboli leur capacité à former des colonies en agar mou et à digérer le Matrigel. 
Par contre, il n'y a pas de difference dans la croissance tumorale lorsque les 
cellules surexperimant ERK4 et les cellules contrôles sont injectées dans des 
souris nues. Cependant, nous avons identifié un polymorphisme dans la 
séquence codante du gène ERK4. La fréquence de ce polymorphisme est la 
même chez les populations asiatique et européenne mais beaucoup moins 
fréquente chez les populations africaines. Nous sommes les premiers à 
rapporter la présence d'un polymorphisme dans la séquence codante du gène 
ERK4. Toutefois, des résultats préliminaires obtenus à partir d'un nombre 
restreint de patients atteints du cancer de la prostate semblent indiquer que ce 
polymorphisme ne serait pas associé à cette maladie. Cependant, l'ensemble 
de nos résultats démontre que le gène ERK4 est un nouveau gène de 
suppression tumorale potentiellement impliqué dans la progression du cancer 
de la prostate. 
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PREFACE 
ln accordance with the "Guidelines concerning thesis preparation" of the Faculty 
of Graduate Studies and Research, three manuscripts (one published in Genes 
Chromosomes and Cancer, one to be submitted to Cancer Research and one to 
be submitted to Human Mutation) have been incorporated in this thesis. The 
Division of Experimental Medicine, Department of Medicine, has approved this 
thesis preparation format. 
This thesis is written in a form that includes manuscripts submitted (or to be 
submitted) for publication, according to the instructions to authors of thesis that 
can be found on the McGiII University Graduate and Post-doctoral Studies 
Faculty web site. Sections of Chapter 1 (Introduction and Literature review) are 
part of a book chapter written by the author of this thesis. Thus, permission from 
the editor can be found in Appendix A. Each manuscript presented in this thesis 
(Chapters 3, 4 and 5) possesses its own Abstract, Introduction, Material and 
Methods, Results, Discussion and Conclusion. Permission from publisher and 
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CHAPTER 1 
INTRODUCTION, LITERATURE REVIEW AND 
OBJECTIVES 
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1.1 Overview of prostate cancer (PCa) 
1.1.1 The prostate gland 
The prostate is a male gland located under the bladder of about the size and the 
shape of a chestnut. Its main function is to produce seminal fluid that is part of 
the semen. The prostate is made up of epithelial glands and a fibro muscular 
stroma. The glandular epithelium (which gives rise to prostate adenocarcinoma) 
is composed of three types of cells: basal cells, luminal secretory cells and 
neuroendocrine cells. Luminal cells secrete the different components of the 
prostatic fluid, express the androgen receptor (AR) and secrete prostatic specifie 
antigen (PSA) in an androgen-dependent manner. The stroma is composed of 
fibroblasts, smooth muscle cells, dendritic cells, nerves and infiltrating mast cells 
and lymphocytes. Stromal cells are androgen-responsive and produce growth 
factors, which act in a paracrine fashion on epithelial cells. This stromal-
epithelial crosstalk is an important regulator of growth, development and 
hormonal responses of the prostate 1. 
1.1.2 Prostate malfunctions 
Many problems are associated with the prostate, as men get older. Benign 
prostatic hyperplasia (BPH) is the most common benign tumor in men older than 
60 years old 2. Benign growth of the prostate gland is accompanied by a 
significant increase in the proliferation rate of epithelial cells in the hyperplasie 
acini 3. This then leads to the constriction of the prostatic part of the urethra, 
resulting in problems to urinate. BPH also increases the risk of bladder and 
kidney infections. Therapies for BPH are mainly medical in nature, including 
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alpha-adrenergic blockade or 5-alpha-reductase inhibition. When medical 
therapy fails then surgery is contemplated, including microwave treatment to 
decrease prostate volume 4 and transurethral ablation of the prostate 
(transurethral prostatectomy: TURP). Although BPH was originally thought to 
lead to prostate cancer, it is now established that it is not the case. 
1.1.3 Incidence 
Prostate cancer is the second leading cause of cancer death in the male 
population in North America with an estimated 230,110 new cases and 29,900 
deaths in USA in 2005 5. These incidences are similar to the Canadian ones, 
since for the same year, it is predicted that 20,500 Canadian will have the 
disease while 4,300 men will die from it 6. In mature prostate, the maintenance 
of prostate-specifie cellular functions requires continuous stimulation by 
androgens. Despite improved early diagnosis of PCa, approximately one-third of 
patients are still diagnosed at a clinically advanced stage 5. Therefore, 
metastatic disease presents a continuing therapeutic challenge and is the most 
common cause of cancer-related death 7. Moreover, progression to an 
androgen-independent state remains the primary cause of mortality in these 
patients 8. 
1.1.4 Risk factors 
There are well-established risk factors for PCa, including: ethnie origin 
(American black males), ageing, family historyand patients in the highest 
quartile of IGF-I (insulin growth factor 1) blood concentrations 9. Diet is also a 
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well-studied risk factor for PCa: while dietary vitamin E, carotenoids and 
selenium protect against the disease, a diet rich in fat, red meat and dairy 
products exerts a promotional effect 10. Familial history is also important in PCa 
since susceptibility loci have been found on chromosomes 1,3,8, 17, 20 and X. 
For example, a locus on chromosome 3p24 is associated with a lod score of 
3.08 in families from Finland 11. However, sorne putative risk factors have been 
excluded: cigarette smoking, alcohol, vasectomy and physical activity 10. 
Environment also plays an important role in the aetiology of PCa. Indeed, the 
incidence of PCa has risen by 5 to 118% in Asian countries. Thus, with graduai 
westernisation, many Asian countries are losing their environ mental protective 
factors such as low fat diet and are acquiring high-risk ones like obesity and a 
diet with a high content of red meats 12. 
1.1.5 Diagnosis 
PCa is usually diagnosed upon palpation by putting a finger in the rectum and 
looking at the volume and the texture of the prostate. It can also be diagnosed 
by dosage of PSA in the patient's serum. PSA has been identifie~ in 1979 and is 
a very useful marker for tumorigenicity as its concentration follows the clinical 
stage of the disease 13. When the PSA concentration in the serum is high (more 
than 10 ng/ml), the clinician can confirm the PCa diagnosis. The screening for 
early-stage disease is logical but its utility is limited by the inability of 
conventional diagnostic and histologie parameters to predict accurately the true 
extent and prognosis of a substantial proportion of clinically localized cancers. 
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This limitation is due to the subjectivity of current grading and staging systems 
C4 and section 1.1.6). There is thus a critical need for new markers that will 
distinguish accurately those histologie lesions and disseminated cells that have 
a high probability of causing clinically important metastatic disease from those 
who will remain indolent. 
1.1.6 Histological and clinical staging 
PCa is hard to stage because of its cellular heterogeneity. In humans, 
heterogeneity is a common phenomenon that includes different histological 
grades among different tumor foci and different genotypes among phenotypically 
, similar foci in one primary tumor 15. 
The Gleason score system is still the most frequently used grading system for 
PCa 16. Unusually, the overall grade is not based on the highest grade within the 
tumor but on an intermediate between the most predominant pattern of cancer 
and the second most prevalent one. These patterns are graded from 1 (most 
differentiated) to 5 (Ieast differentiated) and the two grades are added. If a tumor 
has only one histological pattern, the primary a~d secondary scores are the 
same. The combined Gleason scores (called the Gleason sum) range from 2 
(for tumors uniformly of grade 1) to 10 (for undifferentiated tumor of grade 5). 
However, the Gleason score system has difficulties with inter-observer 
reproducibility. Other problems incJude grading of cribriform patterns, grading of 
small foci of cancer at biopsy, borderline histology between grades and how to 
account for a tertiary pattern 17. Nonetheless, the Gleason score is a powerful 
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prognostic indicator. It correlates with ail important pathological variables seen in 
the radical prostatectomy sample, with the prognosis after surgery and with the 
outcome after radiotherapy 18, 19, 20. For predicting the outcome, the following 
combinations are very helpful: score 2-4 (weil differentiated), 5-6 (moderately 
differentiated), 7 (moderately to poorly differentiated) and 8-10 (poorly 
differentiated). The Gleason score grade also has an influence on the treatment 
given to patients 17. Clinicians use this grading system to predict the probability 
of tumor extension outside of the prostate 21. However, it has not been shown if 
the tumor grade changes or gets worse over time. 
The TNM tumor staging is a standardized system for classifying the extent of the 
disease in order to compare therapeutic intervention and to estimate the 
outcome. The "T" (T1 to T 4) describes the tumor topography and is 
characterized by the size of the tumor at its primary site and/or the involvement 
of local structures. The "N" (N1 to N3) evaluates the presence and extent of 
regional Iymph nodes involvement while the "M" (M1 and M2) indicates the 
spread of the tumor by documenting evidence of distant metastasis 22. 
After modifications of TNM staging system in 1992 and 1997, clinicians found 
that this staging system could still predict progression-free survival after radical 
prostatectomy 23. However, sorne controversies and suggestions for additional 
modifications were proposed 24, 25. Moreover, by conducting a study with 12 PCa 
cases to assess the reproducibility of TNM staging system among 20 physicians 
with special expertise, Campbell et al. found that the ove rail staging 
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reproducibility is less than 80% of consensus 26. Furthermore, in this study, they 
showed that the levels of PSA seem to be even more indicative of the extent of 
PCa than the current clinical staging. Thus, whether the clinical TNM staging 
system reveals the true biological significance of PCa is still questionable 26. 
1.1.7 Clinico-pathology 
PCa is a multiple stage disease (Figure 1) that often originates from prostatic 
intraepithelial neoplasia (PIN), which is characterized by architecturally benign 
prostatic acini lined by cells that seem to be malignant 17. PIN can lead to 
localized PCa where cancer cells are confined into the prostate capsule and still 
androgen-dependent. Unfortunately, PCa often become more aggressive 
(advanced PCa) as it metastasizes to adjacent and remote tissues to form new 
foci of cancer cells in regional Iymph nodes, bones and sometimes lungs and 
liver. At this stage, hormonal therapy to reduce the level of dihydrotestosterone 
(DHT), the active metabolite of testosterone, is used to slow down the 
progression of the disease. However, it is mostly genetic changes that are 
associated with the progression of the disease and it is likely the accumulation 
of these changes, rath.er than their specific order that transform a normal cell 
into a tumorigenic one (Figure 1). 
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Figure 1. Prostate cancer stages. During PCa evolution, different gene 
alterations are associated with the diverse stages, from PIN to androgen-
independent adenocarcinoma. 
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Although the number of men presenting with metastatic PCa has decreased 
significantly over the last several years, the death rate for those men is 
essentially unchanged. To alter the currently inevitable progression of hormone 
refractory PCa to death, new targets and new therapies are needed 27. In PCa 
tissue, the reciprocal loss of cellular differentiation, which occurs during the 
progression of the disease, is largely concomitant with a loss of androgen 
responsiveness by prostatic cells 28. Thus metastatic spread is almost always 
accompanied by eventual insensitivity to androgens and results in patient death. 
1.1.8 Androgen independence 
ln normal conditions, androgens regulate the development and the homeostasis 
of the prostate. They act on prostatic epithelial cells by binding to an intracellular 
protein, the AR that binds both testosterone and DHT. The nuclear AR is 
composed of an activating domain, a DNA-binding domain (DBD) and a ligand-
binding domain (LBD). The LBD binds androgens, anti-androgens and selective 
AR modulators 29. AR dimerizes upon stimulation and binds to androgen-
responsive elements (ARE) in the promoter region of target genes 30. One way 
that AR regulates the proliferation of prostate cells is by stimulating cyclin-
dependent kinases (CDK) 31. 
When androgen-ablation therapy is given to a patient, PCa cells can circumvent 
it by increasing their sensitivity to very low amounts of androgens, by up 
regulating AR expression, or by amplifying the AR gene. PCa cells can increase 
the local production of androgens to compensate for the overall decline, 
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increase the amount of AR in the nucleus, the specificity of the AR can be 
changed and thus be activated by other ligands than androgens (Iike epidermal 
growth factor (EGF)), or it can bypass the androgen necessity 30. 
1.1.9 Metastasis 
1.1.9.1 The metastatic cascade 
Metastasis is defined as the formation of progressively growing secondary tumor 
foci at sites discontinuous from the primary lesion. ln the past, extravasation and 
survival at the metastatic site were thought to be inefficient processes as only 
0.1 % of injected cells in an animal model went into secondary organs to form a 
tumor 32. The main factors that could explain why these processes are inefficient 
was the low survival rate of cells shed in the circulation, and the low percentage 
of them that can escape from blood vessels 33. While disseminated cells are 
likely to be present in numerous organs, only certain environments appear to 
allow their survival and subsequent growth 34. However, a recent study by PS 
Steeg in 2003 showed that extravasation and survival at the metastatic site were 
relatively efficient processes 35. 
The formation of a primary tumor requires a cadre of molecular and cellular 
alterations that enable a cell to circumvent normal growth control mechanisms 
as weil as to manipulate its local environ ment 36. One of these changes is the 
development of blood supply that allows tumor cells to be nourished 37. The 
development of clinically significant metastases requires that a cancer cell 
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complete a series of well-defined steps, generally referred to as -the metastatic 
cascade (Figure 2). 
Acquisition of invasive abilities involves loss of adhesion molecules (E-
cadherin/CDH1), initiation of motility and extraceUular-matrix (ECM) proteolysis, 
which culminates in the shedding of ceUs into the blood circulation either directly 
or via the Iymphatics 38. Beyond this step, survival of ceUs in the blood stream, 
their arrest at a distant organ, and initial extravasation were found to be efficient 
processes 35. At the secondary site, ceUs arrest by binding to specifie molecules 
like ~-galactoside-binding lectin, galectin 3 (LGALS3), or TF (Thomsen-
Friedenreich) antigen 39 in particular organs or tissues 7. They can thus form a 
metastatic focus in this organ. 
The next phase of the metastatic colonization is subdivided into the survival of 
ceUs after extravasation, and their persistence of growth. However, survival and 
persistence of growth were shown to occur inefficiently and the rate of invasion 
and metastatic colonization predicted the overall metastatic ability 35. 
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Figure 2. The metastatic cascade. Primary prostate cancer needs to undergo 
different steps to develop into macroscopic metastases. 
13 
Primary 
malignant 
neoplasm 
Recruitment 
development 
of a vascular 
supply: 
angiogenesis 
~ 
Recruitment and 
development 
of a vascular 
supply 
... Invasion 
Progressive growth 
~ 
Arrest 
extravasation 
Survival 
~ Overt surface 
metastases 
\...... J 
'Y' 
Metastatic colonization 
~ Cell .survival signaling: 
,,----------- " survive, 
Macroscopic 
metastases 
Microscopie 
metastases 
Continued growth and 
development of 
secondary metastases 
mainly to lungs, bones and liver 
+- Viable œil c1usters 
i enter the cell cycle, 
divide 
~ 
..... 
Disseminated 
cells at the 
secondary 
site 
1.1.9.2 Bone metastases 
T 0 explain the homing of cancer cells to specific organs, Ewing proposed in 
1928 the haemodynamic theory. This states that the development of metastases 
in a given organ is dependent on the blood volume flowing into that organ 40. 
Unfortunately, this cannot be applied to bones since they do not have a high 
blood flow in the red marrow. It is now accepted that PCa cells possess 
inherent capacities, which not only direct them to bones, but also enable them to 
survive, proliferate and colonize bones 41. Indeed, PCa cells loss their E-
cadherin expression for the cadherin 11 (or OB cadherin) which targets them to 
the bones 42. 
Bones have several unique features in their morphological structure and 
cellularity. They have a hard calcified matrix, which shows relatively low 
cellularity and metabolic activity. This matrix stores a variety of osteoblast-
derived growth factors which may serve as essential nutrients for cancer cells 
which localize in bones 41. These growth factors are constantly released into the 
bone marrow cavity. Thus, bones provide a fertile microenvironment which 
facilitates colonisation by metastatic cancer cells 41. Bones are a target organ 
for both breast and PCa metastases, which validates the "seed and soil" theory 
proposed by Paget more than a century ago 43. This theory states that PCa cells 
(the "seeds") need to encounter a fertile microenvironment (the "soil") to grow 
and develop metastases. 
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There are two patterns by which cancer cells can affect bones: osteolytic (breast 
cancer cells) and osteoblastic (PCa cells). PCa cells themselves produce factors 
like endothelin 1 (ET-1) 44 which stimulate osteoblastic bone formation. 
Moreover, sorne factors like bone morphonogenic proteins (BMPs), transforming 
growth factor-131 (TGFI31) and TGFI32, insulin-like growth factor 1 (IGF1) and 
IGF2, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) 
45 regulate osteoblast function by activating signalling pathways involved in the 
regulation of osteoblast proliferation and differentiation. 
Primary PCa grows at a relatively slow rate. When spread to bones, its growth is 
accelerated, suggesting that the bone microenvironment provides proliferation-
stimulating factors for metastatic PCa cells. 
1.1.10 Treatments 
When detected early enough, choices have to be made in order to treat organ-
confined PCa. Here is an extensive list of possible treatments: watchful waiting; 
early, deferred, intermittent, or sequential androgen suppression; external or 
conformai external beam radiotherapy; iodine or palladium seed brachyth~rapy; 
high dose rate brachytherapy; cryotherapy; and/or radical retropubic, perineal or 
laparoscopie prostatectomy 46. 
It is encouraging that a new generation of treatments is emerging to help 
patients with advanced PCa. Those are; combination chemotherapy; 
biphosphonates; calcitriol; antibodies against PSMA; bortezomib; thalidomide; 
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immunotherapy; BCL2 antisense; inhibition and/or blockade of growth factor 
receptor or growth factor receptor pathways 27. However, it is still too early to 
say if any of these treatments will really improve the survival time of patients 
with advanced PCa. 
1.2 Genetic alterations in PCa 
ln order to become malignant, normal cells have to activate oncogenes and 
inactivate tumor suppressor genes (TSGs). For example, proto-oncogenes 
participate in normal cell proliferation, encoding a variety of proteins that function 
as growth factors, growth factor receptors, regulators of replication or 
transcription, modifiers of protein function, or in other signalling pathways. 
Alterations of these critical processes can cause aberrant growth and contribute 
to neoplastic transformation. Oncogenes can be activated by insertional 
mutagenesis, amplification, point mutation, and translocation 47. As they function 
in a dominant manner, the presence of an altered and activated oncogene is 
sufficient to cause tumors despite the presence of one normal allele, 47. 
On the other hand, TSGs are defined as genes that suppre~s tumor growth and 
function in a recessive manner. If one copy of the gene is already missing 
because of an inherited defect, then the loss or inactivation of the sole remaining 
allele results in complete absence of that gene's product, which can lead to 
cancer. Indeed, the inactivation of both alleles of a gene, termed the "two-hit" 
hypothesis by Knudson in 1971, explained the epidemiology of retinoblastoma 
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48. Later on, biallelic inactivation of the RB1 gene was confirmed to be causative 
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TSGs can be inactivated by different mechanisms, which allow a cell to progress 
through the cell cycle, to become resistant to apoptosis, and to escape the 
normal controls of the cell and immune system. There are three mechanisms by 
which a cell can inactivate a TSG: point mutation, deletion, often seen as loss of 
heterozygosity (LOH), and promoter methylation. 
The metastatic spreading of cancer cells to other tissues requires the 
inactivation of another set of genes called metastasis suppressor genes 
(MSGs). MSGs are defined as genes whose encoded proteins suppress the 
formation of spontaneous macroscopic metastases, without affecting the growth 
of the primary tumor 7. Using mainly MMCT, metastasis-suppressor activities 
have been reported on chromosomes 1,6,7,8,10,11,12,16, and 17 50,51. So 
far, thirteen genes have been shown to meet the MSG criteria: KA/1, K/SS1, 
MAP2K4, CD44, BRMS1, NME1, NME2, RHOGD/2, RK/P, SSECKs, VDUP1, 
CDH1, and T/MPs 52. However, only KA/1,. MAP2K4, and CD44 have been 
implicated in PCa and are described below. 
1.3 Chromosomal alterations in prostate cancer 
Genetic alterations are common features of cancer. Indeed, chromosomal 
rearrangements or loss of particular regions have been reported for almost ail 
chromosomes. Moreover, MMCT (see section 1.4) experiments have shown that 
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TSGs lie on human chromosome 1,3-13, 17-19,22, and X 53. However, these 
genetic modifications are not randomly distributed since specifie chromosomal 
regions have been associated with certain types of cancers 54. Indeed, some 
genetic alterations are specifie to PCa, and it is thought that PCa arises as a 
consequence of at least five cumulative genetic changes 55. Allelie losses of 
chromosomes 2q, 3p, 5q, 6q, 7 q, 8p, 9p, 10p, 10q, 11 p, 11 q, 12p, 13q, 16q, 
17p, 17q, 18q, and 21q have been shown to be assoeiated with progression 
and/or initiation of PCa 56. The most frequent alterations in advanced PCa are 
the loss of chromosomes 7q 57, 8p 58, 59, 60, 10q 61, 62, 63, 16q 64,65,66, 17q 67, 68 , 
and 18q 69, 66 and the gain of chromosome arms 7q, 8q, and Xq 70. Furthermore, 
the more sensitive Comparative Genomic Hybridization (CGH) technique has 
led to the identification of more genetic alterations in PCa, including losses of 
genetic material on chromosomes 2q, 5q, 6q, 9p, 13q, 15q, and 17p 71,72. The 
loss of these regions suggests that they contain one or more TSG. Moreover, 
introduction of human chromosomes 2 73, 6 74,775,876,1077,11 78, 12 79,13 80, 
16 81, 17 82, 18 83, 19 84, and 20 85 in human or rat Du nning PCa eell lines 
resulted in reduction or loss of their metastatic properties, without affecting their 
tumorigenicity. 
1.4 The use of microcell-mediated chromosome transfer to clone TSG/MSG 
1.4.1 The technique 
MMCT is a technique that has been in use for more than thirty years; it allows 
the transfer of a single chromosome (or chromosome fragments) from one cell 
to another. MMCT necessitates the generation of microcells, which are small 
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nuclei containing one or few chromosomes, surrounded by a plasma membrane. 
Although such microcells are not viable, they can be fused to other cells, and 
upon appropriate selection, the resulting microcell hybrids will have incorporated 
the chromosome(s) from the microcells into the genetic material of the recipient 
cells (Figure 3). MMCT can be carried out with somatic cells, embryonic 
carcinoma (EC) or embryonic stem (ES) cell recipient, to study in vitro or in vivo 
the effects of the transferred genetic mate rial 53. 
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Figure 3. Scheme of the microcell-mediated chromosome transfer technique. 
Rodentlhuman donor cells are fused with recipient rat or human PCa cells. Each 
hybrid contains a tagged human chromosome, which allows selection for cells 
that has incorporated it. 
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The first successful cell fusion experiments were carried out in the 1950s, using 
Sendai or other viruses as fusing agents. The major goal at this time was to 
increase efficiency of fusion between two complete cells. The potential of this 
method was apparent as a major gathering of the leaders took place in 1968 to 
explore the study of intergenomic relationship and predict future uses for cell 
hybrids. Meanwhile, it had been known since the 1950s that cells became 
multinucleate following treatment with mitosis-inhibiting agents su ch as 
colcemid. These multinucleated cells can then be enucleated by cytochalasin 8 
treatment followed by centrifugation. This process drags the condensed 
metaphase chromosomes out of the cells, along with a covering of nuclear and 
cell membrane, thus forming microcells. These two technologies (cell fusion and 
microcell formation) were then combined into a single process for fusing donor 
microcells containing single or small numbers of chromosomes with recipient 
cells to make fully functional hybrids. In 1977, Fournier and Ruddle at Yale 
University reported the fusion of mouse microcells with human Hela or Chinese 
hamster ovary (CHO) cells. These hybrid cells contained small numbers of 
mouse chromosomes in a human or hamster background. Thus, the MMCT 
technology had arrived, at a time when less than 100 genes were assigned to 
specific human chromosomes. 
ln the early cell fusion experiments, it was noted that certain chromosomes 
tended to be preferentially lost, but this was unpredictable in individual 
experiments. Approaches were then developed for selection of specific 
chromosomes. In 1967, Weiss and Green used culture medium containing 
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hypoxanthine, aminopterin and thymidine to select for an endogenous human 
locus (the thymidine kinase (TI<) gene), by maintaining the chromosome 
encoding the human TK gene in a mouse background 86. Using other hybrids, 
the human TK gene was eventually mapped to human chromosome 17 87. New 
plasmid vectors and transfection technologies allowed integration of exogenous 
selectable markers into host chromosomes, thus allowing their selection in 
culture 88. Since these transfected markers are inserted randomly into the host 
genome, the selection of any of these tagged chromosomes became possible. 
Presently, dual selectable markers (such as HyTK fusion protein) are used to 
select microcell hybrids in culture (in media containing hygromycin 8), or 
revertant cells that will have lost the introduced chromosome (in media 
supplemented with ganciclovir). 
1.4.2 Usage 
MMCT experiments have shown that TSGs lie on almost ail human 
chromosomes (see section 1.3). Indeed each normal human chromosome has 
been transferred into cancer cell lines, and the resulting hybrids experienced 
either suppression of in vitro growth, or diminished tumorigenicity in vivo 53. 
Such experiments indicate that these human chromosomes encode one of more 
tumor/metastasis suppressor genes implicated in PCa progression. 
1.4.3 TSG/MSG identified using MMCT 
ln PCa, MMCT has lead to the cloning of the KA/1 (CD82) TSG/MSG. This gene 
was indeed identified when introduction of human chromosome 11 into Dunning 
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AT6.1 rat PCa cells completely abolished their tumorigenic properties both in 
vitro and in vivo 89. This MSG also decreases PCa cell invasiveness and motility 
both in vitro and in vivo 90. The KAI1 protein is a member of the tetraspanin 
superfamily (also known as the transmembrane 4 superfamily (TM4SF» which is 
characterized by four highly conserved transmembrane domains and is involved 
in regulation of cell proliferation and motility 91. KA/1 is also implicated in breast 
carcinoma, since its expression is inversely correlated with the metastatic 
potential of sorne human breast cancer cells lines. The nearly ubiquitous 
expression of this gene suggests that it could function as a metastasis 
suppressor gene in other tumor types. Accordingly, exogenous expression of 
KAI1 in highly metastatic B 16-BL6 murine melanoma cells also alters cell-cell 
interactions 92. The exact mechanisms by which KAI1 is able to suppress 
metastasis are still not known. However, it could be through the interactions 
between KAI1 and its partners, such as E-cadherin, ~1 integrin, and epidermal 
growth factor receptor (EGFR). These membrane proteins have indeed already 
been implicated in metastasis progression. 93. 
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 
(MAP2K4) gene is another MSG that has been identified following transfer of 
chromosome 17 into Dunning rat PCa cells 94 and is described below. 
Using MMCT, Ichikawa et al. transferred a copy of human chromosomes 7,8,9, 
10, 11, 12, and 17 into the highly metastatic Dunning R-3327 rat PCa cells. 
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They found that hybrids containing human chromosomes 7, 8, 10, 11, 12, or 17 
showed decreased ability to metastasize to the lung without any loss of 
tumorigenicity 94. Further molecular and cytogenetic analyses of microcell 
hybrids demonstrated that putative metastasis suppressor genes were located 
on human chromosomes 7q21-22, 7q31.2-32, 8p21-12, 10q11-22, 11p13-11.2, 
12p11-q13, 12q24-ter, and 17pter-q23. The identification of regions on 
chromosomes 11 p and 17p is not surprising since they encode respectively the 
KA/1 (at 11 p11.2), and MAP2K4 (at 17p12) suppressor genes. This proves that 
MMCT is useful to identify tumor and metastasis suppressor genes implicated in 
PCa initiation and/or progression. Although other suppressor genes have been 
identified using other methods, such tumorigenic or metastasis suppression in 
hybrids likely indicates that more suppressors exist. 
1.5 Chromosomes and genes implicated in prostate cancer 
As mentioned in Figure 1 and section 1.2, many genetic alterations are seen in 
PCa cells. Indeed, allelic losses of 2q, 3p, 5q, 6q, 7q, 8p, 9p, 10p, 10q, 11p, 
11q, 12p, 13q, 16q, 17p, 17q, 18q, and 21q are associated with PCa 
progression and/or initiation 56. An extensive list of putative TSGs/MSGs 
classified by chromosome can be found with the corresponding reference in 
Table 1. Here, we review the chromosomes that are the more often affected 
during PCa progression, and the different oncogenes, TSGs and MSGs they 
encode. 
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Table 1. Tumor suppressor and metastasis suppressor genes implicated or not 
yet tested in prostate cancer progression 
Chromo- Gene name TSG ln prostate cancer Reference 
sorne or 
MSG 
1p31 CLCA2 TSG To be tested l:/O 
(TSG in breast cancer) 
1p36 RUNX3 TSG To be tested ~ti 
(TSG in gastric cancer) 
1q21.2 TXNIP MSG To be tested l:/f 
(MSG in melanoma) 
1q32 KISS1 MSG To be tested ~J 
(MSG in melanoma and 
breast cancer) 
2p11.2 RKIP MSG Decreased expression in ~~ 
metastasis, decreases 
metastasis in a murine 
model 
2q14 BIN1 TSG Inactivated in advanced ~~ 
PCa, suppress growth in 
vitro 
3p21.3 RASSF1A TSGs Inhibit LNCaP growth, 1UU 
&C Methylated in PCa ceillines 101 
(PC-3, DU 145, LNCaP) 
3q25.32 TlG1 TSG Decreases PC-3 lUL 
invasiveness, decreases 
tumors in vivo 
6q22.32- CRSP3 MSG To be tested l:/f 
q24.1 (MSG in melanoma) 
6q24-25.2 GRAVIN MSG Decreased in PC-3, LNCaP, lUJ 
DU 145, decreases colonies 
in soft agar and metastasis 
in vivo 
6q24.1 DRG-1 MSG Inhibits lunJJs metastases 1U4 
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7q31.1 CAV1 TSG Methylated in tissues 105 
7q31 TES TSG Decreased expression in lUo 
tissues 
7q31.1- ST7 TSG Suppresses tumor lUf 
q31.3 formation from PC-3 cells 
in vivo 
8p11.2 LSM1 TSG Decreases invasion lOti 
through Matrigel and 
metastases in mice 
8p21 NKX3-1 TSG Expression loss is lU~ 
associated with advanced 
PCa 
8p22 LZTS1 TSG Inhibits colony formation of llU 
LNCaP cells 
8p22 DLC1 TSG MethYJated in tissues 111 
9p21 CDKN2A TSG Decreased in primary 11:l 
PCa, lost in PC-3 cells 
10p14-p15 KLF6 TSG Mutated in PCa tissues, lM 
decreases cell proliferation 
10q21 ANXA 7 TSG Decreased in metastases 114 
and localized PCa, 
decreases colony 
formation and cellgrowth 
10q23 PTEN TSG Decreases PC-3 cells llb 
growth, inhibits 
metastases and 
decreases primary tumor 
size in mice 
10q24-q25 MX/1 TSG Decreases cell 110 
proliferation and colony 
formation 
11p11.2 KA/1 MSG Decreases metastases in 117 
mice, lost in 100% Iymph 93 
node metastases 
11p13 CD44 MSG Methylated in tissues, lost 9J 
in almost ail metastases 
11 q13- BRMS1 MSG To be tested ~;j 
q13.2 (MSG in breast cancer) 
11q23.2 TSLC1 TSG Methylated in PPC-1, l1ti 
suppresses PPC-1 tumors 
in mice 
11q23-q24 BCSC-1 TSG Suppresses colony ll~ 
formation, suppresses 
tumors in vivo 
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12p11.23 PTX1 TSG Decreases PC-3 cells 1LU 
growth 
12p13.1- CDKN1B TSG Lost in advanced PCa, lLl 
p12 has to be inactivated along 
with PTEN 
12p12.3 RhoGDI2 MSG To be tested lLL 
(MSG in bladder cancer) 
12q14.1 WIF1 TSG Decreased in primary PCa lL6 
12q21.1 RTVP-1 TSG Decreased expression by 1L4 
methylation 
12q24.1 NME2 MSG To be tested lM 
(MSG in breast, colon 
cancer and melanoma) 
13q21 KLF5 TSG Suppressed DU 145 125 
growth in vitro 
16q22.1 DERPC TSG Decreased in prostate 120 
tumors, inhibits cell growth 
16q22.1 CDH1 TSG Inhibits invasion of DU 145 127 
cells 
16q23.1 WWOX, Puta- Decreased in PCa cells 1LtI 
WFDC1, tive 
MAF, TSGs 
FOXF1, 
MVD 
17p11.2 MAP2K4 MSG Lost in metastases 129 
17p13.1 P53 TSG Inhibits cell growth, 16U 
suppresses tumor growth 
and metastases 
17q12- LCRG1 TSG To be tested 161 
q21.1 (TSG in laryngeal cancer) 
17q21 BECN1 TSG To be tested 16L 
(TSG in breast cancer) 
17q21.3 NME1 MSG Suppresses DU 145 166 
colony formation and 134 
invasion 
18q21.3 SERPINB5 MSG Decreases tumorigenesis, Mo 
metastasis, down-
regulates migration and 
invasion of PCa cells 
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19q13.2 CEACAM1 TSG Inhibits angiogenesis, 136 
suppresses tumors in vivo 
19q13.4 PEG3 TSG Decreases tumors in vivo lM 
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Chromosome 3 
ln 1997, Dahiya R. et al. found LOH on two regions of chromosome 3: 3p24-26 
and 3p22-12. However, the deletions at 3p24-26 and 3p22-12 were not related 
to the stage or grade of the tumor 138. Since then, the TSG RASSF1A (Ras 
association domain family 1 A) has been implicated in PCa and its location is 
close to the deleted regions reported by Dahiya et al. It has two promoters that 
produce RASSF1A and RASSF1C transcripts 101. The RASSF1A gene is a 
member of the RAS family of proto-oncogenes that play a fundamental role in 
signal transduction pathways involved in cell proliferation and survival. The 
protein has a Ras-binding domain that binds RAS in a GTP-dependent manner 
and its overexpression induces apoptosis. The RASSF1A product may function 
in signal transduction pathways involving Ras-like proteins and the pro-apoptotic 
effect of the protein may require heterodimerization with NORE1 139. The 
RASSF1A gene is inactivated in the PCa celllines LN CaP, PC-3 and DU 145 by 
methylation of its promoter. Interestingly, its re-introduction suppresses the 
growth of LNCaP cells in vitro 101. 
Chromosome 6 
Deletion of the long arm of chromosome 6 (6q) frequently occurs in many 
neoplasms including carcinoma of the prostate, suggesting the location of TSGs 
at 6q. Indeed, the 6q24 region can suppress the tumorigenicity of ovarian cancer 
cells when introduced by MMCT 140. The loss of 6q13-q23 is the second most 
frequently deleted chromosome region in PCa after 10q 141. The well-known 
oncogene P21/CDKN1A is located on this chromosome. It is implicated in the 
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regulation of cell growth by modulating TP53-induced apoptosis 1~. It is thought 
to have a paracrine effect by releasing mitogenic and antiapoptotic factors. The 
P21 protein induces G1-phase arrest by inhibiting the activity of CDK, and 
interacting with the proliferation of cell nuclear antigen (PCNA), thereby directly 
preventing DNA synthesis. P21 expression is associated with the metastatic 
potential and androgen-independent PCa (AIPC) phenotype 142. 
Chromosome 7 
The 7q31chromosome region contains many putative TSGs su ch as TES, 
CA V2, CA V1, MET, CAPZA2, STl, and WNT2. Using real-time RT -PCR, 
Chene L. et al. demonstrated that CA V1, CA V2, MET, and TES mRNA 
expression was lower in prostate tumors than in normal prostate tissues 106. 
The transfer of human chromosome 7 into the PCa cell line PC-3 led to a two-
fold increase in tumor latency in mice 143. Moreover, a 1.5 megabase region at 
7q31.1 (between microsatellite markers 07S486 and 07S655) was shown to be 
essential for suppression of the malignant phenotype of PC-3 cells 143. 
The oncogene EZH2 is located on human chromosome 7q and encodes a 
transcription repressor, which is activated in advanced PCa. This suggests that 
repression by this protein could enhance the capability of a tumor to progress 
towards metastasis, possibly by down-regulating a TSG. A report showed that 
EZH2 mRNA is increased in prostate tumor metastases, compared with 
confined tumors 144 The up-regulation of EZH2 in PCa cells leads to 
transcriptional repression and increased cell proliferation. A number of EZH2-
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repressed genes are TSGs such as the transcription factor ZNFNF1A1, or 
proteins that inactivate cell signalling such as the RHO GTPase-activating 
protein 1 145. 
Chromosome 8 
Several regions on the short arm of chromosome 8 (8p) play different roles in 
prostate tumors. Indeed, Oba et al have shown that gene(s) located at 8p22-
p21.3 are implicated in tumor differentiation, while 8p21.1-p21.2 deletions could 
influence progression of prostate tumors 146. There is also a statistical 
correlation between advanced tumor grade and frequency of 8p deletions 147. By 
transferring yeast artificial chromosomes (YACs) spanning the frequently 
deleted region 8p21-p22 into rat PCa cells, Cabeza-Arvelaiz et al. have 
identified a candidate suppressor gene known as FEZ1 (LZTS1). Although the 
exact function of the FEZ1 protein is not known, it contains a leucine-zipper 
domain, which suggests that the FEZ 1 gene encodes a putative DNA 
transcription regulator. This gene inhibits stable colony-forming efficiencies 
when transfected into LNCaP human PCa cells 110. 
The 8p21-p12 region also encodes a MSG able to suppress the metastatic 
ability of rat PCa cells. When transferred into rat AT6.3 PCa cells, a 60kb region 
of chromosome 8p inhibits metastatic spreading to the lung, following injections 
in the f1ank of nude mice. Interestingly, this 60kb is located in the frequently 
8p21-p12 deleted region in human PCa cells, a further indication that this region 
harbors a MSG for PCa 76. Due to its location at 8p21, the androgen-regulated 
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homeobox NKX3-1 gene had become a TSG candidate for PCa 148. It encodes 
a transcription factor homeodomain highly expressed specifically in the prostate. 
NKX3.1 undergoes LOH associated with tissue differentiation, and loss of 
androgen responsiveness during PCa progression. Furthermore, its expression 
is lost in the two androgen-independent ceillines PC-3 and DU 145, suggesting 
that its expression might be androgen-regulated. NKX3.1 could play a role in the 
opposing processes of androgen-driven differentiation of prostatic tissue, and 
loss of differentiation during the progression of the disease 148. Moreover, mice 
with a single NKX3.1 allele (+/-) develop prostatic hyperplasia and PIN. The 
hyperplasic lesions of these mice retain Nkx3.1 protein expression from the 
remaining wild-type allele, suggesting that haploinsufficiency contributes to 
tumorigenic progression 149. Indeed, when only one allele is lost, the function of 
the gene is abrogated and it contributes to tumor progression 150. 
Chromosome 9 
The TSG CDNK2A (P16) is located on chromosome 9p21 and encodes a CDK 
inhibitor. It acts as a negative regulator of cell cycle progression through the 
G.1/S phase. Various mechanisms have been described to explain its 
inactivation: homozygous deletion, point mutation, and aberrant methylation. Ali 
these mechanisms lead to an increased progression through the cell cycle. In 
patients with either primary or metastatic PCa, no mutations were detected in 
the CDKN2 gene. LOH at this locus is found in about 20% of the primary tumors 
and in 46% of the metastatic cancers. The commonly used PCa cell line PC-3 
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has a dense methylation pattern of the COKN2 promoter, whlle no normal 
prostate tissues contain aberrant methylation 151. 
Chromosome 10 
Introduction of human chromosome 10p into human PCa resulted in 
suppression of their malignant phenotype, suggesting the presence of prostate 
TSG on 10p 152. Moreover, a 1.2Mb region located at 10p15.1 and flanked by 
markers 010S1172 and 010S226 has been shown to contain a TSG for PCa 
153. This TSG could weil be the KLF6 gene, since LOH at this locus is often seen 
in PCa 113. Human chromosome 10 also encodes two other important TSG for 
PCa progression: PTEN located at 10q23.3 and ANXA7 at 10q21.1-q21.2. The 
ANNEXIN 7 (ANXA 7) gene is located at 1 Oq21, which has been shown to 
contain a TSG for PCa 154. The protein has calcium binding properties and 
GTPase activity. The expression of ANXA7 is lower in metastatic and local 
recurrence of hormone refractory PCa. Its expression inversely correlates with 
the stage of the disease. ANXA7 protein expression is decreased in recurrent 
PCa 155. Moreover, 35% of the primary tumor examined by Srivastava et al. 
showed LOH near the ANXA7 gene 114. It has been reported that human tumor 
cell proliferation, and colony formation were markedly reduced when the gene 
was introduced in LNCaP and DU 145 cells 114. 
The TSG PTEN (Phosphatase and tensin homologue deleted on chromosome 
ten)/MMAC1 (mutated in multiple advanced cancers 1) on chromosome 10q23 
encodes a protein tyrosine phosphatase which has PIP3 (phosphatidylinositol 
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3,4,5-triphosphate) (a product of the PI3 (phosphatidylinositol) kinase pathway) 
for substrate 156. PTEN acts as a negative regulator for the PI3 kinase/Akt 
signaling pathway, which control cell cycle progression and apoptosis 157. It is 
mutated in its catalytic domain at high frequency (60%) in primary PCa 158, 159, 
although PTEN loss is a late event in PCa progression 160. 
Chromosome 11 
Glutathione-S-transferase (GSTP1) is located on chromosome 11, and encodes 
for a family of isoenzymes that provide protection to cells by catalyzing 
intranuclear detoxification of electrophilic metabolites of carcinogens and 
reactive oxygen species. Their epigenetic silencing is the most common (>90%) 
genetic alteration so far repqrted in PCa 161. The GSTP1 promoter is heavily 
methylated in PCa cell lines and tissues. Furthermore, a significant association 
between GSTP1 promoter hypermethylation both with a Gleason score of 7 or 
more and the presence of Gleason grade 4 and/or grade 5 was found in patients 
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The MSG CD44 is a transmembrane protein that mediates cell adhesion by 
binding to specifie ECM components 93. Its expression inversely correlates with 
the grade and metastatic stage of prostate tumors 163. It is thought that CD44-
mediated metastasis suppression may occur through contact inhibition of cancer 
cell growth within micrometastatic foci at the secondary site 93. 
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Chromosome 12 
Jaeger et al. (2004) identified a 4.2Mb discontinuous region at 12q24.3 that 
suppresses the metastatic properties of rat PCa cells by more than 90%. 
Interestingly, a number of potentially important genes, such as vitamin D 
receptor, multiple integrin subunits, and WNT inhibitory factor 1 are not retained 
in the non-metastatic hybrids. This suggests the activity of a novel MSG or a 
previously-uncharacterized function of a known gene 79. Furthermore, we have 
previously shown that introduction of a portion of chromosome 12 (12pter-
12q13) into the human PCa cell line DU 145 suppressed their tumorigenic 
properties 164. Taken together, these results argue for the presence of at least 
two tumor suppressor genes on this chromosome. To our knowledge, no TSG 
implicated in PCa has yet been mapped to these regions. 
Chromosome 13 
Dong JT., et al studied the LOH of different regions of chromosome 13 in PCa 
specimens. They showed that the frequencies of LOH at 13q14, 13q21, and 
13q33 were 62%, 57% and 34%, respectively 165. Two TSGs located in these 
regions were implicated in PCa: KLF5 and RB1. Kruppel-like factor 5 and 6 
(KLF5 and KLF6) are TSGs implicated in PCa. They are ubiquitously expressed 
zinc finger transcription factors of unknown function that are located on 
chromosome 13 and 10, respectively. KLF6 can up-regulate the cell cycle 
regulatory protein CDKN1A (described previously) in a TP53-independent 
manner, and also reduces cell proliferation, whereas KFL5 activates the 
transcription of genes implicated in cell proliferation and differentiation. LOH and 
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hemizygous deletion are the main mechanisms by which KFL5 is inactivated. 
LOH of KLF6 is detected in 77% of primary PCa. Frequent genomic deletion and 
loss of expression, as weil as cell growth suppression indicate that KLF5 is a 
reasonable candidate for the TSG at 13q21 125, a region that is frequently 
deleted in PCa 113. 
The long arm of chromosome 13 (13q) is frequently deleted in PCa 71. The TSG 
RB1 is a cell cycle regulator, which is located in this commonly lost region. In 
normal cells, RB 1 sequesters the E2F transcription factor, thus preventing the 
transcriptional activation of genes implicated in the S-phase progression. In the 
late G 1 phase, RB is phosphorylated by the CDK2/cyclin E complex, which 
inhibits RB binding to E2F. The S-phase can then occur. When the RB gene is 
mutated in a cancer cell, it cannot be dephophorylated by a phosphatase at the 
end of the cell cycle. Thus, the RB protein is always free and the E2F 
transcription factor is constitutively active. This allows the cell to escape the 
G1/S-phase control point. RB was originally implicated in retinoblastoma 166 but 
since then, its inactivation has been associated with many other tumors 167. RB 
gene expression is decreased or absent in a significant proportion of sporadic 
PCa 168. 
Chromosome 16 
A PCa susceptibility locus has been mapped to the long arm of chromosome 16, 
at 16q23.2 169. Indeed, this region exhibits a high frequency of allelic imbalance 
(AI) in tumors from 51 men diagnosed with PCa using the same linked markers. 
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This suggests the presence of a candidate TSG implicated in the development 
of both familial and possibly non-familial forms of PCa 169. Numerous studies 
have suggested the presence of one or more TSG on 16q22.1. A new gene has 
been mapped to this region: DERPC (decreased expression in renal and 
prostate cancer). This gene encodes a basic, proline- and glycine-rich nuclear 
protein. The protein is ubiquitously expressed and its expression is decreased in 
renal (67%), and prostate carcinomas (33%). Exogenous DERPC over 
expression in LNCaP cells causes alterations of nuclear morphology, and has 
an inhibitory effect on PCa cell growth 126. 
1.6.7 Chromosome 17 
Loss of 17p is associated with higher Gleason score 170, a finding that is not 
surprising considering the numerous TSGs/MSGs located on this chromosome. 
Indeed, the oncogene HER-2-NEU, the TSGs TP53 , and BRCA 1, and the MSG 
MKK4 are aillocated on this chromosome. 
It has been suggested that the breast cancer susceptibility genes BRCA 1 at 
17q21 and BRCA2 at 13q12 might be involved in PCa 171, 172. However, only few 
mutations of these genes were detected in PCa tissues. Indeed, Sinclair CS et 
al (2000) screened 22 high-risk PCa families for BRCA 1 and BRCA2 mutations, 
but found only one previously identified BRCA2 mutation, and two unreported 
BRCA2 intron polymorphisms. Contrary to what is seen in breast cancer, no 
truncating mutations were found 173. This suggests that BR CA 1 and BRCA2 
have a limited role in familial PCa susceptibility. 
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Located on chromosome 17, the oncogene HER-2-NEU is a receptor tyrosine 
kinase that belongs to the EGF family. The over expression of the receptor 
tyrosine kinase is associated with the progression to AIPC, and activates PSA 
transcription. Initially, HER-2-NEU confers survival to tumor cells by activating 
the AR pathway in an androgen-independent manner 174. 
TP53 modifications represent the most common genetic change in human 
malignancies 175. This TSG is located on chromosome 17p13, and encodes a 
53kDa nuclear phosphoprotein which functions as a cell-cycle regulator that 
inhibits the progression of genetically damaged cells through the S-phase. 
Therefore, when TP53 function is disrupted, cells with damaged DNA can divide 
and propagate the genetic defect to daughter cells. TP53 mutation leads to 
genetic instability, a hallmark of malignant progression 176. TP53 is classically 
inactivated by point mutations 177. The short-arm of chromosome 17 is 
commonly deleted in human tumors and the remaining TP53 allele frequently 
harbours point mutations 178. Another major function of TP53 appears to be in 
mediating the cellular response to DNA damage, and helping to maintain 
genomic stability 179. TP53 is involved in the regulation of expression of genes 
induced during cell growth arrest triggered by DNA-damaging agents 179. When 
a cell encounters agents that cause DNA damage, TP53 halts cell cycle 
progression by inducing transcription of mitotic inhibitors including CDKN1A. 
CDKN1A binds to and inhibits cyclin kinase complexes, preventing 
phosphorylation of specific substrates which in turn inhibits the passage from G1 
to S phases 180. During this time, the cell attempts to repair the damaged DNA. If 
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such damage is irreparable, TP53 triggers apoptosis. The TP53 status is 
different in the three commonly used PCa ceillines DU 145, PC-3 and LNCaP. 
For example, in DU 145, two mutations were found in the TP53 gene: a mutation 
at codon 274 (pro > leu), and a second mutation at codon 223 (val > phe) were 
present. The PC-3 cens are hemizygous for chromosome 17p, and the single 
copy of the TP53 gene has a base pair deletion at codon 138 that generates a 
frame shift and a new in-frame stop codon at position 169 181, thus completely 
inactivating the putative encoded protein . 
The mitogen-activated protein kinase kinase 4 (MAP2K4) gene at 17p11.2 
can suppress rat PCa in vivo 182. It is also a member of the MAP kinase family 
(mitogen-activated protein kinase). Its activation occurs in response to cell 
stress, leading to proliferation, apoptosis, and differentiation 93. In normal 
prostatic tissue, there are high levels of MAP2K4 in the epithelial but not in the 
stromal compartment. In PCa, there is an inverse correlation between Gleason 
pattern and MAP2K4 expression. The protein is down regulated during PCa 
progression, arguing that MAP2K4 has a role for deregulation of its signalling 
cascade in clinical disease. There is also LOH in 31% of PCa tissues 129. 
Chromosome 18 
Deletions of chromosome 18 have been associated with many cancers including 
colorectal 183, pancreatic 184, ovarian 185, head and neck squamous cell 
carcinoma 186, lung 187, and PCa 188, 189, 190, 191, 192. Functional evidence for the 
presence of a TSG on human chromosome 18 was demonstrated when the 
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introduction of this chromosome into pancreatic cancer celfs resulted in 
suppression of their tumorigenic phenotype 184. 
Cytogenetic, allelotype and somatic cell hybrid studies have shown that 18q may 
carry a TSG that plays a role in the carcinogenesis of PCa. The introduction of 
18q into the commonly used PCa cell line DU 145 and PC-3 completely 
abolished their tumorigenicity 189, 193. Moreover, LOH on 18q was reported in 30-
40% of PCa patients, indicating that it may play a role in PCa progression 66. 
Two minimally lost regions have been described: one of them is between 
018S1119 and 018S64, and the other is located between 018S848 and 
o 18S58. However, no previously isolated TSG maps to these intervals 191. 
The chromosomal band 18q21 harbours the tumor suppressor genes DCC 
(deleted in colorectal cancer), SMA0410PC4 (deleted in pancreatic cancer 4), 
and SMA02l0PC2 (deleted in pancreatic cancer 2) 194. SMA02 and SMA04 are 
components of the signalling pathways of serine-threonine kinase receptors for 
TGF-beta 190, but none of these genes is mutated in PCa specimen 195. 
However, the loss of SMAD2 and SMAD4 protein expression. is linked to 
increased Gleason score 196. The long arm of chromosome 18 also encodes for 
the well-known oncogene BCL2, as weil as the MSG MASPINISERPINB5, 
which is implicated in PCa progression. 
The BCL-2 oncogene is located on the long arm of chromosome 18, and is 
implicated in PCa progression. It encodes an anti-apoptotic protein that is 
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localized to the ~itochondrial outer membrane. It prevents apoptosis by 
suppressing the release of the caspase-activating protein cytochrome c trom 
mitochondria 197. In normal prostate tissue, the expression of BCL-2 is confined 
to basal cells and undetectable in secretory cells. This correlates with the level 
of differentiation of these two kinds of cells. This protein was also found in BPH 
but not in PIN 198. BCL2 and BCL-X levels were found to correlate with the 
development of PCa, which suggests that they are associated with a hormone-
insensitive metastatic phenotype 199. 
However, despite ail the studied oncogenes (RAS, CDKN1A, EZH2, HER-2-
NEU, BCL2 for example), none of them has been linked conclusively to the 
initiation or early progression of PCa. 
The MSG MASPIN (SERPINB5) is located on chromosome 18, and encodes a 
serine protease inhibitor. In human primary PCa, MASPIN expression is 
consistently down regulated at the critical transition from non-invasive, low-
grade disease to highly invasive, high-grade PCa 200. The reduced MASPIN 
expression in these patients correlates with a high Gleason grade 201. Stable cell 
lines expressing MASPIN had decreased tumorigenic potential, as assessed by 
anchorage independent growth in soft agar assay compared to controls. 
MASPIN stable transfectants showed decreased metastatic potential and 
increased adhesion to fibronectin and laminin 135. 
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Chromosome 19 
The TSG CEACAM1 is located on chromosome 19, and encodes a cell-
adhesion molecule of the immunoglobulin superfamily. The protein has four 
extracellular Ig-like domain and a cytoplasmic domain 136. It has also been 
shown to mediate homophilic cell adhesion through its first Ig domain 202. The 
anti-tumor effect of CEACAM1 may be due to inhibition of tumor angiogenesis 
by increased secretion of antiangiogenic factors from the cells. Its expression in 
DU 145 cells induces the production of a factor that specifically blocks the 
growth of endothelial but not epithelial cells 136. In patients, down regulation of 
CEACAM1 is associated with loss of cell polarity. It coincides with the formation 
of the complex glandular architecture of Gleason grade 4 pattern 203. 
1.6 Hypothesis 
As described in this chapter, almost every human chromosome has been shown 
to encode TSGs and/or MSGs implicated in PCa progression. Thus, we 
hypothesize that by transferring the chromosomes that are the most frequently 
lost during PCa progression, we could identify chromosomal regions encoding 
TSGs/MSGs implicated in this disease. Such an approach also represents the 
first step in identifying the suppressor genes themselves. 
As mentioned previously, we chose to use the MMCT technique, as it is a 
powerful tool to identify chromosomes/regions encoding TSGs/MSGs. The PC-3 
cell line was isolated from a bone metastasis of a patient; bone metastases 
represent the deadly part of this disease. We used PC-3-derived cell lines PC-
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3M-Pro4 and PC-3M-LN4 since they have, when orthotopically injected, different 
tumorigenic and metastatic properties (PC-3M-Pro4 grows rapidly in the 
prostate, whereas PC-3M-LN4 is also very aggressive and metastasizes to 
Iymph nodes). These cell Iines have been previously selected in vivo by several 
passages in the prostate of nude mice. Thus, they have been exposed to the 
prostate microenvironment and are most Iikely to mimic the disease than other 
models isolated from a brain metastasis (DU 145) or rat PCa cells (Dunning). 
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1.7 Goals of this study 
ln order to further characterize the suppressor genes implicated in PCa 
progression, the aims of this study were to: 
1. Transfer human chromosomes that are implicated in PCa progression 
into two PC-3-derived ceillines (PC-3M-Pro4GP1 and PC-3M-LN4GP2). 
2. Identify chromosome(s) that suppress (es) the tumorigenic properties of 
these PCa cells both in vitro and in vivo. 
3. Characterize in vitro and in vivo the hybrids containing an exogenous 
copy of human chromosome 18. 
4. Identify the region on chromosome 18 that is responsible for the les-
tumorigenic phenotype seen in our hybrids. 
5. Characterize candidate genes present in this region 
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CHAPTER2 
MATERIAL AND METHODS 
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2.0 Preface 
The material and methods are described in five major sections corresponding to 
the order of the experiments in Chapters 3, 4, and 5. 
(a) Microcell-mediated chromosome transfer into prostate cancer cells. 
(b) Characterization of microcell hybrids in vitro. 
(c) Nude mice injections of microcell hybrids. 
(d) Chromosome 18 mapping and identification of the region containing the 
tumor suppressor gene. 
(e) Characterization of candidate genes 
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2.1 Microcell-mediated chromosome transfer into prostate cancer cells 
2.1.1 Ceillines and culture 
2.1.1.1 PCa ceillines 
PC-3M-LN4 and PC-3M-Pro4, obtained from I.J. Fidler (Department of Cancer 
Biology, The University of Texas M. D. Anderson Cancer Center, Houston, 
Texas, 77030), were derived from orthotopic injections of PC-3M cells into the 
prostate of nude mice 204. PC-3M-LN4 is a highly metastatic (Iymph node) 
human PCa cell line, while PC-3M-Pro4 grows very aggressively in the prostate. 
PC-3M was derived from the PC-3 cell line obtained from a bone metastasis of a 
patient with PCa 205. PC-3M-LN4 and PC-3M-Pro4 were kept in RPMI 1640 
supplemented with 10% fetal bovine serum (FBS, Invitrogen, Burlington, ON, 
Canada). The geneticin-resistant PC-3M-LN4GP2 and PC-3M-Pro4GP1 cell 
lines were generated upon Lipofectamine 2000 (LF2000, Invitrogen) transfection 
of the pQBI25 plasmid (Q-BIOgene, Carlsbad, CA, USA). These cells were kept 
in RPMI 1640 with 10% FBS and 400 ug/ml of geneticin (Invitrogen). B78MC 
hybrids are microcell hybrids from our mouse/human hybrid panel 206, and 
contain tagged human chromosomes in the B78 mouse melanoma background. 
B78MC hybrids were kept in DMEM (Dulbecco's modified Eagle medium; 
Invitrogen) supplemented with 10% FBS and 400 ug/ml of hygromycin B (Roche 
Diagnostics, Laval, QC, Canada). The Pro4B- and LN4B-microcell hybrids were 
grown in RPMI 1640 with 10% FBS, 400 ug/ml of geneticin and 400 ug/ml of 
hygromycin B. 
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2.1.1.2 Generation of ceillines expressing green fluorescent protein 
Prior to transfection, the ceUs were plated at 40% confluency. The next day, 5 ug 
of pQBI25 plasmid DNA suspended in 250 ul of Opti-MEM (Invitrogen), was 
mixed with 5 ul of LF2000 (1 mg/ml) diluted in 250 ul of Opti-MEM, and incubated 
20 mins at room temperature. Meanwhile, the ceUs were washed with 2 ml of 1X 
PBS (0.137 M NaCI; 2.7 mM KCI; 10.14 mM Na2HP04; 1.76 mM K2HP04; pH 
7.4). Then, serum-free media (RPMI 1640) and the DNA-LF2000 mix were 
added to the flasks. The ceUs were then placed at 37°C with 5% C02 for 5 hours. 
The DNA-LF2000 complex was removed and replaced with complete media 
(RPMI 1640 supplemented with 10% FBS). On the next day, the cells were 
diluted 1: 10 and incubated for 24 hours after which selective media was added 
(RPMI 1640 supplemented with 10% FBS and 400 ug/ml of geneticin). Clones 
were picked 10 days after transfection, and were called PC-3M-Pro4GP1 to 3, 
and PC-3M-LN4GP1 to 5. 
2.1.2 Microcell-mediated chromosome transfer 
The microceU-mediated chromosome transfers were done essentially as 
described by Fournier in 1981 207 (Table 2). Briefly, plastic bullets, made from 
the bottom of 150 mm Petri dishes, were sterilized overnight in 95% ethanol. 
Bullets were then dried in a laminar flow hood for 1 hour (bullets were inverted 
after 30 mins). A sterile 15 mg/ml solution of concanavalin A (Sigma, Oakville, 
ON, Canada), and a sterile 75 mg/ml WSC (1-cyclohexyl-3-(2-morpholinoethyl) 
carbodiimide metho-o-toluene-sulfonate, Sigma) solution were prepared in 0.9% 
NaCI. The bullets were crosslinked with concanavalin A and WSC for 1-2 hours. 
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Table 2. Microcell-mediated chromosome transfer schedule 
Day 1 Day2 Day3 Day 4 Day 5 
Sterilize Crosslink Prepare Trypsinize Add selection 
bullets bullets microcells fused cells 
Micronucleate Perform 
donor cells fusion 
49 
The mixture was removed, and the bullets were washed and stored in sterile 
PBS overnight at 4°C. The next day, donor cells (1 x 106 B78MC hybrids in 
1.2 ml of PBS) were spread on dried bullets. The bullets were flooded with 
40 ml of complete media (DMEM with 10% FBS and 400 ug/ml of 
hygromycin B), and incubated at 37°C for 2 hours. B78MC hybrids 
containing different tagged chromosomes (10, 10p, 12, 18, translocated 3 
and 17) were micronucleated in presence of colcemid (0.06 J.1g/ml) (Sigma, 
Oakville, ON, Canada) for 24 hours. Micronucleated cells were harvested in 
enucleation media (500 ml of serum-free media with 10 ug/ml of cytochalasin 
B (Sigma» at 27,000g for 30 mins at 28 to 34°C. The microcells were then 
resuspended in 15ml of serum-free media, and filtered through 8 um and 5 
um polycarbonate filters (Fisher Scientific) to eliminate intact cells. The 
microcells were centrifugated and resuspended in 1 ml of serum-free media. 
Meanwhile, recipient cells (PC-3M-Pro4GP1 and PC-3M-LN4GP2) were 
plated in 25 cm2 flasks (Fisher Scientific, Nepean, ON, Canada) until70-80% 
confluency on the day of microcell fusion. These recipient cells were rinsed 
with serum-free media, and then 1 ml of microcells suspended in serum-free 
media and 1 ml of phytohemagglutinin (PHA; 200 ug/ml) were added to each 
flask and incubated 15 mins at 37°C. PHA was removed and cell fusion was 
performed in presence of 50% (w/w) polyethylene glycol 1600 (Fisher 
Scientific) for 60 sec. The cells were rinsed three times with serum-free 
RPMI1640 medium, and complete medium (RPMI 1640 with 10% FBS) was 
added to the flask and incubated overnight. The resulting microcell hybrids 
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(Pro4B ... and LN4B ... ) were selected in RPMI 1640 medium containing 10% 
FBS + 800 ~g/ml hygromycin B + 800 ~g/ml geneticin. Individual hybrids 
(clones) were picked after 21 days, expanded and characterized. 
2.2 ln vitro characterization of microcell hybrids 
2.2.1 Confirmation of chromosome transfer 
2.2.1.1 Alu-PCR FISH 
B78MC hybrids could contain between one and few human chromosomes. 
Since mouse chromosomes do not contain Alu repetitive elements in 
contrast to human chromosomes, a rapid screening of these hybrids was 
performed using the Alu PCR FISH technique 208, 209. Briefly, human inter-
Alu DNA sequences are amplified using the following four Alu primers: 
451 (5' -GTGAGCCGAGATCGCGCCACTGCACT -3'), 
450 (5'-AAAGTGCTGGGATTACAGG-3'), 
153 (5'-GGGATTACAGGCGTGAGCCAC-3') and 
154 (5'-TGCACTCCAGCCTGGGCAACA-3') (Sigma). 
The amplified products were labelled with biotin, and used as probe in 
Fluorescence ln situ hybridization (FISH) on normal human chromosome 
spreads 210. Under these conditions human chromosomes present in the 
B78MC hybrids could be identified, based on their size and on the position of 
their centromere as mouse chromosomes are often acrocentric and will not 
hybridize to the Alu probe. 
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2.2.2 Microsatellite mapping 
To determine which specific human chromosome(s), or chromosome 
fragment(s) was/were transferred in each 878MC hybrids; genomic mapping 
using microsatellite markers was performed. 
2.2.2.1 Genomic DNA extraction 
High quality genomic DNA was obtained as follows: 70-80% confluent cells 
were rinsed twice with 0.9% NaCI, scraped off the plate, and centrifugated at 
16,250g. The cell pellets were mixed to 300ul of fresh TSM (140 uM NaCI, 
10 uM Tris-HCI, pH 7.4, 1.5 mM MgCb) + 0.5% NP40 (nonidet P 40, Sigma) 
and incubated on ice for 3 mins. The cells were then harvested 10 sec by 
centrifugation at 16,250g, and the pellets were resuspended in nuclei 
dropping buffer (0.075 M NaCI, 0.024 M EDTA, pH 8.0) containing 0.2 mg/ml 
of proteinase K (Roche Diagnostics) and 0.5% sodium dodecyl sulfate 
(SOS), and incubated overnight at 37°C. 5 ml of water and 5 ml of 6M NaCI 
were added and the samples were mixed for 2 hours. The cells debris were 
removed by centrifugation at 755g for 20 mins, and two volumes of 100% 
ethanol were added to the supernatant. The precipitated DNA was then 
spooled and resuspended overnight in TE (10mM Tris-HCI, pH 8.0, 1 mM 
EDTA, pH 8.0) and re-precipitated by adding % volume of 7.5 M NH4acetate 
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and two volumes of 100% ethanol. The DNA was then spooled and 
resuspended in TE-4 (10 mM Tris-HCI, pH 8.0,0.1 mM EDTA, pH 8.0). 
2.2.2.2 Mi~rosatellite mapping 
PCR reactions were carried out in 1 X PCR buffer, 75 uM of dNTPs without 
dCTP, 0.66 uM dCTP, 0.01 umol of Alpha 32p_dCTP, 0.05U of Taq DNA 
polymerase, 1.6 uM of each primer, and 100 ng of genomic DNA. The 
following PCR program was used: 94°C for 2 mins, followed by 35 cycles of 
94°C for 30 secs, annealing temperature (from 53 to 65°C according to each 
primer pair) for 30 secs, and 72°C for 30 secs, and a final extension at 72°C 
for 10 mins. After PCR amplification, 10 ul of sequenase stop solution (95% 
formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene 
cyanol) were added. The stopped PCR reactions were denatured at 95°C for 
5 mins, and electrophoresed through a 4% acrylamide gel. The gel was dried 
for 2h at 80°C, and autoradiographed overnight in order to reveal the 
amplified microsatellites. 
2.2.3 Invasion assay 
We used a Boyden chamber assay 211 to assess invasive potential. Briefly, 
25,000 cells were added to the chamber coated with Matrigel (Fisher 
SCientific), and RPMI 1640 medium supplemented with 5% FBS was added 
to the bottom chamber to serve as chemoattractant. The chambers were 
incubated at 37°C for 22 hours, and filters were stained with a Diff-Quick 
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staining kit (Dade Behring, Newark, DE). Invasive cells from flVe random 
fields were counted under a contrast phase microscope at 200X 
magnification. Ali invasion experiments were performed twice in 
quadruplicate (n=8), and the results were expressed as percentage of the 
invasion obtained with the parental cell line. 
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2.2.4 Soft agar assay 
Soft agar assays were performed according to Rizzino, 1987 212. Briefly, a 
1 ml base layer of 0.5% agar is poured into each of 6 wells. Then, the cells 
are trypsinized, counted and resuspended to a concentration of 3,000 cells 
per ml. The top layer of agar (2 ml of media containing 0.5% agar) is mixed 
with one ml of cells (3000 cells), and put on the top of the base layer. The 
plates are incubated for 10 days in a 37°C incubator with 5% CO2, stained 
with crystal violet, scanned with a PowerLook 2100XL scanner (UMAX, 
Dallas, TX), and counted on the computer screen. In sorne cases, qualitative 
assessment of growth was performed; where colony formation of hybrids 
was compared to those of parental cell lines which were arbitrary assigned 
the symbol +++ (with a varying scale of 0 to ++++). Each soft-agar assay 
was performed three times on six wells per cell line (n=18) and the p values 
were calculated using a two-tailed Student's t-test (see Chapter 4 for 
details). 
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2.3 ln vivo characterization of microcell hybrids 
2.3.1. Nude mice injections 
Ali mouse injections were done according to Canadian Council for Animal 
Care guidelines, after approval by the McGiII University Animal Care 
Committee. For the nude mouse injections (nu/nu; six to eight weeks of age; 
Charles River Laboratory, St-Constant, QC, Canada), the cells were 
trypsinized, counted, and resuspended in 1X HBSS (Hank's balanced salt 
solution, 0.4 mM KH2P04, 0.6 mM MgS04, 5.4 mM KCI, 1.3 mM CaCb,; 
Invitrogen) at 1 million cells in 200 ul for subcutaneous injections, and one 
million cells in 16.6 ul for orthotopic injections. Mice were monitored, and 
weighed three times per week, and were sacrificed when the subcutaneous 
tumor reached 1000mm3, or when the animais became moribund for 
orthotopic injections. Five mice were injected for each cell line tested (see 
chapter 4 for details). 
2.3.2 Tumor processing 
Tumors were excised, and digested twice for 15 mins at 37°C with type 1 
collagenase (Invitrogen). The cells were seeded into flasks, and fed with 
complete media supplemented with antibiotics. Two days later, complete 
media containing selective agents and antibiotics was added (see chapter 4 
for details). 
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2.4 Chromosome 18 mapping and identification of the region encoding 
the tumor suppressor gene 
2.4.1 Genotyping of human chromosome 18 
We characterized our chromosome 18 hybrids by using 27 microsatellite 
markers (see Table 5 in chapter 4 and section 2.2.2.2 for details). Briefly, 
100 ng of genomic DNA from our hybrids was amplified in presence of 32p_ 
dCTP in triplicate with microsatellite markers and electrophoresed through a 
4% acrylamide gel. The gel was dried, and autoradiographed to X-Ray film 
overnight. 
2.4.2 Microarray experiment 
2.4.2.1 RNA extraction 
Briefly, the cells were scraped off the tissue culture plate, centrifugated, and 
mixed with TSM + NP40 as described previously (section 2.2.2.1). After a 3 
mins Iysis on ice, the cells were harvested, and the supernatant was mixed 
with TSE + S (10mM Tris-HCI, pH 7.4, 150mM NaCI, 5mM EDTA, pH 7.4, 
0.2% SOS). After, two phenol-chloroform-isoamyl alcohol (25:24:1) (Fisher 
Scientific), and one chloroform-isoamyl alcohol (24:1) extractions were done. 
The RNA was then precipitated with 1/10 volume of 3 M sodium acetate 
(NaOAc), 2 volumes of 100% ethanol, and 10 ug of glycogen (Roche 
Diagnostics) at -80°C overnight. The samples were centrifugated for 15 
mins at 4°C and the pellets were rinsed twice with 70% ethanol, air-dried, 
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and resuspended in OEPC-treated water (Sigma). Each sample was 
electrophoresed through aga rose gel to assess its quality. 
2.4.2.2 Microarray experiments 
We used a 19k3 cONA microarray (Microarray Center at University Health 
Network, Ontario Cancer Institute, Toronto, ON, Canada) containing more 
than 19 200 human genes or ESTs spotted in duplicate. Three separate 
experiments were done comparing the expression profile of different sets of 
hybrid cells, as weil as a subcutaneous tumor derived from our less 
tumorigenic hybrids: LN4B156-2 vs LN4B156-6 in duplicate by swapping the 
dyes and TLN156-6-3 vs LN4B156-6. 
The reverse transcriptase labelling reactions were prepared in the following 
mix: 1X First strand buffer (Invitrogen), 150 pmol of AncT primer (Sigma), 5 
mM of dNTP-dTTP (Amersham Pharmacia, Baie d'Urfée, QC, Canada), 1.5 
mM of dTTP (Amersham Pharmacia), 1.5 mM of AA-dUTP (Sigma), 0.1 M of 
OTT (Invitrogen), 2 ng of Arabidopsis control RNA, and 10 ug of total RNA 
(see section 2.4.2.1). The reactions were incubated at 65°C for 5 mins, then 
at 42°C for 5 mins. SuperScriptil reverse transcriptase (O.03U; Invitrogen) 
was added, and the reactions were incubated at 42°C for 2 to 3 hours. The 
reactions were incubated at 95°C for 5 mins. 2 mM of NaOH was added, and 
the reactions were heated at 65°C for 15 mins. Then, 2 mM of HCI and 1 mM 
of Tris-HCI, pH7.5 were added to neutralize the reactions. The labelled 
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cDNA were purified using the Amicon Microcon PCR purificatiOA columns 
(Fisher Scientific) following manufacturer's instructions. To the purified 
samples, 1.8 mM of NaHC03 pH 9.0, and each dye (Alexa 555 and Alexa 
647, Molecular Probes, Burlington, ON, Canada) were added. The reactions 
were incubated in the dark for 1 hour. They were purified using microcon 
column as described previously, and were combined together. Then, 1/10 
volume of 3M NaOAc, 1 volume of 95% isopropoanol (Fisher Scientific), and 
10 ug of glycogen were added. The samples were precipitated at -20°C for 
30 mins, centrifugated at 16,250g for 10 mins, the pellets were washed with 
70% ethanol, and resuspended in 5 ul of Sigma water. 
A hybridization solution was prepared (20:1 :1, Dig Easy Hyb (Roche 
Diagnostics): sonicated calf thymus DNA (10 mg/ml) (Sigma): yeast tRNA 
(10 mg/ml) (Invitrogen)), and incubated at 65°C for 2 mins. The combined 
Alexa 555/Alexa 647 reactions were added to the hybridization solution, and 
incubated at 65°C for 3 mins. The reaction was then loaded onto the 
microarray, and incubated in a moist chamber (VWR, Mississauga, ONT, 
Canada) (filled with Dig Easy Hyb) overnight at 37°C. Washing solutions 
were prepared as following: 1X SSC + 0.1% SDS (preheated to 50°C), and 
1X SSC at room temperature. Three staining dishes (Diamed, Mississauga, 
ONT, Canada) were filled with preheated 1X SSC + 0.1% SDS, and placed 
in a 50°C water bath. Two staining dishes were filled with room temperature 
1 X SSC. The first 1 X SSC container was used to split the two slides by 
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dipping and agitating them. The slides were washed three times 15 mins 
each in 1X SSC + 0.1% SOS at 50°C. The slides were rinsed in 1X SSC, 
th en in 0.1X SSC, spin-dried at 45g for 5 mins, and stored at 4°C in the dark. 
The microarrays were scanned using SCANarray 5000 (Perkin Elmer, 
Woodbridge, ON, Canada), and the fluorescent signais of the dyes were 
quantified using QuantArray version 3 (Perkin Elmer). The data analysis was 
done using the R software version 2.1.1 (www.r-project.org). The data were 
normalized within each slide using the loess sub-grid method. They were 
further normalized between the slides with the quantile method. Then, the 
data were submitled to a linear model (SAM, significant analysis of 
microarrays) to get the significant differentially expressed genes. 
2.5 Characterization of candidate genes located around the D18S51 
region 
2.5.1 Real-time PCR 
The expression of the ERK4 and MASPIN genes were assessed by real-time 
quantitative PCR. The amplification was adjusted to the GAPDH expression 
level, and gene-specifie Quantitect primers (Qiagen, Mississauga, ON, 
Canada) were used for PCR amplification. A PCR mix was prepared for each 
sample tested: 1X of 2X DyNAmo SYBR Green qPCR kit (New England 
Biolabs, Pickering, ON, Canada), 1X Quantitect primer mix (Qiagen), 50 ng 
of Reverse Transcriptase reaction in a final volume of 25 ul. The PCR 
efficiency of each primer set was determined by sequential dilutions of the 
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purified PCR amplicon (1:4 to 1 :256). PCR reactions were electmphoresed 
through an aga rose gel, and a dissociation curve was added to the PCR 
program to make sure that the right amplicon was amplified; each reaction 
was repeated 8 times. The following PCR program was run on an MXI4000 
(Stratagene, LaJolla, CA, USA) thermal cycler: stage 1: 50°C for 2 mins, 
stage 2: 95°C for 15 mins, stage 3: 40 cycles of 95°C for 15 secs, 60°C for 
15 secs, and 72°C for 32 secs and stage 4: 95°C for 15 secs, 50°C for 15 
secs, and 95°C for 15 secs. The mean Ct (cycle threshold) and standard 
deviation were calculated using Microsoft Excel 2000. The delta Ct (CtTARGET 
- CtGAPDH) and its standard deviation were calculated using the same 
program. The delta-delta Ct method was use to calculate the fold changes 
as recommended by the manufacturer, and a Student t-test was used to 
determine the significance of the findings. 
2.5.2 Western immunoblot 
Cells were grown to 90% confluency and washed twice with cold PBS. 
Then, the cells were scraped off in Brij97 Iysis buffer (1 % Brij 97,25 mM 
Hepes, pH 7.4,150 mM N.aCI, 5 mM EDTA, 1 mM Na3V04, 10 mM P-
glycerophosphate, 10 mM pyrophosphate, 100 units/ml aprotinin, 1 0 ~g/ml 
leupeptin, 25 ~M p-nitrophenyl p'-guanidino-benzoate, 1 mM 
phenylmethylsulfonyl fluoride, 10 mM iodoacetamide) (ail reagents are fram 
Sigma), and incubated on ice for 5 mins. The Iysed cells were then 
centrifugated at 13,000g for 10 mins at 4°C. The supernatants were 
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combined and the proteins were quantified with the BCA protein assay kit 
(Pierce Biotechnology Inc., Rockford, IL, USA), according to the 
manufacturer's protocol. Fort Y micrograms of proteins were boiled 5 mins in 
2X Laemmli buffer (62.5 mM Trsi-HCI pH 6.8, 40% v/v glycerol, 5% SOS, 
0.005% bromophenol blue containing 10% of P-mercaptoethanol (Sigma», 
and electrophoresed through a 10% acrylamide SOS-PAGE gel. The 
proteins were then transferred (1 hour) onto a nitrocellulose membrane (Bio-
Rad laboratories, Hercules, CA, USA), and blocked for 1 h in TBST (25 mM 
Tris-HCI pH 8.0, 125 mM NaCI, 0.1 % tween 20) + 5% non-fat dry milk (Bio-
Rad Laboratories). The membranes were incubated overnight with the 
appropriate primary antibody in TBST + 5% non-fat dry milk. For the BCL2 
and MASPIN proteins, monoclonal anti-human antibodies were used 
(Chemicon, Temecula, CA, USA) at a 1 :5000 dilution. For the ERK4 protein, 
a polyclonal antibody was obtained from Dr. Sylvain Meloche's laboratory 
(IRIC, Université de Montréal, Montreal, QC, Canada), and used at a dilution 
of 1 :2000 (a peptide located in the C-terminal portion of ERK4 (amino acids 
361 to 497) was used to immunize rabbits and generate a polyclonal 
antibody). After 16 hours, the membranes were washed 3 times for 15 mins 
in TBST, and incubated 1 h at room temperature with the secondary antibody 
conjugated to horseradish peroxydase (donkey anti-rabbit for ERK4 (Bio/Can 
Scientific, Etobicoke, ON, Canada) and goat anti-mouse for MASPIN and 
BCL2 (Fisher Scientific» in TBST + 5% non-fat dry milk. The bound 
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antibodies were detected using the ECL detection kit (GE Healthcare, Baie 
d'Urfe, QC, Canada). 
2.5.3 Proteasome inhibition 
Since the ERK4 protein was undetectable in our cell lines, they were treated 
for 12 hours with 25 uM of the proteasome inhibitor MG132 (Cedarlane, 
Hornby, ON, Canada). As a control, cells were also incubated in PBS for 12 
hours. Proteins were extracted and Western immunoblotled using the 
polyclonal anti-ERK4 antibody (see section 2.5.2 for the procedure). 
2.5.4 Sequencing 
The entire coding sequence of the ERK4 gene was amplified using the 
Phusion high-fidelity DNA polymerase (New England Biolabs), according to 
manufacturer's instructions. Briefly, a PCR reaction containing 1X Phusion 
HF buffer, 200 uM of each dNTP, 0.5 uM of each primer, 0.02 U/ul of 
Phusion DNA polymerase, 100 ng of genomic DNA or 50 ng of cDNA was 
prepared in a final volume of 20 ul. The following PCR program was ran: 
98°C for 30 secs, followed by 40 cycles of 98°C for 10 secs, annealing 
temperature for 30 secs and 72°C for 30 secs with a final extension of 72°C 
for 10 mins. The primers used for amplification of the ERK4 mRNA or 
genomic DNA were: 
mapk464 (5'-TGGGCAGCTCCAGATCACTG-3') and 
mapk802c (5' -ACGATGT ACGCCACGCTGAA-3') 
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(for mRNA or genomic DNA); 
mapk672 (5' -CACGCGCTCCGAGAGATCAA-3') and 
mapk1520c (5'-GTTAGCGGCCATCAGCACGA-3') (for mRNA); 
mapk1487 (5'-GAGATCGACGACATCGTGCT -3') and 
mapk1841 c (5' -AGTAGTGGTGCGGCTTGTTG-3') (for mRNA). 
The annealing temperatures varied from 60 to 69°C. The PCR reaction 
products were electrophoresed through a 1.5% agarose gel, the amplified 
product was extracted from the gel using the Qiagen gel extraction kit, and 
sent to the McGill University and Genome Quebec Innovation Centre 
(Montreal) for sequencing. The primers used for sequencing were the same 
as the ones used to perform the PCR amplification. Briefly, the PCR 
products were purified and resuspended in 2 ul to be amplified with the Big 
Dye Terminator (Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer's protocol. The following PCR conditions were used for 
amplification: 96°C for 1 min, 25 cycles of 96°C for 30 secs, 50°C for 10 
secs, 60°C for 4 mins. The PCR products were precipitated, centrifugated, 
washed, dried, and the pellets were resuspended in formamide. The 
fluorescence was then read on an ABI 3730xl DNA analyser (Applied 
Biosystems). 
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2.5.5 ERK4 vector construction and transfection 
We obtained the ERK4 expression vector from Dr. Sylvain Meloche. The 
vector pcDNA3ERK4-wt encodes the normal sequence of the ERK4 gene. 
The full-Iength ERK4 insert was introduced into the pcDNA4 His/Max B 
vector (Stratagene). This introduces a His tag at the N-terminal of the 
protein. The construct was then transfected into PC-3M-LN4GP2 cells (see 
section 2.1.1.2 for transfection procedure). Clones were selected in 
presence of zeomycin (800 ug/ml). ERK4 protein over expression was 
confirmed by Western immunoblot (see section 2.5.2 for the Western blot 
protocol), using the polyclonal antibody obtained from Dr. Sylvain Meloche's 
laboratory (see section 2.5.2 for details). 
2.5.6 Characterization of ERK4 transfectants 
Transfected cells over expressing or not the ERK4 protein were assessed by 
invasion and soft agar assays as described previously (sections 2.2.3 and 
2.2.4). 
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CHAPTER3 
Published manuscript: 
Chromosome 18 suppresses the 
tumorigenic properties of human prostate 
cancer cells 
Gagnon A., Ripeau J-S, Zvieriev V., and Chevrette M. 
Genes Chromosomes and Cancer, 2006, 
Mar; 45(3): 220-230. 
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3.0 Preface 
This published manuscript summarizes the results obtained by transferring 
human chromosome 18 into the PC-3-derived prostate cancer ceU line PC-
3M-Pro4GP1 and PC-3M-LN4GP2. It highlights the different properties of 
our chromosome 18 hybrids and the process by which we narrowed down 
the region encoding a new TSG to about 10Mb on the long arm of 
chromosome 18. The proof of this published manuscript can be found in 
Appendix C and the permission from publishers in Appendix B. We also 
included a preface summarizing the construction of the B78MC hybrid panel 
as weil as the transfer of chromosomes 8, 10, 12, and t(17:3, with unknown 
breakpoints ). 
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3.0.1 A mouse/human hybrid panel 
ln the 1990's, Dr. Chevrette's laboratory used normal human foreskin 
fibroblasts (HSF), along with the mou se melanoma cell line 878, to generate 
a mouse/human hybrid panel 206. 8riefly, the tgCMV-HyTk plasmid encoding 
the hygromycin phosphotransferaselthymidine kinase fusion gene 213 was 
introduced into the HSF cell population. 8y doing 50, at least one human 
chromosome per cell was tagged, and could then be transferred into another 
cell. This allows positive selection of the tagged chromosome with 
hygromycin 8, and its negative selection using gangiclovir. Microcell-
mediated chromosome transfer (see section 2.1.2) was used to transfer the 
tagged chromosomes from HSF to the 878 mouse melanoma cell line. The 
resulting hybrids (over 200 were isolated) were named 878MC hybrids 
(where MC stands for microçell) (Figure 4). 
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Figure 4. Scheme of the construction of the 878MC hybrid panel. Microcell-
mediated chromosome transfer was used to introduce normal human 
chromosomes from HSF into the mouse melanoma cell line 878. The 
resulting hybrids, selected in presence of hygromycin 8 and ouabain (mou se 
cells are naturally more resistant to ouabain than their human counterparts) 
were mouse/human hybrids containing one or more normal human tagged 
chromosomes. 
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3.0.2 Characterization of the B78MC hybrids by PCR 
A PCR based assay was used to identify which human chromosomes were 
present in each 878MC hybrid. 8riefly, PCR reactions were done using 
human based microsatellite markers from Invitrogen. Three different markers 
per chromosome were used (Table 3). The PCR program was as follow: 
94°C 2 mins, 94°C 45 secs, annealing temperature between 53°C and 62°C 
45 secs, 72°C 1 min, 35 cycles and 7 mins at 72°C. The reactions were 
electrophoresed through an aga rose gel (Figure 5). To ensure that no 
contaminant was amplified, a normal human cell line (HSF) was used as 
positive control and the mouse melanoma cell li ne 878 as a negative control 
(data not shown). 
3.0.3 Microcell-mediated chromosome transfer 
As mentioned in Chapter 1, sorne genetic alterations are specifie for PCa 70. 
Therefore, using our mouse/human hybrid panel, we have transferred sorne 
of the most important chromosomes for PCa progression (chromosomes 10, 
12, 17, and 18) into two PCa cell lines. The following 878MC hybrids, and 
the human chromosomes (chr) they contained were used. 878MC75 (chr 
10), 878MC77 (chr 10), B78MC9 (chr 12), 878MC57 (t(17:3) with unknown 
breakpoints) and 878MC156 (chr 18). The presence of these human 
chromosomes in different hybrids was also confirmed using Alu-PCR-FISH 
(data not shown). 
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Table 3. Mierosatellite makers used to eharaeterize B78MC hybrids 
Chromosome Polymorphie Position on the PCR produet PCR-
(estimated mierosatellite ehr (Mb) length (bp) annealing 
size based on marker (based on NCBI temperature 
NCBI database) 
database) 
1 (254Mb) 01S468 p arm (3Mb) 171-223 53 
01S2809 parm(11Mb) 123-147 53 
01S423 P arm (23Mb) 162-168 53 
6 (171Mb) 06S254 P arm (70Mb) 250-264 57 
06S278 P arm (108Mb) 125-139 55 
06S305 P arm (162Mb) 204-230 55 
7 (158Mb) 07S639 P arm (67Mb) 261 53 
07S527 . P arm (93Mbl 273-297 53 
07S666 p arm (99Mbl 155-169 57 
07S498 q arm (142Mbl 137-153 53 
8 (146Mb) 08S1824 P arm (3Mbl 226-248 53 
08S511 _p arm (13Mbj 135 55 
08S1731 P arm (14Mb) 217-241 57 
08S1821 P arm (38Mb) 144-168 57 
10 (135Mb) 010S196 q arm (47Mb) 99-109 53 
010S1692 q arm (104Mbl 182-211 57 
010S169 q arm (128Mbl 99-117 53 
12 (132Mb) 012S368 q arm (51Mbj 200-216 62 
012S325 q arm (53Mbj 209-229 55 
012S90 q arm (57Mbj 166-182 55 
13 (114Mb) o 13S279 q arm (70Mb) 241-257 53 
013S1230 q arm (88Mbl 217-275 53 
013S261 q arm (11 OMbl 169 53 
16 (88Mb) 016S415 q arm (44Mb) 208-234 55 
016S400 q arm (54Mb) 192-202 53 
o 16S5.04 q arm(70Mbl 267 55 
17 (80Mb) 017S1850 q arm(29Mbl 232-274 55 
017S1853 q arm (54Mbl 130-156 55 
017S1154 q arm (60Mb) 354 57 
18 (76Mb) D18S1148 q arm (56Mb) 132-154 53 
018S1147 q arm (57Mb) 204-232 57 
o 18S554 q arm (72Mb) 167 53 
018S1097 q arm (73Mb) 177-215 54 
Y (57Mb) OYS390 q arm (15Mb) 212 57 
OYS58S2 q arm (22Mb) 267 54 
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Figure 5. Confirmation of chromosomes present in 878MC hybrids. The 
D1751154 microsatellite marker was PCR amplified from different 878MC 
hybrid DNA. The presence of the 264 bp amplicon indicates that these 
hybrids contain this chromosome 17 region (60 Mb). 
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We have chosen two very aggressive PC-3-derived celilines, called PC-3M-
Pro4 and PC-3M-LN4 204, as recipients for our microcell-mediated 
chromosome transfers. For ease of detection, we have transfected both cell 
lines with the pQBI25 plasmid (Q-BIOgene, Carlsbad, CA, USA) encoding 
the green fluorescent protein gene (GFP), and allowing for the selection of 
cells with geneticin (G418). The resulting cell lines were called PC-3M-
Pro4GP1 to 3, and PC-3M-LN4GP1 to 5 (see section 2.1.1.2 for details). 
We fused the different B78MC hybrids with both PC-3M-Pro4GP1 and PC-
3M-LN4GP2, and obtained Pr04BX- (Pro4B75-, Pro4B77 -, Pro4B9-, 
Pro4B57-, Pr04B156-), and LN4BX- hybrids (LN4B77-, LN4B9-, LN4B57-, 
LN4B156-). Analysis of the different hybrids showed that transfer of the se 
different human chromosomes into PCa cells affects a variety of pathways 
implicated in different aspects of tumorigenicity (Table 4). We have choosen 
to concentrate our efforts on the human chromosome 18. 
The results obtained by transferring human chromosome 18 into our two PC-
3-derived cell lines are detailed in the following published manuscript entitled 
"Chromosome 18 suppresses the tumorigenic properties of human prostate 
cancer cells". 
72 
Chromosome 18 suppresses tumorigenic properties of human prostate 
cancer ceUs 
Audrey Gagnon 1, Jean-Sébastien Ripeau 1,2, Valerii Zvieriev 1, and Mario 
Chevrette 1,2* 
1Department of Medicine, Division of Experimental Medicine, McGiII 
University, Montreal, Canada 
2Department of Surgery, Division of Urology, McGiII University, Montreal, 
Canada. 
Footnotes: 
This work was supported by grants from CANVAC and the Prostate Cancer 
Research Foundation of Canada. 
*To whom requests for reprints should be addressed at: Dr. Mario 
Chevrette, The Research Institute of the McGiII University Health Centre, 
1650 Cedar Ave., Room R4-113, Montréal, Québec H3G 1A4, Canada. 
Phone: 514-934-1934 extension 44278, Fax: 514-934-8261, email: 
mchevr@po-box.mcgill.ca 
73 
Running title: 
Chromosome 18 suppresses human prostate cancer tumorigenicity. 
KeyWords: 
Prostate cancer, chromosome transfer, chromosome 18, suppression of 
tumorigenic/metastatic properties. 
3The abbreviations used are: PCa, prostate cancer; FBS, fetal bovine serum; 
FISH, Fluorescence in situ hybridization; TSG, tumor suppressor gene; chr, 
chromosome. 
74 
3.1 Abstract 
Although prostate cancer is still the most diagnosed cancer in men, most 
genes implicated in its progression still remain to be identified. Chromosome 
abnormalities have been detected in human prostate tumors, and many of 
them are associated with prostate cancer progression. Indeed, alterations 
(including deletions or amplifications) of more than fifteen human 
chromosomes have been reported in prostate cancer. We hypothesized that 
transferring normal human chromosomes into human prostate cancer cells 
will interfere with their tumorigenic and/or metastatic properties. We have 
used microcell-mediated chromosome transfer to introduce human 
chromosomes 10, 12, 17, and 18 into highly tumorigenic (PC-3M-Pro4) and 
highly metastatic (PC-3M-LN4) PC-3-derived cell lines. We have tested the 
in vitro and in vivo properties of these hybrids. Introducing chromosome 18 
into the PC-3M-LN4 prostate cancer cell line greatly reduced its tumorigenic 
phenotype. We observed retarded growth in soft agar, decreased 
invasiveness through Matrigel, and delayed tumor growth into nude mice, 
both subcutaneously and orthotopically. This phenotype is associated with a 
marker present in the 18q21 region. Combined with the loss of human 
chromosome 18 regions often seen in patients with advanced prostate 
cancer, our results show that chromosome 18 encodes one or more tumor 
suppressor genes whose inactivation contributes to prostate cancer 
progression. 
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3.2 Introduction 
With an estimation of 232,090 new cases and 30,350 deaths in the USA in 
2005, prostate cancer (PCa) is still the most diagnosed cancer in men, and 
the second leading cause of their cancer deaths 5. However, despite these 
alarming figures, there is still no treatment that can cure the most advanced 
stages of the disease, when the cancer has become androgen-independent. 
Furthermore, as it progresses, PCa metastasizes to bones and Iymph nodes, 
which further complicates its treatment 214. Thus, there is an urgent need for 
new therapies, but these are likely to require a betler understanding of the 
mechanisms and genes implicated in the progression of this disease. 
Genetic alterations are a common feature of cancer. Indeed, in different 
tumor types, chromosomal rearrangements or loss of particular regions have 
been reported for almost ail chromosomes. However, these modifications 
are not randomly distributed, but specifie regions have been associated with 
certain types of cancer 54. Unfortunately, in PCa, such analysis is 
complicated by the heterogeneity of tumor samples. Cytogenetic analysis of 
human prostate tumors revealed that alterations of many chromosomes are 
associated with PCa 56. Indeed, numerous studies have shown deletions of 
chromosome arms 7q 215, 57, 8p 60,58,59, 10q 63, 61, 62, 16q 216, 66, 64, 17q 68, 67, 
and 18q 66, 217, 69 in advanced PCa. The sensitive comparative genomic 
hybridization method has led to the identification of more genetic alterations 
in PCa, including los ses of genetic material on human chromosome arms 2q, 
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5q, 6q, 9p, 13q, 15q, and 17p 72, 71. The loss of these regions could indicate 
that they encode tumor suppressor genes. Functional evidence to that effect 
has been gathered from the transfer of normal human chromosomes in PCa 
celllines. 
Almost every human chromosome has been transferred into either rat or 
human PCa cells for assessment of their tumor-suppressive properties. 
Thus, human chromosome arm 8p 76 and chromosome 12 51 suppressed the 
tumorigenicity of rat PCa cells. Similarly, introduction of human 
chromosomes 2, 7,8, 10, 11, 12, 13, 16, 17, 19, and 20 in rat Dunning cell 
lines resulted in reduction or loss of their metastatic properties, sometimes 
without affecting their tumorigenicity 81, 84,218,85,80. 
The analysis of ratlhuman hybrids containing human chromosome 11 has 
led to the identification of a new metastasis suppressor gene called CD82 
antigen that encodes the KAI1 protein 89. Reduced expression of KAI1 is 
associated with progression of PCa 219 and epithelial ovarian carcinoma 220, 
as weil as with bladder 221, breast 222, gastric 223, and colorectal cancer 224. 
Reduced expression of KAI1 was also detected in metastatic forms of 
oesophageal squamous cell 225 and hepatocellular carcinoma 226. 
Introduction and expression of KAI1 into melanoma cells was accompanied 
by a reduction of their invasive and metastatic properties 92, further 
establishing the metastasis-suppressive activity of the KAI1 protein. 
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Other genes have also been shown to suppress metastasic properties 
without affecting primary tumor growth. These genes are CD44 (Iocated at 
11p13), MAP2K4 (17p11.2), NME1 (17q21.3), NME2 (12q24.1), KISS1 
(1q32), and BRMS1 (11q13.1-2). However, only three of them (CD82, CD44, 
and MAP2K4) act as metastasis-suppressor genes in PCa 93. 
Chromosome transfer has also been performed in human PCa cell lines, 
where introduction of chromosomes 2 73, 8p 227, 10p 152, 12 164, and 19 84• 228 
showed tumor-suppressing activity. 
Cytogenetic, allelotyping, and somatic-cell hybrid studies have shown that 
the long arm of human chromosome 18 (18q) likely carries one or more 
tumor or metastasis suppressor gene(s) that play a role in PCa progression. 
Indeed, loss of heterozygosity on 18q was reported in 30-40% of PCa 
patients 66. However, introduction of human chromosome arm 18q into the 
DU 145 PCa cellline abolished its tumorigenicity 189, whereas transfer of an 
intact chromosome 18 into the PC-3 PCa cell line interferes with both the 
tumorigenic and metastatic properties of these cells 193. 
Tumor suppressor genes have been identified on the long arm of 
chromosome 18. Indeed, cytogenetic band 18q21 encodes the tumor 
suppressor genes DCC (geleted in çolorectal çancer), SMAD4/DPC4 
(geleted in Qancreatic çancer 1), and SMAD2IDPC2 (geleted in Qancreatic 
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çancer ~). However, their implication in PCa is still controversial229• Indeed, 
the SMAD2 and SMAD4 proteins seem to be lost as the Gleason score 
increases230• Moreover, and although studies in PCa patients identified loss 
of two chromosome 18 minimal regions (between markers 01851119 and 
018564 (52940 and 55575 kbp), and between 0185848 and 018558 
(40053 and 70193 kbp», no tumor-suppressor gene has yet been mapped to 
these intervals 231. 
To identify tumor- or metastasis-suppressor genes, we have used microcell-
mediated chromosome transfer to introduce different tagged normal human 
chromosomes (10, 12, 17, and 18) into the tumorigenic PC-3M-Pro4 and 
metastatic PC-3M-LN4 PCa cell lines. Here we show that introduction of 
chromosome 18, and not the others, into human PCa cells is sufficient to 
affect both their in vitro and in vivo tumorigenic properties. Indeed, such 
hybrids experienced decreased invasiveness, lost their anchorage-
independent growth capacity, and harboured a delayed tumor growth upon 
both subcutaneous and orthotopic injections in nude mice. 
3.3 Materials and methods 
3.3.1 Cell Lines 
PC-3M-Pro4 and PC-3M-LN4 human PCa cell lines 232 were obtained from 
I.J. Fidler (Department of Cancer Biology, The University of Texas M.D. 
Anderson Cancer Center, Houston, TX). PC-3M-Pro4 cells are highly 
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tumorigenic, whereas PC-3M-LN4 ceUs are highly metastatic to Iymph nodes 
when injected orthotopically into the prostates of nude mice. 80th cell lines 
were derived upon orthotopic injections of PC-3M into the prostates of nude 
mice. PC-3M was derived from the PC-3 ceU line obtained from a bone 
metastasis of a patient with PCa 205. PC-3M-LN4 and PC-3M-Pro4 were kept 
in RPMI 1640 medium supplemented with 10% fetal bovine serum (F8S; 
Invitrogen, 8urlington, ON, Canada). Geneticin-resistant PC-3M-Pro4GP1 
and PC-3M-LN4GP2 ceU lines were generated upon Lipofectamine 2000 
(Invitrogen) transfection of the pQ8125 plasmid (Q-810gene, Carlsbad, CA). 
This plasmid encodes the green fluorescent protein gene and contains the 
neomycin phosphotransferase gene that confers resistance to geneticin. 
These cells were kept in RPMI 1640 with 10% F8S and 400 J.1g/ml of 
geneticin (Invitrogen). 878MC9, 878MC57, 878MC75, 878MC77, and 
878MC156 are microcell hybrids from our mouse/human hybrid panel 233, 
and contain a tagged human chromosome (12, a translocated chromosome 
3 and 17 with unknown breakpoints, 10p, 10, and 18, respectively) in the 
878 mouse melanoma background. 878MC hybrids were kept in DMEM 
(Dulbecco's modified Eagle medium; Invitrogen) supplemented with 10% 
F8S and 400 J.1g/ml of hygromycin 8 (Roche Diagnostics, Laval QC, 
Canada). PC-3M-Pro4- and PC-3M-LN4-derived microcell hybrids (su ch as 
Pro48156- and LN4877- hybrids; see below) were grown in RPMI 1640 with 
10% FBS, 400 J.1g/ml of geneticin, and 400 J.1g/ml of hygromycin B. 
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3.3.2 Microcell-mediated chromosome transfer 
Microcell fusion was done as described 207. B78MC hybrids containing 
different tagged chromosomes (10. 10p. 12. translocated 3 and 17. 18) were 
micronucleated in the presence of colcemid (0.06 Jlg/ml) (Sigma. Oakville. 
ON. Canada) for 24 hours. The resulting microcells were fused to either PC-
3M-Pro4GP1 or PC-3M-LN4GP2 cells in the presence of 50% (w/w) 
polyethylene glycol 1600 (Fisher Scientific. Nepean. ON. Canada) for 60 
sec. The cells were rinsed three times with serum-free RPMI 1640. and 
complete medium (RPMI 1640 with 10% FBS) was added to the flask and 
incubated overnight. The resulting microcell hybrids (Pro4B ... and LN4B ...• 
Table 4) were selected in RPMI 1640 medium containing 10% FBS + 800 
Jlg/ml hygromycin B + 800 /-tg/ml geneticin. 
3.3.3 Invasion assay 
We used a Boyden chamber assay 211 to assess invasive potential. Briefly. 
25.000 cells were added to the cham ber coated with Matrigel (Fisher 
Scientific). and RPMI 1640 medium supplemented with 5% FBS was added 
to the botlom cham ber to serve as chemoattractant. The chambers were 
incubated at 37°C for 22 hours. and filters were stained with a Diff-Quick 
staining kit (Dade Behring. Newark. DE). Filters were then put onto 
microscope si ides (Fisher Scientific). and invasive cells from five random 
fields were counted under a contrast phase microscope at 200X 
magnification. Ali invasion experiments were performed twice in 
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quadruplicate (n=8), and the results were expressed as percentgge of the 
invasion obtained with the parental cell line. The p values were calculated 
using a two-tailed Student's t-test. 
3.3.4 Soft-agar assay 
The soft-agar assays were performed as described previously 234. Briefly, 1 
ml of 0.5% agar (Fisher Scientific) diluted in appropriate media was put into 
6-well plates to form the basal layer. Then 3,000 cells were mixed with 0.5% 
agar and put on top of the basal layer. Plates were incubated at 37°C for 21 
days. Growing cell foci were stained with 200 III of a 0.03% crystal violet 
(Sigma, Oakville, ON, Canada) solution in 100% methanol (Fisher Scientific). 
Qualitative assessment of growth was performed; where colonies formation 
of hybrids was compared to those of parental cell lines, which were arbitrary 
assigned the symbol +++. For quantitative evaluation, plates were scanned 
on a PowerLook 2100XL scanner (UMAX, Dallas, TX). The number of 
colonies was counted on the computer screen, and converted to a 
percentage of colonies obtained with the parental cell line. Each soft-agar 
assay was performed three times on six wells per cell line (n=18) and a 
Student's t-test was used to assess the significance of the findings. 
3.3.5 Nude mouse injections 
Ali mou se injections were done according to Canadian Council for Animal 
Care guidelines, after approval by the McGiII University Animal Care 
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Committee. Male nude mice (nu/nu; six to eight weeks of age; Charles River 
Laboratory, St-Constant, QC, Canada) were injected with PCa cells. One 
million cells, in 200 J.11 of Hanks balanced saline solution (HBSS; Invitrogen) 
were injected subcutaneously in the upper backs of nude mice. Mice were 
sacrificed when tumors reached a size of 1000 mm3. For orthotopic 
injections, one million cells were resuspended in 16.6 J.11 of HBSS and 
injected with a push button-controlled dispensing device (Hamilton Syringe 
Company, Reno, NY) into the dorsal lobe of the prostate. The mice were 
sacrificed when they became moribund. A Kaplan-meier graph was used to 
determine if there was a statistically significant difference between the 
surival of the mice injected with our hybrids versus the ones injected with 
parental cells. 
3.3.6 Tumors in culture 
Tumors were excised and digested two times for 15 min at 37°C with 350 
U/ml of type 1 collagenase (Invitrogen), and cell suspensions were seeded 
into culture flasks containing RPMI 1640 supplemented with 10% FBS and 
1 % penicillin (5000 IU/ml) 1 streptomycin (5000 J.1g/ml) (Invitrogen). Two days 
later, complete selective medium (RPMI 1640 with 10% FBS + 400 J.1g/ml 
geneticin + 1 % penicillin (5000 IU/ml) 1 streptomycin (5000 J.1g/ml) was 
added. 
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3.3.7 Genotyping of hybrids 
Tb identify 878MC hybrids that contained the selected tagged human 
chromosomes, we performed PCR by using polymorphie microsatellite 
markers. We used 010S196, 010S1692, and 010S169 for chromosome 10; 
012S43, 012S90, o 12S325, and 012S368 for chromosome 12; 017S1850, 
017S1853, and 017S1154 for chromosome 17; as weil as 018S66, 
018S1148, and 018S554 for chromosome 18. Subsequent analysis by 
fluorescence in situ hybridization (FISH) of 878MC57 revealed that this 
hybrid contains a translocation between chromosomes 3 and 17; however 
the breakpoints were not determined. We thus selected five hybrids that 
contained human chromosomes 10, 10p, 12, a translocated 3;17, and 18 
(878MC77, 878MC75, 878MC9, 878MC57, and 878MC156, respectively). 
The presence of the desired chromosome was also confirmed by Alu-PCR-
FISH as described previously 164. To characterize LN48156- hybrids further, 
we used 27 human chromosome 18 microsatellite markers (Table 5). The 
polymorphie markers (heterozygosity > 0.8) used were: 018S59, 018S63, 
018S976, 018S42, 018S843, 018S542, 018S44, 018S877, 018S847, 
018S1133, 018S67, 018S1157, o 18S535, 018S65, 018S1145, 018S46, 
018S487, 018S1109, 018S39, 018S1155, 018S51, 018S1270, 018S382, 
018S541, 018S58, 018S50, and 018S1141 (www.invitrogen.com). Markers 
018S847, 018S39, 018S58, 018S50, and 018S1141 were non-informative 
as they could not distinguish the exogenous chromosome 18 from the 
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endogenous, whereas markers 018863, 0188843, 01881157, 01881109, 
and 0188382 were not transferred. 
3.4 Results 
3.4.1 Introduction of human chromosome 18 into PC-3M-LN4GP2 cells 
interferes with their in vitro tumorigenic properties 
From our mouse/human microcell hybrid panel 206, we have identified 
878MC-hybrids (Table 4) containing tagged human chromosomes that have 
been implicated in PCa progression (chromosomes 10, 12, 17, and 18). 
These tagged chromosomes were transferred into highly tumorigenic PC-
3M-Pro4GP1 and highly metastatic PC-3M-LN4GP2 cell lines to generate 
the Pro48- and LN48-derived hybrids (Table 4). We have compared the 
anchorage dependence and invasiveness of our hybrids to their parental 
human PCa cells by using growth in soft agar and a 80yden chamber assay. 
Although transfer of the translocated chromosome (3;17, with unknown 
breakpoints) into PC-3M-LN4GP2 cells could significantly decrease its 
tumorigenic potential (see tumor formation of LN4857-5 in Table 4), this 
translocated chromosome did not significantly reduce the in vitro tumorigenic 
properties of the two parental cell lines (see invasion and soft agar assays 
for Pro4857- and LN4857- hybrids; Table 4). Similarly, the in vitro and in 
vivo properties of the PC-3M-Pro4GP1 cells were not affected when 
chromosome 8 was transferred into them (data not shown), confirming that 
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chromosome transfer per se is not sufficient to inhibit the malignant 
properties of these cells. 
We th en quantitatively measured the ability of ail our LN48156 hybrids 
(LN48156-1, 2, 3, 6, 13, 14, 16, and 20) to grow in an anchorage-
independent manner. Four hybrids (LN48156-6, 13, 16, and 20) formed 
statistically fewer colonies than the parental cells (P<0.001; Table 4). 
Although clonai variation is often seen in soft-agar assays, these highly 
significant results contrast with the anchorage-independent growth obtained 
with another geneticin-resistant PC-3M-LN4 clone (PC-3M-LN4GP1) that 
formed 74% as many colonies as did PC-3M-LN4GP2. Thus, introduction of 
human chromosome 18 into PC-3M-LN4GP2 cells suppresses the ability of 
sorne LN48156 hybrids to invade through Matrigel, and to form anchorage-
independent colonies. Although LN48156-14 cells were not able to invade 
through Matrigel, they formed four times more colonies in soft agar than did 
the parental PC-3M-LN4GP2 cells (P<0.00001; Table 4). Such important 
clonai variation is similar to what was observed in chromosome 18 hybrids 
generated by Padalecki et al. (2003) and could indicate that the integrity of 
the transferred chromosome 18 was not the same in ail hybrids (sorne 
chromosomes for example could harbour deleted portions), a characteristic 
often seen in microcell hybrids193. Moreover, the properties of the LN48156-
14 hybrid could argue that invasiveness and anchorage-independent growth 
are under the control by different genes on chromosome 18. 
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TABLE 4. Phenotypic Changes Associated with Human Chromosome Transfer in PC-3M-Pro4GP1 
and PC-3M-LN4GP2 Prostate Cancer Cell Unes 
Mouse/human Properties of hybrids 
parental hybrids Invasion assays Soft agar assays 
(transferred (Parental = 100%) (Parental = +++ or 100%) 
chromosomes) 
B78MC75 nIa Pro4B75-2 ++ 
(chr 10p) Pro4B75-3 ++ 1/2 
Pro4B75-11 +++ 
Pro4B75-12 + 
Pro4B75-14 + 
B78MC77 nia Pro4B77-2: + 1/2 
(chr 10) Pro4B77-10: + 1/2 
Pro4B77-15: + 
B78MC9 Pro4B9-4: 88% (p = 0.49) Pro4B9-11: +++ 
(chr 12) Pro4B9-8: 217% (p = 0.02) Pro4B9-17: ++ 
Pro4B9-17: 568% (p=0.0007) Pro4B9-18: ++ 
Pro4B9-41: 107% (p = 0.75) Pro4B9-21: ++ 1/2 
Pro4B9-22: +++ 
B78MC57 nia Pro4B57-1: ++ 1/2 
(chrt(3;17» Pro4B57-3: ++ 
Pro4B57-6: +++ 
Pro4B57-7: ++ 1/2 
Pro4B57-8: + 1/2 
B78MC156 nia Pro4B156-10: + 1/2 
(chr 18) Pro4B156-12: ++ 
_ .. -
Tumor Tumor 
formation * formation ** 
(subcutaneous) (orthotopic) 
Pro4B75-12: Pro4B75-12: 
3/10 (p = 0.002) 2/5 (p = 0.14) 
nia nia 
nia nia 
Pro4B156-10: nia 
3/5 (p = 0.07) 
Mouse/human Properties of hybrids 
parental hybrids Invasion assays Soft agar assays 
(transferred (Parental = +++ or 100%) (Parental = 100%) 
chromosomes) 
~78MC77 LN4877-9: 35% (p=0007) LN4877-2: + 1/2 
(chr 10) LN4877-50:: 73% (p = 0.17) LN4877-9: ++ 
LN4877-60: 63% (p = 0.09) LN4877-37: + 1/2 
LN4877-80: 22% (p=0.00007) LN4877 -44: + 
LN4877-45: ++ 
878MC9 LN489-34: 2% (p=0.000006) LN489-31: ++++ 
(chr12) LN489-35: 10% (p=0.00016) LN4B9:.33: +++ 
LN489-34: +1/2 
LN489-35: ++ 
LN489-36: +++ 
878MC57 LN4857-4: 250% (p=0.007) LN4B57 -4: ++ 
(chrt(3;17» LN4857 -5: 142% (p=0.15) LN4B57-5: +1/2 
LN4857-6: 265% (p=0.003) LN4857-6: ++ 
LN4857-7: 281% 9p=0.0011) LN4857-7: ++ 
878MC156 LN48156-1: 58% (p=0.98) LN4B156-1: ++++, 289% (p=0.005) 
(chr 18) LN4B156-2: 75% (p=0.16) LN4B156-2: +++, 91% (p=0,45) 
LN4B156-3: ++++, 227% (p=0.0003) 
LN4B156-14: ++++, 396% (p=0.00000001) 
LN4B156-6: 42% (p=0.0002) LN4B156-6: +, 4% (p=0.00001) 
LN48156-14: 19% (p=0.0000009) LN48156-13:+, 23% (p=0.00002) 
LN48156-16: ++, 58% (p=0.0002) 
LN4B 156-20: ++, 58% (p=O .0006) 
* ln subcutaneous injections, PC-3M-Pro4GP1 formed tumors in 9/10 mlce 
and PC-3M-LN4GP2 formed tumors in 2/5 mice. 
*" ln orthotopic injections into the prostate, PC-3M-Pro4GP1 formed tumors in 3/3 mice 
and PC-3M-LN4GP2 formed tumors in 9/13 mice. 
Turnor Tumor 
formation" formation "" 
(subcutaneous) (orthotopic) 
LN4877-44: nIa 
2/5 (p = 0.54) 
nia nia 
LN4857-5: nia 
2/10 (p = 0.04) 
LN48156-2: 
5/5 (p=0.08) 
LN4B156-6: LN4B156-6: 
2/10 (p=0.05) 2/3 (p=0.03) 
3.4.2 Introduction of human chromosome 18 into PC-3M-LN4GP2 cells 
interferes with their in vivo tumorigenic properties 
To test the in vivo tumorigenic properties of our hybrids, one million ceUs 
from the selected hybrids, and trom parental PC-3M-Pro4GP1 and PC-3M-
LN4GP2 cells were injected subcutaneously into nude mice. We tested 
LN4877 -44 and Pr04875-12 hybrids, containing, respectively, an introduced 
chromosome 10 or a 10p fragment. A statistically significant difference in 
tumor formation was obtained with the Pr04875-12 hybrid (P=0.002; Table 
4). 8ecause they displayed opposite phenotypes in invasion and in soft-agar 
assays, we also injected LN48156-2 and LN48156-6 hybrids. Indeed, 
LN48156-2 hybrid ceUs were 75% as invasive as was the parental ceUline 
and formed as many colonies (91%) in soft agar (Table 4). In contrast, 
LN48156-6 ceUs were 42% as invasive as PC-3M-LN4GP2 ceUs, and 
formed 25 times fewer colonies (3.8%; Table 4). The few tumors (2 out of 
10) obtained upon injection of LN48 156-6 ceUs grew much slower than those 
obtained by either PC-3M-LN4GP2 or LN48156-2 cells (Fig. 6A). Indeed, 
mice injected with PC-3M-LN4GP2 or LN48156-2 cells became moribund 
much earlier (on average, 31 and 50 days earlier, respectively) than did mice 
injected with LN48 156-6 ceUs (Fig. 6C, P=0.05). 
Furthermore, there was no statistically significant difference in tumor growth 
between parental cells and the LN48156-2 (Fig. 68; P=0.08), or LN4877-44 
hybrid containing an extra human chromosome 10 (P=0.54, Table 4). This 
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difference in tumor formation was also observed when LN48 156-6 cells were 
injected directly into the dorsal lobe of the prostate of nude mice. Indeed, 
there was a significant delay (Fig. 60; P=O.03) in orthotopic tumor growth 
between LN48156-6 and PC-3M-LN4GP2 cells. 
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Figure 6. Subcutaneous and orthotopic injections of prostate cancer cells 
into nude mice. A. Graphie representation of subcutaneous tumor growth 
following injections of 1 x 106 PC-3M-LN4GP2, LN48156-2, and LN48156-6 
cells. Tumor growth was measured three times a week. 8 and C. Kaplan-
Meier curves comparing survival rate (until mice became moribund) of mice 
upon subcutaneous injection of PC-3M-LN4GP2 cells and LN48156-2 cells 
(8) and LN48156-6 cells (C). D. Kaplan-Meier curve comparing survival rate 
of mice upon orthotopic prostatic injections of 1 x 106 PC-3M-LN4GP2 and 
LN48156-6 cells. Mice were sacrificed as they became moribund. 
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Taken together, these experiments demonstrate that the chromosome 18 
introduced into LN4B156-6 cells was responsible for the suppression of their 
tumorigenic phenotype. However, once orthotopic tumor growth was 
established, both hybrid and parental cells formed regional Iymph node 
metastases. Thus, even if LN4B156-6 cells showed delayed tumor growth, 
they still escaped the primary tumor mass to form metastases in 
retroperitoneal Iymph nodes. 
After sacrificing the mice, we excised and cultured the tumors from both 
subcutaneous and orthotopic groups. Ali cultured tumor cells were still 
expressing the green fluorescent protein gene (data not shown) and still 
contained polymorphie markers from the introduced chromosome 18 
(TLN156-hybrids; Table 5), confirming that tumors were derived from the 
injected hybrid cells. 
3.4.3 A region of human chromosome 18 is associated with the 
reduced tumorigenicity of LN4B156-6 cells 
FISH with a chromosome 18-specific painting probe did not reveal any major 
differences in the chromosome 18 introduced in LN4B156 hybrids (data not 
shown). We complemented this analysis by genotyping the hybrids using 
twenty-seven polymorphie markers (Figure 7 and Table 5). To identify which 
allele was present in the parental cell lines, we tested each marker with DNA 
from the B78MC156 mouse/human hybrid and from the PC-3M-LN4GP2 
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human prostate cancer cellline. Five markers (0188487,018539,018858, 
018850, and 01881141; Table 5) could not distinguish the alleles present in 
878MC156 from those of PC-3M-LN4GP2 cells, whereas five markers 
(018863, 0188843, 01881157, 01881109, and 0188382; Table 5) were 
not transferred into PC-3M-LN4GP2 hybrids. 
We then tested ail twenty-seven polymorphie markers on LN48156 hybrids 
to determine which regions of chromosome 18 had been transferred. As 
seen in Table 5 (see also 01881133 in Figure 7), most markers had been 
transferred into both LN48156-2 and LN48156-6 hybrids. However, an 
additional allele of 018851 was present in the LN48156-6 hybrid (allele 1A; 
Figure 7 and Table 5). This additional allele was also present in LN48156-13 
(Figure 7), another hybrid that forms fewer colonies in soft agar (Table 4). 
Interestingly, 018851 allele 1A was lost in one of the two tumors that 
eventually developed from subcutaneous injections (TLN 156-6-3; Figure 7) 
and in one of the two tumors occurring after orthotopic injections of 
LN48156-6 cells (OLN156-6-5; Figure 7). Allele 1A was also seen faintly in 
878MC156 DNA, which could indicate that a subpopulation of these cells 
contained either only allele 1A, or both 1 and 1A alleles. Indeed, FISH 
experiments with a human chromosome 18-specific painting probe showed 
that a small portion of chromosome 18 was present in 23% of the 
878MC156 cell spreads examined. This result could explain why the allele 
1 A band was hardly detectable in 878MC156. Moreover, direct sequencing 
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of the 018551 amplification products obtained from 878MC156 DNA 
revealed that this ceilline contains two 018551 alleles. 
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TA8LE 5. Genotyping of Chromosome 18 in Parental Cells and LN48156- Hybrids and Tumors 
Marker Cytoband Position (kbp) 878 878MC156 PC3MLN4GP2 LN48156-2 TLN156-2-2 LN48156-6 
018S59 18p11.3 634 0 1 2 1,2 1,2 1,2 
018S63 18p11.3 3426 0 1 2,3 2,3 2,3 2,3 
01&5976 18p11.2 5238 0 1 2,3 1,2,3 1,2,3 1,2,3 
018S42 18p11.2 5891 0 1 2 1,2 1,2 1,2 
o 18S843 18p11.1 8603 0 1 2,3,4 2,3,4 2,3,4 2,3,4 
o 18S542 18p11.1 11550 0 1 2,3 1,2,3 1,2,3 1,2,3 
018S44 18q11.1 19875 0 1 2 1,2 1,2 1,2 
018S877 18q11.1 26613 0 1 2,3 1,2,3 1,2,3 1,2,3 
018S847 1~g11.2 27591 0 1 2,3 1,2,3 1,2,3 1,2,3 
018S1133 18q12 31986 0 1 2 1,2 1,2 1,2 
018S67 18q12 35855 0 1 2 1,2 1,2 1,2 
018S1157 18_q12 37751 0 1 2,3,4,5 2,3,4,5 2,3,4,5 2,3,4,5 
o 18S535 18q12 38036 - 0 1 2 1,2 1,2 1,2 
018S65 18q12 40425 0 1 2,3 1,2,3 1,2,3 1,2,3 
018S1145 18q12 40435 0 1 2 1,2 1,2 1,2 
018S46 18q21 48376 0 1 2,3 1,2,3 1,2,3 1,2,3 
o 18S487 18q21 51673 0 1 1,2 1,2 1,2 1,2 
018S1109 18q21 57430 0 1 2,3,4 2,3,4 2,3,4 2,3,4 
018S39 18q21 54001 0 1 1,2 1,2 1,2 1,2 
018S1155 18q21 56848 0 1 2,3 1,2,3 1,2,3 1,2,3 
D18S51 18q21 60734 0 1,1A 2,3 1,2,3 1,2,3 1,1A,2,3 
018S1270 18q21 61178 0 1 2,3 1,2,3 1,2,3 1,2,3 
o 18S382 18q22 63354 0 1 2,3 2,3 2,3 2,3 
018S541 18q22 69959 0 1 2 1,2 1,2 1,2 
018S58 18q23 72125 0 1 1,2 1,2 1,2 1,2 
018S50 18q23 75252 0 1 1,2 1,2 1,2 1,2 
018S1141 18q23 76658 0 1 1 1 1 1 
For each marker, the allele present in the mouse/human hybrid 878MC156 (donor cells) is identified 
by "1", pOlymorphie alleles derived from the prostate cancer cellline PC-3M-LN4GP2 are represented by "2" to "5" ; 
"0" indicates the -absence of this marker. 
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Figure 7. Genotype of 018S1133 and 018S51 markers in prostate cancer 
cells and hybrids. The left panel shows a representative autoradiogram of 
PCR analysis of microsatellite polymorphie marker 018S1133 for DNA 
extracted from cell cultures of mouse/human hybrid B78MC156 (allele 1), 
human prostate cancer celiline PC-3M-LN4GP2 (allele 2), microcell hybrids 
LN4B 156-2 and LN4B 156-6, and from tumor derived from nude mice 
injection of these two microcell hybrids (indicated by TLN 156-2-2 and 
TLN156-6-3). The right panel shows a representative autoradiogram of PCR 
analysis of microsatellite polymorphie marker 018S51 for DNA extracted 
from cell cultures of mouse/human hybrid B78MC156 (alleles 1 and 2), 
human prostate cancer cell line PC-3M-LN4GP2 (alleles 2 and 3), microcell 
hybrids LN4B156-1, -2, -3, -5, -6, -13, -14, -16, and -20, and from tumor-
derived from nude-mouse injection (both subcutaneous (TLN) and orthotopic 
(OLN)) of LN4B156-2 and LN4B156-6 microcell hybrids (TLN156-2-2, 
TLN156-6-3, TLN156-6-6, OLN156-6-1, and OLN156-6-5). For each marker, 
PCR amplification was performed three times. 
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3.5 Discussion 
Deletions of chromosome 18 regions have been associated with many 
cancers, including colorectal 183, pancreatic 184, ovarian 235, head and neck 
squamous cell carcinoma 186, lung 187, and prostate carcinoma 192,231,236,229, 
188, Functional evidence for the presence of tumor suppressor gene(s) on 
human chromosome 18 was demonstrated when introduction of this 
chromosome into pancreatic cancer cells resulted in suppression of their 
tumorigenic phenotype 184, Similar results were obtained in PCa ceillines DU 
145 and PC_3 236, 193, As compared to DU 145 cells, PC-3 and its derivatives 
likely represent a more appropriate model for study of prostate cancer. 
Indeed, PC-3 cells were derived from bone metastasis, a common feature 
seen in patients at an advanced stage of the disease. In contrast, the DU 
145 cell line was derived from a brain metastasis, which rarely occurs in 
patients. Although PC-3 cells form metastases upon injection into the left 
cardiac ventricle 193, the use of a more aggressive PC-3-derived cell line 
(PC-3M-LN4) allows the study of metastatic cancer progression as it appears 
in human patients. Indeed, PC-3M-LN4 cells form Iymph-node metastases 
upon orthotopic injection into the prostate of nude mice 204. Thus, injecting 
cancer and hybrid cells orthotopically more appropriately mimics the 
conditions present in PCa patients and further confirms that chromosome 18 
is implicated in PCa progression. 
Introduction of human chromosome 18 into the metastatic PC-3M-LN4GP2 
cell line considerably affects its tumorigenic properties. Both LN4B 156-6 and 
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LN48156-14 hybrids have a reduced capacity to invade through Matrigel, 
whereas LN48156-6, LN48156-13, LN48156-16, and LN48156-20 hybrids 
have a reduced ability to grow in an anchorage-independent manner, a 
feature also observed by Padalecki et al. (2003) in their PC-3-derived 
hybrids193• Furthermore, the LN48156-6 hybrid also shows significantly 
delayed tumor growth upon subcutaneous (P= 0.05) and orthotopic (P=0.03) 
injections into nude mice. However, in the prostate environ ment, LN48156-6 
cells did form proportionally more tumors (two mice out of four; 50%) than 
when injected subcutaneously (two mice out of ten; 20%). Such results could 
indicate that the natural prostatic environ ment is a more appropriate site than 
is under the derma (subcutaneous) for the establishment and growth of 
tumorigenic cells. Moreover, once established in the prostate, ail tumors 
were also able to metastasize to Iymph nodes. Upon orthotopic injection, ail 
mice became moribund due to uremia and had to be sacrificed. As seen in 
Figure 6, almost ail mice orthotopically injected with parental PC-3M-
LN4GP2 cells became moribund in less than 75 days, whereas it took up to 
134 days after LN48 156-6 orthotopic injections. 
Our results thus confirm and complement those obtained by Padalecki et al. 
(2003) and further suggest the presence of one or more chromosome 18 
tumor/metastasis suppressor genes implicated in PCa progression 193. Such 
suppressor genes are likely to be inactivated during the time it took the 
tumors to form in the animal. According to this hypothesis, it is worth noting 
that LN48156-6-tumor-derived cells (TLN 156-6-3) displayed a significant 
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increase in their capability to form colonies in soft agar (409%;-P= 1x10-7) 
when compared to PC-3M-LN4GP2 (data not shown). As reported for 
nonpapillary renal cell carcinoma, such inactivation could result from 
chromosomal rearrangement 237. In renal cell carcinoma-derived microcell 
hybrids, such rearrangements often not only occur in the introduced 
chromosome, but also affect endogenous homologous chromosomes and 
other polysomic chromosomes 238. 
The characterization of LN48156-hybrids (Table 4 and Figure 6) revealed 
that sorne hybrids had reduced in vitro and in vivo tumorigenic properties 
(see, for example, LN48156-6, LN48156-13), whereas others (like 
LN48156-1 and LN48156-2) were at least as tumorigenic as were the 
parental PC-3M-LN4GP2 cells. Such differences could be due to the fact 
that hybrids like LN48156-2 contain an introduced chromosome 18 in which 
the suppressor gene is already inactivated or deleted. Although FISH 
analysis did not show any chromosomal differences between LN48156-2 
and LN48156-6 hybrid cells (data not shown), genotype analysis of these 
hybrids pointed to the 18q21 region. Indeed, when compared to tumorigenic 
hybrids, many hybrids having a reduced tumorigenic phenotype (either in 
vitro or in vivo) carried an extra 018S51 allele (allele 1A). The fact that this 
allele is often lost in cancer cells derived from LN48156-6 subcutaneous or 
orthotopic injections further validates that this region is important in PCa. 
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The chromosome band 18q21 region encodes few identified tumor 
suppressor genes. Among them, the DCC gene has been associated with 
colorectal cancer progression, whereas the SMAD2 and SMAD4 genes are 
inactivated in pancreatic cancer. However, because these genes are rarely 
mutated in PCa 239, 195, 192, 229, the involvement of these three genes in this 
disease is probably limited. Accordingly, a preliminary analysis using the 
19k7 microarray containing 19,200 human genes 
(www.microarrays.ca/products/types.html) did not reveal any variation in the 
expression level of the SMAD4 gene when PC-3M-LN4GP2 cells were 
compared to LN48156-6 cells (data not shown). This further suggests that 
SMAD4 is not implicated in the decreased tumorigenic phenotype observed 
in the LN48156-6 hybrid and that a not yet identified suppressor gene could 
be present in the 18q21 region. Moreover, these three genes are located 
more than 10 megabases (Mb) away (DCC is located at 49 Mb, SMAD2 at 
43.5 Mb, and SMAD4 at 47 Mb) from the D18S51 locus (59 Mb) 
(www.ncbi.nlm.nih.gov/mapview/maps.cgi?taxid=9606&chr=18).Thus.itis 
very unlikely that these genes are implicated in the less tumorigenic 
phenotype of our LN48156-6 hybrid. 
Whatever its inactivation mechanism, the chromosome 18-encoded 
suppressor gene is likely to be implicated (directly or indirectly) in cell-cell 
adhesion or cell-matrix interaction, because sorne of our LN4B156 hybrids 
had a decreased ability to grow in an anchorage-independent manner and to 
invade through Matrigel. Inactivation of the suppressor gene is unlikely to 
99 
happen over the time required for performing the invasion assay (22 hours) 
or even the soft-agar assay (21 days). Such suppressive in vitro properties 
are similar to what has been reported for the CD82 metastatic suppressor 
gene 93 in both prostate and breast cancer cells. However, the presence of 
the suppressor gene in the LN48156-6 hybrid was unable to inhibit Iymph 
node metastasis formation once tumors had developed after orthotopic 
injections in the prostate. Presently, we cannot rule out the probability that 
this suppressor gene could also affect metastatic development, because the 
suppressor gene is likely to be inactivated by the time the cells form tumors 
in the mice. Such inactivation could also interfere with its putative 
metastasis-suppressing properties. 
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CHAPTER4 
IDENTIFICATION AND 
CHARACTERIZATION OF CANDIDATE 
GENES 
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4.0 PREFACE 
This chapter is written in a manuscript format with its own Introduction, 
Material and methods, Results and Discussion sections. It will be submitted 
to Cancer Research in early 2006. Contribution of co-authors can be found 
at page XVIII and permission from co-authors in Appendix D. 
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4.1 Abstract 
Prostate cancer is the second leading cause of cancer death in the USA. 
However, the mechanisms underlying this important disease are not weil 
understood. Thus, there is a need for identifying new tumor suppressor 
genes implicated in prostate cancer progression. We have assessed the 
expression of the MA SPIN, BCL2 and ERK4 genes in tumorigenic and less 
tumorigenic hybrids containing an extra copy of normal human chromosome 
18. Here we show that mRNA levels of the MASPIN and ERK4 genes are 
down regulated in highly tumorigenic cells compared to less tumorigenic 
hybrids, and that the level of BCL2 is up regulated in these same cells. 
However, there is no difference in the MASPIN or BCL2 protein level 
between tumorigenic and less tumorigenic cells, suggesting that MASPIN or 
a BCL2 repressor are not implicated in the less tumorigenic phenotype of our 
chromosome 18 hybrids. Introduction of the wild-type ERK4 gene into 
human prostate cancer cells completely abolished their ability to invade 
through Matrigel and their anchorage-independent growth potential. 
However, subcutaneous injections of the ERK4-over-expressing cells into 
nude mice did not result in any reduced growth rate or delay. That could 
argue that in vivo, ERK4 needs a partner to perform its tumor suppressing 
function. Alternatively, it could also be necessary to in je ct these cells 
orthotopically to fully assess the effect of ERK4 on these cells. Nevertheless, 
ERK4 is a good candidate for a new tumor suppressor gene for prostate 
cancer since it is down regulated in human prostate cancer cells and 
suppresses colony formation and invasiveness in vitro. 
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4.2 Introduction 
Prostate cancer (PCa) is still the second leading cause of cancer death 
among American males. Indeed, 232,090 new cases and 30,350 deaths are 
expected in 2005 5. Despite these alarming statistics, there is still no efficient 
treatment for advanced stages of the disease. Moreover, the molecular 
mechanisms of this disease are not weil understood. Thus, there is a need 
for identifying molecular markers and genes such as tumor suppressor 
genes implicated in PCa progression. 
There are specific chromosomes that are lost during PCa progression. 
Indeed, cytogenetic analyses showed the alteration of specific chromosomes 
in PCa 56. Indeed, numerous studies showed deletions of chromosome arms 
7q 215, 57, 8p 60, 58, 59, 10q 63, 61, 62, 16q 216, 66, 64, 17q 68, 67, and 18q 66, 240, 69 in 
advanced PCa. The loss of these chromosomes indicates that they encode 
one or more tumor suppressor gene(s) (TSG) implicated in PCa progression. 
Almost ail human chromosomes have been tested for their tumor 
suppressive properties by transferring them into either rat of human PCa 
cells. Indeed, introduction of chromosomes 2 73, 8p 227, 10p 152, 12 164, 18 241, 
and 19 84, 228 showed a tumor suppressing activity when transferred into 
human PCa cells. The loss of chromosome arm 18q is found in 30-40% of 
PCa tumors 66. The transfer of this chromosome into the PCa cell lines DU 
145 and PC-3 completely abolished their tumorigenic potential 189, 193, 242. 
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However, even if studies in PCa patients identified two minimal regions of 
chromosomal loss, no TSG was identified in these regions 231. 
Mitogen-activated protein kinases (MAPK) are a family of serine/threonine 
kinases that play a role in transmitting extracellular signais inside the cell 243. 
Indeed, these proteins are key components of intracellular signalling 
pathways implicated in a variety of cellular processes such as proliferation, 
differentiation, and survival 243. The extracellular-regulated kinases (ERK) 
family of threonine/tyrosine kinases is composed of eight members named 
ERK1 to ERK8. The classical members of the family (ERK1 and ERK2) are 
ubiquitouslyexpressed kinases that, once phosphorylated, translocate to the 
nucleus, and activate transcription factors involved in important cellular 
processes such as survival, proliferation, and differentiation 243. The ERK1 
and ERK2 proteins are up regulated in PCa specimens compared to normal 
prostate tissues 243. Two non-classical members of the ERK family (ERK3 
and ERK4) share 50% homology with ERK1 and ERK2 in their kinase 
domain. They also contain a long C-terminal tail that is not present in the 
ERK1 and ERK2 proteins. Moreover, their phosphoacceptor site (SEG) is 
different from the Thr-X-Tyr site commonly found in the activation loop of 
ERK1 and ERK2 244. However, the exact cellular function of ERK3 and ERK4 
is still unknown. 
As reported previously 245, we have transferred a copy of normal human 
chromosome 18 into the PC-3-derived cell line PC-3M-LN4GP2. Subsequent 
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in vitro and in vivo characterization of these hybrids demonstrated that the 
chromosome cytoband 18q21 suppresses the tumorigenicity of these human 
PCa cells. Genotyping studies showed that the D18S51 locus was linked to 
the suppressed phenotype of the chromosome 18 hybrids. In the present 
study, we characterized three candidate genes located close to the D18S51 
locus (MA SPIN, BCL2, and ERK4) to determine if they are candidates for 
new tumor suppressor genes implicated in PCa progression. 
4.3 Material and methods 
4.3.1 PCa cell line. 
The generation of the geneticin-resistant PC-3M-LN4GP2 cell line was 
described previously 246. Briefly, the PC-3M-LN4 cellline was obtained from 
Dr. I.J. Fidler (M.D. Anderson Cancer Centre, Houston, TX) and was stably 
transfected with the green fluorescent protein (GFP}-encoding plasmid 
pQBI25 (Q-BIOgene, Carlsbad, CA). The cells were then kept in RPMI 1640 
media supplemented with 10% FBS and 400ug/ml of geneticin (Invitrogen, 
Burlington, ON, Canada). 
4.3.2 ERK4 vectors construction and stable transfection. 
The ERK4-wt sequence was cloned into the pcDNA4 His/Max B vector 
(Stratagene, LaJolla, CA), introducing a His tag at the N-terminal region of 
the gene. The V38M polymorphism in the ERK4 gene was introduced by 
PCR amplification to generate the ERK4V38M expression vector. Integrityof 
the sequence and of the open reading frame of these constructs was 
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confirmed by sequencing. The ERK4-wt expression plasmid was stably 
transfected into PC-3M-LN4GP2 cells. Briefly, the cells were plated at 50% 
confluency, and transfected with 5 ug of plasmid DNA using the 
Lipofectamine™ 2000 method (Invitrogen). Clones were picked 10 days after 
transfection, and were named LN4GPerk4wt-1 to 10. Over-expression of the 
ERK4 transcript was confirmed by real-time PCR and the presence of the 
protein (wild-type) was confirmed by Western immunoblot using the 
polyclonal antibody described in Chapter 2 (section 2.5.2). 
4.3.3 Real-time PCR 
The expression of the ERK4 mRNA was assessed by real-time quantitative 
PCR. The amplification was adjusted to GAPDH expression level and gene-
specifie Quantitect primers (Qiagen, Mississauga, ON, Canada) were used 
for PCR amplification. Briefly, a PCR mix was prepared for each sample 
tested: 1X of 2X DyNAmo SYBR Green qPCR kit (New England Biolabs, 
Pickering, ON, Canada), 1X Quantitect primer mix (Qiagen), 50 ng of RT 
reaction in a total volume of 25 ul. The PCR efficiency of the primer sets was 
determined by sequential dilutions of the purified PCR amplicons (1:4 to 
1 :256). PCR reactions were electrophoresed through an agarose gel, and a 
dissociation curve was added to the PCR program to insure that the right 
amplicon was amplified; each reaction was repeated 8 times. The following 
PCR program was ran on an thermal cycler MX4000 from Stratagene: stage 
1: 50°C for 2 mins, stage 2: 95°C for 15 mins, stage 3: 40 cycles of 95°C for 
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15 secs, 60°C for 15 secs and 72°C for 32 secs and stage 4: 95°C for 15 
secs, 50°C for 15 secs and 95°C for 15 secs. The mean Ct (cycle threshold) 
and standard deviation were calculated using Microsoft Excel 2000 
(Microsoft, Mississauga, ON, Canada). The delta Ct (Ct ERK4 - Ct GAPDH) 
and its standard deviation were calculated using the same program. The 
delta-delta Ct method was use to calculate the fold changes as 
recommended by the manufacturer, and a Student t-test was used to 
determine significance of the findings. 
4.3.4 Western immunoblot 
Cells were seeded to 90% confluency, washed twice with ice cold PBS, 
scraped off in Brij97 Iysis buffer (1 % Brij 97, 25 mM Hepes, pH 7.4, 150 mM 
NaCI, 5 mM EOTA, 1 mM Na3V04, 10 mM P-glycerophosphate, 10 mM 
pyrophosphate, 100 units/ml aprotinin, 1 0 ~g/ml leupeptin, 25 ~M p-
nitrophenyl p'-guanidino-benzoate, 1 mM phenylmethylsulfonyl fluoride, 
10 mM iodoacetamide; ail reagents are from Sigma, Oakville, ON, Canada), 
and incubated on ice for 10 mins. Extracts were centrifugated at 13,0009 for 
10 mins at 4°C. Supernatants of matched samples were combined, and 
proteins were quantified with the BCA protein assay kit (Pierce 
Biotechnology Inc., Rockford, IL), according to the manufacturer's protocol. 
40 ug of proteins were boiled 5 mins in 2X Laemmli buffer (62.5mM Tris-HCI 
pH 6.8, 40% v/v glycerol, 5% SOS, 0.005% bromophenol blue containing 
10% of B-mercaptoethanol (Sigma», and electrophoresed through a 10% 
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acrylamide SDS-PAGE gel. The proteins were then transferred (1 hour) onto 
a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA), and 
blocked for 1 h in TBST (25 mM Tris-HCI pH 8.0, 125 mM NaCI, 0.1 % tween 
20) + 5% non-fat dry milk (Bio-Rad Laboratories). The membranes were 
incubated overnight with the appropriate primary antibody in TBST + 5% 
non-fat dry milk. For the MASPIN and the BCL2 proteins, a monoclonal anti-
human antibody was used (Chemicon, Temecula, CA) at a 1 :5000 dilution. 
For the ERK4 protein, a polyclonal antibody obtained from Dr. Sylvain 
Meloche's laboratory (IRIC, Universite de Montreal, Montreal) was used at a 
dilution of 1 :2000 (see section 2.5.2 for details). After 16 hours, the 
membranes were washed 3 times for 15 mins in TBST, and incubated 1 h at 
room temperature with the secondary antibody conjugated to horseradish 
peroxydase (donkey anti-rabbit for ERK4 (Bio/Can Scientific, Etobicoke, ON, 
Canada) and goat anti-mouse for MASPIN and BCL2 (Fisher Scientific, 
Nepean, ON, Canada» in TBST + 5% non-fat dry milk. The bound antibodies 
were detected using the ECL detection kit (GE Healthcare, Baie d'Urfé, QC, 
Canada), and each experiment was performed three times. 
4.3.5 Sequencing. 
The entire coding sequence of the ERK4 gene was amplified using the 
Phusion high-fidelity DNA polymerase (New England Biolabs), according to 
manufacturer's instructions. Briefly, a PCR reaction containing 1 X Phusion 
HF buffer, 200 uM of each dNTP, 0.5 uM of each primer, 0.0 2U/ul of 
Phu sion DNA polymerase, 100 ng of genomic DNA or 50 ng of cDNA was 
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prepared in a final volume of 20 ul. The following program was ran: 98°C for 
30 secs, followed by 40 cycles of 98°C for 10 secs, annealing temperature 
for 30 secs and 72°C for 30 secs with a final extension of 72°C for 10 mins. 
The primers used for amplification of the ERK4 nucleic acids were: 
mapk464 (5'-TGGGCAGCTCCAGATCACTG-3') and 
mapk802c (5' -ACGATGTACGCCACGCTGAA-3') 
(for mRNA or genomic DNA); 
mapk672 (5' -CACGCGCTCCGAGAGATCAA-3') and 
mapk1520c (5' -GTI AGCGGCCATCAGCACGA-3') (for mRNA); 
mapk1487 (5' -GAGATCGACGACATCGTGCT -3') and 
mapk1841 c (5' -AGT AGTGGTGCGGCTTGTTG-3') (for mRNA); 
annealing temperatures varied from 60 to 69°C. The sequencing on the 
coding sequence of the ERK4 gene was done using primers specifie for 
ERK4 mRNA. Primers mapk464 and mapk802c were used to screen the 
V38M polymorphism in our PCa cases and controls as they can amplify 
genomic DNA. The PCR reactions were electrophoresed through a 1 .5% 
aga rose gel, the PCR products were extracted from the gel using the gel 
extraction kit (Qiagen), and sent to the McGiII University and Genome 
Quebec Innovation Centre (Montreal) for sequencing. Primers used for 
sequencing were the same as for PCR amplification. Briefly, the PCR 
products were purified and resuspended in 2 ul to be amplified with the Big 
Dye Terminator (Applied Biosystems, Foster City, CA) according to the 
manufacturer's protoco!. The following conditions were used for 
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amplification: 96°C for 1 min, 25 cycles of 96°C for 30 secs, 50°C for 10 
secs, 60°C for 4 mins. The reactions were precipitated, centrifugated, air-
dried, and the pellets were resuspended in formamide. The fluorescence 
was then read on ABI 3730xl DNA analyser (Applied Biosystems). 
4.3.6 Soft agar assays 
The soft-agar assays were performed as described previously 212. Briefly, 1 
ml of 0.5% agar noble (Fisher Scientific) diluted in appropriate media was 
put into 6-well plates to form the basal layer. Then 1,000 cells were mixed 
with 0.5% agar and put on top of the basal layer. Plates were incubated at 
37°C for 10 days. Growing cell foci were stained with 200 JlI of a 0.03% 
crystal violet (Sigma) solution in 100% methanol (Fisher Scientific). The 
number of colonies was counted, and converted to a percentage of colonies 
obtained from the parental cell line (number of colonies formed by PC-3M-
LN4GP2 ceilline = 100%). Each soft-agar assay was performed in six wells 
per ceilline and a Student's t-test was used to calculate p values. 
4.3.7 Invasion Assays. 
We used a Boyden chamber assay 211 to assess invasive potential. Briefly, 
25,000 cells were added to the chamber coated with Matrigel (Fisher 
Scientific), and RPMI 1640 medium supplemented with 5% FBS was added 
to the botlom chamber to serve as chemoatlractant. The chambers were 
incubated at 37°C for 22 hours, and filters were stained with a Diff-Quick 
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staining kit (Dade Behring, Newark, DE). Invasive cells from five random 
fields were counted under a contrast phase microscope at 200X 
magnification. Ali invasion experiments were performed in quadruplicate, 
and the results were expressed as percentage of the invasion obtained with 
the parental cell line (parental = 100%). The significance of the findings was 
calculated using a two-tailed Student's t-test. 
4.3.8 Nude mice injections. 
Ali in vivo tumorigenicity assays were done according to Canadian Council 
for Animal Care guidelines, after approval by the McGiII University Animal 
Care Committee. Male nude mice (balb/c, nu/nu; six to eight weeks of age; 
Charles River Laboratory, St-Constant, QC, Canada) were injected with PCa 
cells. One million cells, in 200 J.d of Hanks balanced saline solution (HBSS; 
Invitrogen) were injected subcutaneously in the upper back of nude mice. 
Mice were sacrificed when tumors reached 1000 mm3. 
4.4 Results 
4.4.1 Selecting candidate genes 
After confirming that the D18S51 locus was linked to the less tumorigenic 
phenotype of our hybrids, we chose to analyze three candidate genes 
located around that locus. Based on preliminary microarray data, we decided 
to characterize the only two genes on chromosome 18 (ERK4 and BCL2) 
that were differentially expressed between a tumorigenic (LN4B 156-2) and a 
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less tumorigenic hybrid (LN48156-6). BCL2 is an oncogene in PCa but the 
loss of a BCL2 repressor could be responsible for its up regulation in the 
highly tumotigenic hybrids. Thus, this repressor could be a candidate TSG 
for PCa. Furthermore, and mainly due to its function of a metastasis 
suppressor gene implicated in PCa progression 135, we also analyzed the 
MASPIN gene. 
4.4.2 Real-time peRo 
We used real-time quantitative PCR to determine if the ERK4, BCL2 and 
MASPIN genes were differentially expressed in our tumorigenic and less 
tumorigenic hybrids. When compared to the less tumorigenic hybrid 
LN48156-6, MASPIN is significantly down regulated in the parental cell line 
PC-3M-LN4GP2 (-1.57 fold, p=0.03), in the tumorigenic hybrid LN48156-2 
(-1.86 fold, p=0.02) and in tumors derived from subcutaneous injections of 
these cells (TLN156-6-3 -3.10 fold, p=0.05). Interestingly, MASPIN was 
reported to be down regulated in PCa 247, 248 as weil as in lung cancer 249 
and in Iymphoma 250. As expected for an oncogene, BCL2 is over-expressed 
in the parental cell line PC-3M-LN4GP2 (12.68 fold, p=0.138), in the 
LN48156-2 hybrid (3.88 fold, p=0.01), as weil as in the tumors (2.22 fold, 
p=0.01, data not shown), which is consistent with three previous reports 
mentioning that BCL2 is up-regulated in PCa 251, 247, 252. ERK4 is down 
regulated in the parental cells (-6.295 folds, p=0.226), in the LN48156-2 
hybrid (-20.645 folds, p=0.03), and in the tumors (-1.775, p=0.005, data not 
shown) when compared to the less tumorigenic LN48156-6 hybrid. This 
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gene is down-regulated in two other studies comparing PCa cells and normal 
prostate cells 247, 253, as weil as in adrenal cancer 254, lung cancer 249 and 
small celilung cance~49. 
4.4.3 Western immunoblot 
T 0 verify that these differences in mRNA expression also affect the protein 
level of these genes, we performed Western immunoblot. Antibodies for 
each protein were blotled on a membrane containing 40 ug of total proteins 
from the parental B78MC156 and PC-3M-LN4GP2 cells, from LN4B156-2, 
and LN4B156-6 hybrids, from the derived TLN156-6-3 tumor cells and from 
PC-3M-Pro4GP1, another prostate cancer parental cell line of sorne of our 
hybrids. This cell line was included since the transfer of chromosome 18 in 
these cells did not have any effect on their tumorigenicity (see Chapter 3). 
This will allow us to see if the protein expression varies among tumorigenic 
and less tumorigenic cells. 
As shown in figure 8, there was no difference in the protein expression 
levels of BCL2 or MASPIN between our less tumorigenic and our highly 
tumorigenic hybrids., Moreover, quantification of these blots by 
phosphorimager did not show any significant difference between our hybrids 
(n=3, data not shown). Even if BCL2 or MASPIN protein levels do not vary 
between tumorigenic and less tumorigenic cells, this doesn't rule out the 
possibility that a BCL2 repressor or MASPIN could be responsible for the 
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less tumorigenic phenotype of our hybrids since these genes could still be 
mutated in our hybrids, rendering the produced protein non-functional. 
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Figure 8. MASPIN and BCL2 Western immunoblot. Top and middle panel. 
40ug of proteins were loaded on a 10% SOS-PAGE. BCL2 or MASPIN were 
detected using monoclonal anti-human BCL2 or anti-MASPIN antibody. 
Lanes 1 and 2. Parental mouse/human hybrid B78MC156 and human PC-
3M-LN4GP2 cells. Lane 3. Highly tumorigenic hybrid LN4B156-2. Lane 4. 
Less tumorigenic hybrid LN4B 156-6. Lane 5. Tumor-derived cell line 
TLN156-6-3. Lane 6. Human prostate cancer cell line PC-3M-Pro4GP1 in 
which the transfer of chromosome 18 had no effect on their tumorigenic 
properties. Bottom panel. ACTIN, used as a loading control, was detected on 
the same membrane. 
118 
» () 
-1 
-Z 
~ 
N 
A 
o 
ru 
OJ 
() 
r 
N 
N 
m 
A 
o 
Q) 
. 878MC156 
PC-3M-LN4GP2 
LN4B156-2 
LN4B156-6 
TLN156-6-3 
PC-3M-Pro4GP1 
Since endogenous ERK4 protein was not detectable in our cell lines (PC-
3M-LN4GP2, PC-3M-Pr04GP1, LN48156-2, LN48156-6, TLN156-2-2 and 
TLN156-6-3) by Western immunoblot, we treated the cells with the 
proteasome inhibitor MG132. It has been shown that treating cells with this 
inhibitor greatly increases the protein level of ERK3, a very unstable member 
of the ERK family that is highly degraded by the proteasome complex 255. 
Considering the homology between ERK3 and ERK4, it was worthy to 
determine if such treatment will also affect the stability of ERK4. However, 
even in these stabilizing conditions, the ERK4 protein was not detectable. 
Thus, these experiments assessing mRNA and protein levels of our three 
candidate genes suggest that they could ail still be responsible for the less 
tumorigenic phenotype seen in our hybrids. Since ERK4 has no known 
function, we have decided to pursue its characterization. 
4.4.4 ERK4 over-expression 
The wild-type ERK4 gene was transfected (along with an empty vector 
(mock» into PC-3M-LN4GP2 cells to assess its effect of the tumorigenic 
properties of these cells. Over-expression of the ERK4 mRNA was confirmed 
by real-time PCR. Indeed, the LN4GPerk4wt-1, LN4GPerk4wt-3 and 
LN4GPerk4wt-4 transfected cells are expressing 290 to 650 fold more ERK4 
mRNA than the non-transfected PC-3M-LN4GP2, or the mock-transfected 
LN4GPmock-1 (data not shown). The over-expression of the ERK4 protein in 
stable transfectants was confirmed by Western immunoblot (Figure 9). Since 
endogenous ERK4 protein is not detectable in our non-transfected cells, we 
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assessed the detection threshold level of our polyclonal ERK4 antibody. T 0 
do so, we serially diluted a protein extra ct from an ERK4 over expressing cell 
line 1 to 1/10,000 and performed a Western blot (Figure 10). The ERK4 
protein was detectable in the 1 :100 lane (Figure 10, top panel), while ACTIN 
was detectable in the 1:1000 lane (Figure 10, bottom panel). This indicates 
that transfected cells express at least 100 fold more ERK4 protein than the 
parental cells. Cells over-expressing wild-type ERK4 protein have 
significantly reduced ability to form colonies in soft agar as compared to the 
non-transfected parental cell line (Table 6, see LN4GPerk4wt-1, wt-3, wt-4 
and wt-10 vs PC-3M-LN4GP2, p<0.05). The cells transfected with the empty 
vector (mock) have a slight decrease in their anchorage-independent ability 
but still form 10 times more colonies than the ERK4-over-expressing cells 
(p= 0.0003 to p=0.000005). Moreover, over-expression of ERK4 also affects 
the invasive properties of these cells (Table 7, compare LN4GPerk4wt-1, 3 
and 10 versus LN4GPmock-6 and PC-3M-LN4GP2). Indeed, the 
LN4GPerk4wt-1, 3, and 10 cells are respectively 28% (p=0.002), 23% 
(p=0.0015), and 38% (p=0.008) as invasive as the parental PC-3M-LN4GP2 
cells. There is no significant difference between the invasive properties of 
the non-tranfected PC-3M-LN4GP2 cells and the mock-transfected 
LN4GPmock-6 cells. Taking together, these results show that over-
expression of ERK4 protein greatly reduces the in vitro invasive and 
anchorage-independent properties of human prostate cancer cells. 
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Figure 9. ERK4 is over-expressed in transfected cells. The top panel shows 
the expression of ERK4 in transfected (LN4GPerk4wt-1, LN4GPerk4wt-3, 
LN4GPerk4wt-4 and LN4GPerk4wt-10) and mock-transfected cells 
(LN4GPmock-6). The bottom panel iIIustrates the expression of ACTIN as a 
loading control. In the right panel, the positive control is an extract of 
fibroblasts transiently transfected with ERK4 and the negative control is the 
non-transfected PC-3M-LN4GP2 celiline. 
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Figure 10. Quantification of ERK4 over-expression. Top panel. Seriai dilution 
fram 1 to 1: 10,000 of an ERK4 over expressing pratein extra ct ran of 
acrylamide gel and detected with ERK4 polyclonal antibody. Botlom panel. 
ACTIN detection on the same membrane to control for loading. 
122 
» (') 
--i 
-Z 
~ 
1\.) 
" o ru 
l l 
1 
1:10 
1 :100 
1 :1000 
1:10,000 
Table 6. Anchorage independent growth of prostate cancer cells over-
expressing ERK4, as determined by soft agar assays 
Cellline Colony formation and 
significance * 
LN4GPerk4wt-1 2.74%, p=0.000004 
LN4GPerk4wt-3 6.16 % p=0.000038 
LN4GPerk4wt-4 17% p=0.00005 
LN4GPerk4wt-10 16.58% p=0.000005 
LN4GPmock-6 66.7% p=0.003 
* The number of colonies obtained with PC-3M-LN4GP2 (varying from 511 to 
626) was established at 100%. The experiments were repeated 6 times. The 
p value was generated by a two-tailed Student's t-test. 
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Table 7. Invasive properties of prostate cancer cells over-expressing ERK4, 
as determined by Boyden chamber assays 
Cellline Invasiveness * P values compared to 
parental 
PC-3M-LN4GP2 100% -
LN4GPmock-6 93% 0.794 
LN4GPerk4wt-1 28% 0.002 
LN4GPerk4wt-3 23% 0.0015 
LN4GPerk4wt-10 38% 0.008 
* The number of cells migrating through Matrigel obtained with PC-3M-
LN4GP2 (varying from 75 to 115) was established at 100%. The 
experiments were repeated 4 times. The p values were caculated by a two-
tailed Student's t-test. 
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4.4.5 Nude mouse injections 
Cells over-expressing the ERK4 protein (LN4GPerk4wt-1, and LN4GPerk4wt-
3), non-transfected parental PC-3M-LN4GP2, and mock transfected 
LN4GPmock-2 cells were injected subcutaneously in nude mice. The tumors 
formed by the ERK4 over-expressing cells grow at the same rate as the 
tumors formed by the parental cells, or the mock transfected cells (data not 
shown), and are still over-expressing the ERK4 protein at the same javel. 
These results contrast with the on es obtained when chromosome 18 was 
transferred into the sa me PC-3M-LN4GP2 cells, where tumor formation was 
significantly delayed (see Chapter 3). Such differences argue that in vivo 
suppression of tumorigenicity requires the presence of an additional 
suppressor gene on human chromosome 18. 
4.4.6 ERK4 sequencing 
We have sequenced the full coding sequence of the ERK4 mRNA (bp 414 to 
2153) in three commonly used PCa cell lines, and found a polymorphism at 
bp 603, located in the kinase domain of the ERK4 protein (called V38M since 
it substitutes a valine at position 38 for a methionine). This polymorphism is 
present in ail our hybrids derived from PC-3M-Pro4 and PC-3M-LN4, and in 
two of the commonly used PCa celllines (LNCaP and PC-3). Ali PC-3-derived 
cell lines (PC-3, PC-3M-Pro4 and PC-3M-LN4) are homozygous for the V38M 
polymorphism, while LNCaP cells are heterozygous. A preliminary screening 
was done on 111 Ashkenazi Jewish controls and 70 consecutive Ashkenazi 
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Jewish PCa patients since they are a genetically closed population that would 
allow us to find any link between PCa and the presence of this polymorphism. 
However, no significant difference was found in the frequency of the 
polymorphism between the controls and the cases (p=O.27 (Chi/Fisher exact 
test) and Table 8). Indeed, the allelic frequency is 41% in the controls and 
39% of the Pca cases. However, there was a difference (p=O.06) in the 
Gleason score of the homozygous (-/-) and heterozygous (+/-) V38M patients 
versus the wild type allele (+/+). Indeed, Gleason score was higher in patients 
with a homozygous or heterozygous polymorphism, as compared to the 
patients with no polymorphism. However, the analysis of additional cases is 
needed to statistically establish if this V38M polymorphism is implicated in the 
more aggressive form of the disease. It is interesting to note that 
polymorphisms in other genes, such as the length of the CAG repeat in the 
androgen receptor have been linked to higher risk of developing an 
aggressive PCa 256. 
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Table 8. V38M polymorphism screening 
Position 38 Jewish Jewish 
controls cases 
Normal +/+ 35/111 29/70 
Heterozygous 60/111 28/70 
+/-
V38M 16/111 13/70 
homozygous -/-
Total 111 70 
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4.5 Discussion 
We have suppressed the tumorigenicity of human PCa cells by transferring 
into them a normal copy of human chromosome 18. We have then narrowed 
down the region responsible for this phenotype to a 10Mb region around the 
018S51 marker 257. 
ln this study, we selected three candidate genes located around the 018S51 
locus, and determined their mRNA and protein level in our tumorigenic and 
less tumorigenic hybrids. mRNA levels of both MASPIN and ERK4 were 
significantly down regulated in tumorigenic cells as compared to less 
tumorigenic cells. The mRNA level of BCL2 was up regulated in tumorigenic 
cells when compared to less tumorigenic cells. However, the protein levels of 
MASPIN and BCL2 were not different between tumorigenic and less 
tumorigenic cells. This suggests that MASPIN or a BCL2 repressor might not 
be responsible for the less tumorigenic phenotype of our hybrids. However, 
these two genes could be mutated, which would reder the produced protein 
non-functional. Thus, sequencing these two genes in our hybrids would be 
required before we can rule them out as candidate TSGs in our cell system. 
Moreover, MASPIN has been shown to suppress tumorigenicity when 
introduced into TRAMP C2N PCa cells 135, LNCaP or DU 145 cells 258. 
However, we have not found any independent evidence through a Iiterature 
search that MASPIN suppresses the tumorigenicity of PC-3-derived cells. 
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The ERK4 protein levels were undetectable by regular Western immunoblot, 
or upon proteasome inhibitor treatment. This shows that our cells express 
very low levels, if any, of ERK4 protein. Cell treatment with the proteasome 
inhibitor MG132 failed to allow the detection of these proteins. This is 
interesting since the other non-classical ERK protein ERK3 was shown to be 
very unstable with a half-life of 30 minutes, accordingly that protein could be 
stabilized by proteasome inhibition 255. ERK3 is rapidly degraded by the 
proteasome, but this might not be the case for ERK4. Further studies are 
needed to assess ERK4 protein stability .. 
Here we report that ERK4 is down regulated in tumorigenic cells and, that its 
overexpression in human PCa cells completely abolishes their anchorage-
independent growth potential. Furthermore, the ERK4 overexpressing cells 
show reduced invasiveness through Matrigel. However, when injected 
subcutaneously into nude mice, the ERK4 overexpressing cells form as many 
tumors as the parental cells, or the mock-transfected cells. This could suggest 
that, in vivo, ERK4 needs a partner to perform its tumor suppressing function. 
Such partner would be located around the 018851 region and was directly 
brought into the LN48156-6 cells by the transfer of chromosome 18, or was 
induced bya gene located in this region. This partner would act synergically 
with ERK4 in vivo to suppress the tumorigenictiy of human PCa cells. 
Alternatively, it is also possible that ERK4 is not implicated in in vivo 
tumorigenicity and that it has only an effect in vitro .. In such case, ERK4 will 
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not be the TSG revealed by the transfer of the chromosome 18 in our PCa 
cells, but just a gene located in this region, which happens to inhibit in vitro 
growth properties of these cells. Thus, in vitro, ERK4 cou Id be sutficient to 
suppress the invasiveness and the anchorage-independent growth of PCa 
cells. However, in vivo, there could be a need for adaptation to the mouse 
microenvironment in order to suppress tumor formation, and this can be 
achieved only in presence of ERK4 and its partner(s). There are about 50 
genes around the D18S51 locus, and many of them could be putative ERK4 
partners. For example, there is a serpin and a cadherin cluster that could also 
be TSG implicated in PCa progression. 
The ERK4 gene contains a SNP called V38M that is present in PCa patients 
at the same frequency th an in the populations tested. Thus, the V38M SNP 
does not seem to be linked to PCa. However, with the limited number of 
patients and controls tested, we had only an 80% power of detecting a 2.55 
odd ratio (with 95% confidence intervals). This means that even if there was a 
significant ditference in the allelic frequency of V38M between controls and 
PCa cases, we wouldn't have been able to detect it. Thus, more patients and 
more controls are needed to establish if there is any link between PCa and 
the V38M polymorphism. When the allelic frequency of the 471delAAAG SNP 
of the RNA SEL gene was tested in the same Ashkenazi Jewish controls and 
cases, Kotar et al. 259 found a non-significant odd ratio of 0.47 (p=0.61, 
confidence intervals 0.02). They also argue that a bigger sample size is 
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needed to fully analyse the significance of the allelic frequency of 
polymorphisms linked to PCa in this population. 
ln 2000, Padalecki S. et al. reported two minimal regions of chromosomal loss 
located between markers 018S1119 and 018S64 (52 and 55Mb), and 
between 018S848 and 018S58 (40 and 70Mb) 231 but so far, no TSG has 
been mapped to these intervals. Interestingly, the ERK4 gene is located at 
47Mb (in the second minimallost region), and could thus be the first of many 
TSGs implicated in PCa progression that maps in these intervals. 
4.6 Conclusion 
Even if the final proof is still lacking, our in vitro results suggest that ERK4 
could be implicated in PCa progression. We are currently generating an 
ERK4-V38M construct to assess the influence of this polymorphism on ERK4 
function. Furthermore, we are generating different truncated ERK4 constructs 
that will be stably transfected in our PC-3-derived cells to assess the function 
of the C-terminal tail and the kinase domain of ERK4. These studies should 
help us understand the function of the C-terminal tail of ERK4. 
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5.0 Preface 
This manuscript is a study reporting a comparison of the frequency of the 
V38M polymorphism described in Chapter 4 in three different human 
populations (Asian, European and African). Since it is not related to prostate 
cancer, we have decided to put it in a different chapter. The permission from 
the co-author can be found in Appendix E. 
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5.1 Abstract 
Mitogen-activated protein kinases (MAPK) are implicated in a variety of 
cellular processes such as differentiation, survival, and proliferation. In this 
study, we have identified a polymorphism located in the coding sequence of 
the ERK4 kinase gene. This polymorphism creates an Ncol site. We have 
screened DNA samples from individuals from Asia, Africa (Yoruba), and 
Europe for the presence of this SNP. Interestingly, we found the SNP at the 
same frequency in Asian and European individuals, but at a much lower 
frequency in the individuals from Africa. The SNP homozygosity frequency 
was very low in this group (4/90). To this date, the MAPK4 protein encoded 
by the ERK4 gene has no known cellular function. 
5.2 Introduction 
Mitogen-activated protein kinases (MAPK) are a family of serine/threonine 
kinases that play a role in transmitting extra cellular signais inside the cell 
260. These proteins are key components of intracellular signalling pathways 
implicated in a variety of cellular processes su ch as proliferation, 
differentiation, and survival 261. The extracellular-regulated kinases (ERK) 
family of threonine/tyrosine kinases is composed of eight members named 
ERK1 to ERK8. The classical members of the family (ERK1 and ERK2, 
official name MAPK3 and MAPK1) are ubiquitously expressed kinases that, 
once phosphorylated, translocate to the nucleus, and activate transcription 
factors involved in proliferation and differentiation 243. The ERK1 and ERK2 
proteins are upregulated in PCa specimens, compared to the normal 
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prostate tissue 262. Sorne members of the ERK family are also activated in 
colorectal cancer 263. Two non-classical members of the ERK family (ERK3 
and ERK4, official name MAPK6 and MAPK4) share 50% homology with 
ERK1 and ERK2 in their kinase domain. They also contain a long C-terminal 
tail that is not present in ERK1 and ERK2 proteins. Moreover, their 
phosphoacceptor site (SEG) is different from the Thr-X-Tyr site commonly 
found in the activation loop of ERK1 and ERK2 244. However, the exact 
cellular function of ERK3 and ERK4 is still unknown. 
5.3 Methods 
5.3.1 r.603G>A SNP screening 
We have compared the DNA sequence of controls to the NCSI sequence 
NM_002747. We have searched the NCSI SNP database and found the 
same SNP only in one brain tumor. To establish the frequency of the 
r.603G>A SNP in different populations worldwide, we used DNA from 93 
Asian, 92 European, and 90 African individuals. The r.603G>A SNP 
introduces an Ncol restriction site, which facilitates its detection. Sriefly, we 
PCR amplified the sequence spanning the SNP and digested the products 
with Ncol. The primer set mapk464 (5'-TGGGCAGCTCCAGATCACTG-3') 
and mapk802c (5'-ACGATGTACGCCACGCTGAA-3') was used to amplify 
the sequence surrounding this SNP. Briefly, a PCR reaction containing 1 X 
Phusion HF buffer (New England Siolabs, Pickering, ON, Canada), 200 uM 
of each dNTP (Invitrogen, Surlington, ON, Canada), 0.5 uM of each primer 
(Sigma, Oakville, ON, Canada), 0.02 U/ul of Phusion DNA polymerase (New 
136 
England Biolabs), 200 ng of genomic DNA was prepared in a final volume of 
20 ul. The following program was ran: 98°C for 30 secs, followed by 40 
cycles of 98°C for 10 secs, 65°C for 30 secs and 72°C for 30 secs with a 
final extension of 72°C for 10 mins. The reactions were prepared in a final 
volume of 50 ul using the same reagent concentrations as above. Then, 10ul 
of the PCR reaction was electrophoresed through an aga rose gel to verity 
the quality of amplification. 10 ul of the PCR reaction was digested with 10U 
of Ncol in a total volume of 40 ul. The digestions were electrophoresed 
through an aga rose gel to verify the presence of the SNP (homozygous 
normal G/G= 338 bp; heterozygous GIA = 100 bp, 238 bp; and 338 bp; 
homozygous V38M A/A = 100 bp and 238 bp). An undigested PCR reaction 
was also electrophoresed as a control. 
5.4 Results 
5.4.1 ERK4 sequencing 
We have sequenced the coding region of the ERK4 mRNA (bp 414 to 2153) 
in three commonly used PCa cell lines and found the SNP 
NM_002747:r.603G>A, located in the kinase domain of the ERK4 protein 
(the SNP results in Val38Met since it changes valine 38 for a methionine). 
The commonly used PCa cell lines LNCaP is heterozygous whereas PC-3 is 
homozygous for r.603G>A. A screen of different populations from Asia, 
Africa (Yoruba), and Europe was performed to assess the frequency of this 
SNP. As shown in Table 9, there is a significant difference in the frequency 
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of the SNP between the Asian and the European, compared to the African 
Yoruba population (p<O.00005, two-sided Chi/Fisher exact test). Indeed, the 
allelic frequency is 15% in the African population compared to 33% and 41 % 
among Asian and European individuals, respectively. Also, careful analysis 
of the NCSI publicly available SNP database, failed to reveal any other 
polymorphism or SNP in the whole coding region of the ERK4 gene. Thus, 
the Val38Met polymorphism is the first SNP reported in the coding sequence 
of the ERK4 gene. 
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Table 9. r.603G>A SNP screening 
SNP status Asian African European 
Normal GTG/GTG 43/93 67/90 34/92 
Heterozygous 38/93 19/90 40/92 
GTG/ATG 
V38M 12/93 4/90 18/92 
homozygous 
ATG/ATG 
Total 93 90 92 
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5.5 Discussion 
ln this study, we showed that the ERK4 gene contains a SNP called 
r.603G>A that is present at the same frequency in two of the three 
populations tested. Few SNPs have been reported for the members of the 
ERK family. Indeed, this is the first report of a SNP located in the coding 
sequence of the ERK4 gene. Ali the 213 reported SNPs for this gene are 
located in untranslated regions or in introns. For the ERK1 gene, only 16 
SNPs were reported, and two synonymous SNPs are located in its coding 
sequence (both at amino acid 336). In the ERK2 gene, 307 SNPs were 
reported, and only 3 synonymous ones are located in its coding sequence. In 
the ERK3 gene, 99 SNPs were identified, and this is the only ERK gene in 
which non-synonymous SNPs were reported. Indeed, two nonsynonymous 
SNPs p.Lys254Glu and p.Cys256Arg were identified. Ali other ERK genes 
have SNPs that do not change the encoded amino acids. 8ased on other 
ERK genes, the kinase domain of ERK4 is thought to be responsible for its 
cellular function. The SNP identified in this study is located at amino acid 38 
(p.VaI38Met), which is located in the kinase domain of ERK4. Since it 
changes an amino acid, it might also have an influence on the function or 
cellular localization of the ERK4 protein. Further characterization of ERK4 
function is needed to assess the putative influence of this SNP on the 
function of this protein. 
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CHAPTER6 
GENERAL DISCUSSION 
AND CONCLUSION 
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6.0 Thesis summary 
ln this thesis, we have used the microcell-mediated chromosome transfer 
technique to assess which human chromosome(s) can affect the tumorigenic 
properties of human prostate cancer cells in vitro and in vivo. To do so, we 
transferred chromosomes that are the most frequently lost during PCa 
progression into two very aggressive human PCa cell lines called PC-3M-
Pro4GP1 and PC-3M-LN4GP2. Indeed, we showed that the transfer of 
different chromosomes can have an effect on either in vitro and/or in vivo 
characteristics of human PCa cell lines. This thesis mainly concentrates on 
the transfer of chromosome 18 into PC-3M-LN4GP2 cells. This transfer 
demonstrated that chromosome 18 contains a tumor suppressor gene 
implicated in PCa progression. We narrowed down the region encoding this 
TSG to the 018S51 region using polymorphie microsatellite markers and 
PCR mapping. We characterized three candidate genes (BCL2, MASPIN 
and ERK4), and showed that ERK4 could be responsible for the less 
tumorigenic phenotype seen in our chromosome 18 hybrids (Figure 11). 
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Figure 11. Summary of the thesis showing that we started this the sis with 24 
chromosomes and about 25,000 genes and finished by identifying a good 
candidate for a new tumor suppressor gene implicated in prostate cancer 
progression. 
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24 chr 3 X 106 Mb 25 000 genes 
~ ~ ~ 
chr 18 76 Mb 400 genes 
~ ~ 80 Jenes 18q21 20 Mb 
~ ~ ~ 
018S51 10 Mb 54 genes 
~ ~ genes tested: 3 genes 
MA SPIN, BCL2, ERK4 
~ ~ 
ERK4 putative TSG ~ ~ 1 gene 
ln this thesis: 
1) ln Chapter 3, we show that the transfer of chromosome 10 reduces 
the ability of the PC-3M-LN4 human prostate cancer cells to invade 
through Matrigel. However, chromosome 10 hybrids (LN4877 -) did 
not show any reduced growth ability in nude mice. We also show that 
chromosome 12 can decrease cell invasiveness in PC-3M-LN4, but 
did not have any effect on their anchorage-independent growth in soft 
agar. The transfer of a translocated chromosome t(17:3, with 
unknown breakpoints) had an effect on cell colony formation potential, 
as weil as on in vivo tumorigenic properties but increased their 
invasiveness. 
2) ln Chapter 3, we show that the transfer on chromosome 18 into PC-
3M-LN4GP2 cells decreases their ability to invade through Matrigel. It 
also abolishes their colony formation potential. The cells also have a 
delayed and greatly reduced tumor growth in nude mice, both 
subcutaneously and orthotopically. This suggests that chromosome 
18 encodes a tumor suppressor gene implicated in prostate cancer 
progression. 
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3) ln Chapter 3, we use polymorphie microsatellite markers to narrow 
down the region that encodes the tumor suppressor gene to the 
vicinity of the D18S51 locus. 
4) ln Chapter 4, we characterize three candidate genes (BCL2, MASPIN 
and ERK4) that could be implicated in the less tumorigenic phenotype 
of our chromosome 18-derived LN48156-hybrids. We use real-time 
PCR and Western immunoblot to examine the possibility that a BCL2 
repressor or MASPIN could be responsible for this phenotype. 
5) ln Chapter 4, we show that prostate cancer cells express very little 
amount (if any) of ERK4 protein. The treatment of these cells with a 
proteasome inhibitor did not allow us to detect the ERK4 protein by 
Western immunoblot. 
.In Chapter 4, we show that ERK4 mRNA expression is significantly 
reduced in tumorigenic compared to less tumorigenic cells. We also 
show that cells over-expressing ERK4 have a decreased invasive 
potential. The ERK4-transfected cells also form significantly fewer 
colonies in soft agar compared to the non-transfected or mock-
transfected cells. However, we show that ERK4 overexpressing cells 
do not have reduced or delayed tumor formation when injected 
subcutaneously in nude mice. 
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7) ln Chapter 5, we describe a new SNP, r.603G>A, located in the 
coding region of the ERK4 gene which results in p.VaI38Met. This is 
the first SNP reported in the coding sequence of this gene. 
6.1 General discussion 
ln this thesis, we transfer chromosomes 10, 12, t(17:3, with unknown 
breakpoints), and 18 into two human prostate cancer cells called PC-3M-
LN4GP2 and PC-3M-Pro4GP1. As shown in Chapter 3, transfer of 
chromosomes 10, 12, and t(17:3, with unknown breakpoints) affected 
differently the in vitro and in vivo characteristics of these two prostate cancer 
cell lines. Indeed, the two cell lines chosen for these transfers have been 
isolated differently in vivo 204. The PC-3M-Pro4GP1 cells are very aggressive 
cells in the prostate since they were selected in the prostate of nude mice. 
However, the PC-3M-LN4GP2 cells are also aggressive but form Iymph 
nodes metastases upon injection in nude mice. Thus, their expression profile 
is very different since they have different phenotypes in vitro and different 
tumorigenic and metastatic abilities in vivo. 
When we transferred chromosome 10, we observed reduced invasiveness 
and decreased colony formation in soft agar in both cell lines. The transfer of 
the t(17:3, with unknown breakpoints) into these two celllines increased their 
invasiveness properties, but decreased their colony formation potential in 
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soft agar, and their tumor growth in vivo. Again, this shows that human 
chromosomes contain genes implicated in different processes in vitro and in 
vivo, and that their transfer in cell lines with different properties can have 
opposite effects. The transfer of chromosome 12 into these same cell lines 
had an opposite effect on their invasiveness. Indeed, LN489- cel/s are less 
invasive that parental PC-3M-LN4GP2 cel/s, whereas Pro489- cells are 
more invasive than parental PC-3M-Pro4GP1. The colony formation 
potential of both parental cell lines remained unchanged upon transfer of 
chromosome 12. This shows that chromosome 12 contains genes that could 
be implicated in invasiveness properties, but not in anchorage-independent 
growth. This contrasts with the previous results obtained from this laboratory 
164 where it was shown that transfer of human chromosome del(12)(q13) into 
DU 145 prostate cancer cells completely abolished their tumor growth ability 
in nude mice. The DU 145 cell line was isolated from a brain metastasis from 
a 69 years old prostate cancer patient 264. In vitro and in vivo, DU 145 cells 
have different properties than the PC-3-derived cell lines we have used. 
Thus, the endogenous properties of the cellular model used may explain that 
transfer of chromosome 12 into our PC-3-derived cell lines had a different 
effect than the one expected. Indeed, genetic alterations of the recipient cells 
such as lost TSGs/MSGs, chromosomal aberrations, methylated genes vary 
among cell lines and may account for the differences in the phenotype 
observed after the transfer of a specific chromosome. 
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We have transferred a copy of human chromosome 18 into PC-3M-LN4GP2 
cells. This transfer resulted in two sets of hybrids: one set that were highly 
invasive, formed colonies in soft agar, and formed tumors in nude mice 
(subcutaneously), and a second set that were less invasive, formed less 
colonies in soft agar, and formed fewer and latent tumors in nude mice 
(subcutaneously and orthotopically). However, the transfer of chromosome 
18 in PC-3M-Pr04GP1 cells did not have any significant effect on their in 
vitro or in vivo properties, suggesting that the choice of the recipient cell line 
has an impact and that the MMCT technique itselft does not affect these 
properties. Since we observed major differences in the phenotype of our two 
sets of LN48156- hybrids, we suggested that these differences were due to 
the loss of a TSG in our highly tumorigenic hybrids. Indeed, ail hybrids were 
generated upon transfer of chromosome 18 but the highly tumorigenic 
hybrids have lost (deleted) a TSG encoding region that is still present in the 
less tumorigenic hybrids. Using PCR mapping, we narrowed down the region 
encoding the tumor suppressor to the 018S51 locus. Indeed, one allele 
(allele 1A) was linked to the less tumorigenic phenotype of our hybrids since 
it was present in ail less tumorigenic hybrids, deleted in ail tumorigenic 
hybrids and lost upon tumorigenesis. This argues that a TSG lies around that 
018S51 locus. 
We then analysed three candidate genes located around the 018S51 locus 
(BCL2, MASPIN and ERK4) to determine if any are/were responsible for the 
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less tumorigenic phenotype of our LN48156- hybrids. As shown in Chapter 
4, it is unlikely that a BCL2 repressor or MASPIN are responsible for our less 
tumorigenic phenotype, based on Western immunoblot assays. However, we 
cannot rule them out yet since these two genes might contain a mutation that 
renders the protein inactive, even if it's still produced. Thus, sequencing 
these two genes is needed before stating that they are not implicated in the 
less tumorigenic phenotype se en in our hybrids. 
We have shown that the mRNA expression level of ERK4 was significantly 
reduced in tumorigenic cells, compared to less tumorigenic cells. Moreover, 
ERK4 overexpressing cells show significantly decreased invasiveness, and 
their colony formation in soft agar was completely abolished. However, 
ERK4 alone was not sufficient to inhibit tumor growth in vivo, as the mice 
injected with ERK4 over expressing cells formed as many tumors as the 
ones injected with mock transfected or parental cells. This could argue that 
ERK4 needs one or more partners to perform its tumor suppressor function 
in the mouse environment. Moreover, based on the reduced invasiveness 
results obtained with ERK4 overexpressing cells (Chapter 4), we could 
hypothesize that ERK4 has a metastatic suppressor effect, rather than a 
tumor suppressor effect. Thus, orthotopic injection of these ERK4 
overexpressing cells in the prostate of nude mice is needed to assess if 
ERK4 can suppress the formation of metastases to Iymph nodes, lungs or 
bones. It is also possible that the inhibitory effects of ERK4 are seen only in 
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vitro and that ERK4 is not implicated in the less tumorigenic phenotype seen 
in our hybrids. 
To assess the TSG/MSG potential of ERK4, we used tranfection (over 
expression). In this system, ERK4 mRNA was overexpressed by more than 
250 fold while the level of ERK4 protein increased at least by 100 fold. This 
most likely does not reflect physiological lever since the ERK4 protein is not 
detectable in non-transfected cells. Thus, it is still possible that-the reduced 
colony formation potential and invasiveness are due to the overexpression 
itself. Then, the in vitro effects of ERK4 would have been over estimated. To 
avoid such unphysiologicallevel, ERK4 could be cloned under the control of 
a weaker promoter like its own promoter (once characterized). In such 
instance, the lever of ERK4 expression should mimic the lever seen in our 
chromosome 18 hybrids, thus representing a betler estimate of what 
happens in the cell physiologically. 
We have sequenced the coding sequence of the ERK4 gene in the 
commonly used prostate cancer cell lines LNCaP, DU 145, and PC-3 and 
found that LNCaP was heterozygous, PC-3 homozygous for a SNP located 
at bp603 of the ERK4 mRNA (r.603G>A) while DU 145 is normal at this 
SNP. This SNP is nonsynonymous since it changes a valine for a methionine 
(p.VaI38Met). We have screened 111 Ashkenazi Jewish controls, and 70 
Ashkenazi Jewish PCa cases for the presence of this SNP (Chapter 4). We 
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found it at the same frequency in controls and PCa cases, suggesting that it 
is not linked to PCa risk. These sam pie sizes provided a 80% power to 
detect significant odds ratios of approximately 2.55 or greater. Thus, if there 
were an obvious effect of this SNP with PCa, we would have detected il. 
However, very large sample sizes of more than 2500 cases, and 2500 
controls would be needed to exclude an effect of 1.5 fold or less. Thus, a 
study with larger sample sizes is needed to know if the presence of this 
V38M SNP is linked to PCa establishment or its progression. 
Our study was done on DNA extracted from patient's blood. Thus, we could 
have found a higher allelic frequency if we had used microdissected prostate 
tumors, and compared it to surrounding normal prostate tissue and blood 
from the same patient. Indeed, if this SNP is linked to PCa in some patients, 
the allelic frequency would be a lot higher in prostate tumors and 
surrounding tissues compared to the same patient's blood. This SNP could 
be the first hit of a two hit phenomenon 265: a certain proportion of the 
population harbours this SNP on one allele, and just needs to modify the 
second allele directly in prostate cells to render these cells malignanl. That 
could expia in why we did not find any link between this SNP in the blood of 
Ashkenazi Jewish cases and controls. 
We also screened an Asian, a European, and an African (Yoruba) population 
to assess the frequency of this SNP. We found the same frequency in the 
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Asian and European populations, as we found in the Ashkenazi Jewish 
group. Interestingly, the frequency of V38M homozygosity was very low 
(4.4%) in the African population compared to 12.9%, 19.6% and 14.4% 
respectively, in the three populations tested (Asian, European, and 
Ashkenazi Jewish). The allelic frequency was also lower in the African 
individuals (15%) compared to 33%, 41% and 40% for the three other 
populations examined. This variation in allelic frequency is probably due to 
the fact that the Yoruba population has a very low genetic diversity and that 
their genetic pool is closed. Thus, this polymorphism is probably recent since 
only the populations with a high genetic pool (Asian, Ashkenazi Jewish and 
European) have a high allelic frequency. 
More impirtantly, this thesis sets the bases for many other studies. Indeed, 
we have transferred chromosome 10, 12, t(17:3, with unknown breakpoints) 
and 18 into PCa celiS and characterized hybrids from each of these 
transfers. We have shown that other chromosomes than 18 encode TSG 
implicated in PCa progression and these could be further studied. We have 
narrowed down the region of chromosome 18 that encodes a TSG for PCa 
to a region of about 10Mb. Many candiate genes in this region could be 
screened for their potential role in PCa. Moreover, we suggest three 
candidate genes that could be implicated in PCa progression: ERK4, 
MASPIN and a BCL2 repressor. Even though the protein levels of BCL2 and 
MASPIN do not vary, they could still be responsible for the less tumorigenic 
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phenotype seen in our LN4B 156-hybrids and should thus be sequenced and 
further ,analysed. We also provide sorne evidence that ERK4 suppresses 
PCa cells invasiveness and colon y formation in vitro and its MSG potential 
should be assessed in vivo by orthotopic injection in nude mice. 
6.2 Future studies 
The exact cellular function of the ERK4 protein is not known, and the role of 
its different domains is not weil understood. Based on its homology to other 
members of the ERK family, it is possible that the kinase domain of ERK4 is 
responsible for its function. Interestingly, ERK3 and ERK4 are the only two 
members of the ERK family to have long C-terminal tails 244. Thus, we are 
generating C-terminal tail truncated, and kinase domain mutated constructs 
that will be transfected in PC-3M-LN4GP2 cells. Then, these stable 
transfectants will be assessed for invasiveness and anchorage-
independence to verify if these ERK4 constructs are still functional and still 
have a tumor suppressor activity. These experiments will allow us to 
understand the importance of the C-terminal tail and the kinase domain of 
ERK4 for its tumor suppressor function. We are also collecting prostate 
cancer tumors, normal tissue surrounding these tumors, as weil as blood 
from the same patient to assess the frequency of the p.val38Met SNP. That 
should tell us if this SNP is linked in any way to PCa. Lastly, nude mice 
orthotopic injection of ERK4 overexpressing cells will reveal if ERK4 is a 
MSG implicated in PCa in vivo. 
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Chromosome 18 Suppresses Tumorigenic Properties 
of Human Prostate Cancer CeUs 
Audrey Gagnon.1 Jean-Sébastien RipeaUt r.2 Valerii Zvieriev. r and Mario Chevrette l .2* 
IDepartmentofMedicine, Division of Experimental Medicine, McGili Universrty. Montreal. Canada 
lDepartment of Surgery. Division of Urology. McGiII University. Montreal. Canada 
Although prostate cancer is still the most diagnosed cancer in men, most genes implicated ln lts progression are yet to be Iden-
tified. Chromosome abnormalities have been detected in human prostate tumors, many of them assodated with prostate can-
cer progression. Indeed, alterations (including deletions or amplifications) of more than 15 human chromosomes have been 
reported in prostate cancer. We hypothesized that transferring normal human chromosomes into human prostate cancer cells 
would Interfere with the!r tumorigenic and/or metastatic properties. We used microcell-mediated chromosome transfer te 
introduce human chromoi>omes 10, 12, 17, and la into highfy tumorigenic (pC-3M-Pro4) and highly metastatic (pC-3M-LN4) 
PC-3-derived cell lines. We tested the in vitro and in vivo prapertie$ of these hybrids. Introducing chromosome 18 into the 
PC-3M-LN4 prostate cancer ceU line greacly reduced lt!> tumorigenic phenotype. We observed retarded growth in soft agar, 
decreased invasÎVeness through Matrigel, and delayed tumor growth into nude mice. bath $ubcutaneously and orthatopically. 
This phenotype is assoclated wlth a marker in the 18q21 reg/on. Comblned with the foss of human chromosome 18 regions 
often seen in patients with advanced prostate cancer, our results show that chromosome 18 encodes one or more tumor-sup-
pressor genes whose inactivation contributes to prostate cancer progression. @ 2005 Wiley-LIss, Inc. 
'INTRODUCTION 
." :jii{@i:i'tiiH:t~UWft:: ,;t: :,;:~ ~:"il}[~4Wf.%j;{ " 
,:yffi"" et al.~''1Jt95), 8p (Bova et a1., 1993; Macoska et al., 
With an estimated 232,090 new cases 
deaths in the United States in 2005, 
cer (PCa) is still the mose diagnosed 
and the second leading cause of theÏc 
(Jemai et al., 2005). However, despit 
ing figures, there is still no treatment 
the most advanced stages of the dise 
cancer has become androgen indep 
thermore, as lt progresses, PCa meti§~~sizes 
bones and lymph oodes, which further co . at 
its treatment (Hanks et a!., 1989). Thus, the!.' 
urgent need for new apies, but are likely 
to require a better 
nisms and genes i 
chis disease. 
Genetic alterarions are a cornmon feature of can-
cer. Indeed, in different tumor types, chromosomal 
rearrangements or 105s of particular regions have 
been reported for almost aIl chromosomes. How-
ever, these modifications are not randomly distrib-
med; specifie regions have been associated with 
certain types of cancer (IVIiteiman et al., 1997). 
Unfortunately, in PCa, such analysis is complicated 
by the heterogeneity of tumor sarnples. Cytoge-
netic analysis of human prostate tu mors revealed 
that alterations of many chromosomes are associ-
ated with PCa (Kawana et al., 2002). Indeed, 
nUmerous studies have shawn delerions of chromo-
some arms 7q (Zenkillzen et al., 1994; Takahashi 
@ 2.005 Wiley-Liss, Ine. 
995; S . . et aL, 1995), lOq (Gray et al., 1995; ht-
ann, 1 d,Komiya et al., 1996), 16q (8ergerheim 
1., 19!J~ ~l:mimi etaI., 1991; Suzuki et al., 1996), 
(G "t,J" 1995; Williams eca!., 1996), and 18q 
t "ri) 1991; Gao et al., 1993; Latil et aL, 
adv~ced PCa. The sensitive comparative 
hYl{'dization rnethod has led to the identi-
on of.î!iélditional genetic alterations in pea, 
including .)/~s of genetic material on human omo-
mosom(Çi!arms 2q, 5q, 6q, 9p, 13q, lSq, and 17p 
,!_>\~isa'~6;pi et aL, 1995; Che.r et aL, 1996). The 10s5 of 
th . ns could indicatç;,~that they encode 
<lli; 'ional evidence to 
~rom the ~ransfer of 
i'iPCa coUlmes. no 
Almost every Imman chromosome has been 
transferred into either rat or human PCa cells for 
assessment of their tumor-suppressive properties. 
Thus, human chromosome aml 8p (Nihei et a1., 
2002) and chromosome 12 (Luu et al., 1998) sup-
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pressed the tumorigenicity of rat PCa ceUs. Simi- band 18q21 encodes the rumor-suppressor genes 
lady, the introduction of human chromosomes 2,7, DCC (deleted in colorectal cancer), SillAD4/DPC4 
8, 10, 11, 12, 13, 16, 17, 19, and 20 in rat Dunning (deleted in pancreatic cancer 4), and SillAD2/DPCZ 
cell lines resulted in reduction or 108s of their (deleted in pancreatic cancer 2). However, these genes 
metastatic properties, sometimes "vithout affecting are not implicared in PCa progression (Yin et aL, 
their tumorigenicity (Mashimo et al., 1998; Gao 2oo!). Moreover, and although studies in PCa patients 
et al., 1999; Ichikawa et a1., 2000; Goodarzi et aL, identified 10ss of two chromosome 18 minimal regionS 
ZOOI; Hosoki et al., 2002). (between marke.rs D1881119 and DI8864, kbp 52940 
Analysis of rat/human hybrids containing human and 55575, and between D18S848 and D18S58, kbp 
chromosome Il has led to the identification of a 40053 and 70193), no tumor-suppressor gene has yet 
new metastasis-suppressor gene caUed CD82 that been mapped to these· intervals (Padalecki et al., 
encodes the KAlI pmtein (Dong et al., 1995). 2000). 
Reduced expression of KAIl is associated with pro- To identify tumor- or metastasis-suppressor genes, 
gression of PCa (Lijovic et al., 2002) and epithelial we used microcell-mediated chromosome transfe! to 
ovariall carcinoma (Liu et al., 2000), as weil as with introduce differellt tagged normal human chromo-
bladder (Su et al., 2004), breast (Yang et al., 2000), somes (10, 12, 17, and 18) into the tumorigenic PC-
gastric (Hinoda et al., 1998), and colorectal (Lom- 3M-Pro4 and metastatic PC-3M-LN4 PCa celilines. 
hardi et al., 1999) cancer. Reduced expression of We shO\~'ed that only the introduction of chromo-
KAIl was al80 detected in meta8tatic forms of sorne 18, not the others, iuto human PCa cells was 
esophageal squamous cells (Uchida et al., 1999) suffic.ient to aftèct both cheir in vitro and in vivo 
and hepatocellular carcinoma (Guo et al., 1998). tumorigenic properties. Indeed, sucb hybrids experi-
The introduction and expression of KAlI iuta mela- enced decreased imrasiyeness, lost thoir anchorage-
noma cells was accompanied by a reduction of independent growth capacity, and harbored a de-
cheir invasive and metastatic properties okâ**,*,wKlà"'yëct;tumor grov:rth afrer both subcutaneous and 
et al., 1(98), further establishing the st~~i~~~,:w;tlïWJïorthot~p1G;)njections into nude mice. 
suppressÎve activity of the KAIl protei 
Ocher genes have also been shown 
rnetastatic properties without affecting 
growth. These genes are CD44 (Hp 
(17pU.2), N.tlfEI (17q21.3), NME2 (12 
(lq32), andBRll1S1 (l1q13.1-Z). Howe 
ofthem (CD8Z, CD44, and l',IAPZK4) a 
sis-suppressor genes in PCa (Kauffman 
Chromosome transfer has a150 been pe 
human PCa cell lines, where introductio 
and PC-3M-LN4 human PCa cell 
et al., 1996) were obtained from 
mosomes 2 (Mashimoto et a!., 2000), 8p (Xu ~"t~!tF.'l!;éÜïdif!iitl'fiîl 
Department of Cancer Biology, the 
Texas M. D. Ande.rsou Cancer Cen-
on, TX). PC-3M-Pro4 cens are highly 
ic, whereas PC-3M-LN4 cells are highly 
2003), 10p ~1urak.am· et al., 
1994), and 19 (Gao 
showcd tmTIOr-SlllDIIlr; 
Cytogenetic, 
studies have shown that the long afm of human 
chromosome 18 (18q) likely carries one or more 
tu mor- or metastasis-suppressor genes that play a 
cole in PCa progression. Indeed, 10ss ofheterozygos-
ity on 18q ,vas reporred in 30%-40% ofPCa patients 
(Kumini et al., 1991). However, introduction of 
human chromosome aem 18q into the DU 145 PCa 
cell line aboHshed its tumorigenicity (padalecki et 
aL, 2001), whereas transfer of an intact chromosome 
18 into the PC-3 PCa cellline interfered\vith both 
the tumorigenic and metastatic properties of these 
cells (Padalecki et aL, 2003). 
Tumor-suppressor genes have been identified on 
the long aml of chromosome 18. Indeed, cytogenetic 
GIlJJI!S, CAro/llos(unes & Cm,eer DOl lO.lOO2/gcc 
to lymph nodes n injected ortho-
de mice. Both cell 
lntû t e 0 
was derived from the PC-3 cell1ine obtained from 
a bone metastasis ûf a patient with PCa (Kaighn 
et aL, 1979). PC-3~'I-LN4 and PC-3M-Pr04 were 
kept .in RPl\H 1640 medium supplemented \vith 
10% fetal bovine serum (FBS; Invitrogen, Buding-
ton, Ontario, Canada). Geneticin-resistant PC-3.M-
Pe04GPl and PC-3tvI-LN4GP2 cell lines were 
generated upon Lipofectamine 2000 (lnviuogen, 
Burlington, Ontario, Canada) transfection of the 
pQBI25 plasmid (Q-BIOgene, Carlsbad, CA). This 
plasmid encodes the green fluorescent protein 
gene and con tains the neomycin phosphotransfer-
ase gene, which confers resistance to geneticin. 
These ceUs were kept in RPMI 1640 with 10% 
Tl 
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FBS and 400 Ilg/ml of geneticin (Invitrogen, Bur-
lington, Ontario, Canada). B'78MC9., B78MCS·7, 
B78MC75, B78MC77, and B78MC156 arc micro-
ceU hybrids from our mouse!human hybrid panel 
(Speevak ct al., 1995) and contain a tagged human 
chromosome (chromosome 12, chromosome 3 trans-
located with chromosome 17 with unknown break-
points, chromosome lOp, chromosome 10, and chro-
mosome 18, respectively) in the B78 mause mela-
noma background. B78MC hybrids were kept in 
DMEM (Dulbecca's madified Eagle medium; Invi-
trogen, Burlington, Ontario, Canada) supplemented 
with 10% FBS and hygramycin B at a concentration 
of 400 Ilg/ml (Roche Diagnostics, Laval Quebec, 
Canada). PC-3M-Pr04- and PC-3M-LN4-derived 
microcell hybrids (such as Pr04B156 and LN4B77 
hybrids; see beIow) were grown in RPMI 1640 with 
10% FBS, 400 llg/m1 of geneticin, and 400 Ilg/ml of 
hygromycin B. 
quadruplicate (n = 8), and the results were ex-
pressed as the percentage of the invasion obtained 
with the parental ceilline. 
Soft-Agar Assay 
The soft-agar assays \Vere performed as de-
scribed previously (Rizzino, 1987). Briefty, 1 ml of 
0.5% agar (Fisher Scientific, Nepean, Ontario, 
Canada) diluted in appropriate media was poured 
into six-weU plates ta form the basal layer. Then 
3,000 cells were rnixed with 0.5% agar and poured 
on top of the basal layer. Plates were incubated at 
37"C for 21 days. Gm\ving cell foei were stained ,vith 
200 J.l1 of a 0.03% crystal yiolet (Sigma, Oakville, 
Ontario, Canada) solution in 100% methanol (Fisher 
Scientific, Nepean, Ontario, Canada). Qualitative 
assessment of growth was performed, in which the 
colony formation of hybrids was compared to rhat of 
the parental cell lines, which were arbitrarily as-
Microcell-Mediated Chromosome Transfer signed the symbol +++. For quantitative evalua-
tion, plates were scanned on a PowerLook 2100XL 
l\.Hcrocel1 fusion was done as described (Four- scanner (lTh1AX. Dallas, TX). The number of colo-
nier, 1981). B78MC hybrids containing different· d th d ;)ki~was counte on e computer screen an con-
tagged chromosomes (10, lOp, 12, transloc~t~dit:S"1i1' ve~'th.to a percentage of colonies obtained with the 
and 17, and 18) were micronucleated in th6
P
pre arentai'b(;J,lline. Eachsoft-agarassaywasperformed 
ence of Colcemid (0.06 ~tg/ml; Sigm "'Oakvi six wells per cellline (n = 18). 
Ontario, Canada) for 24 hr. The res 
ecUs were fused to either PC-3M 
PC-3M-LN4GP2 cells in the pres 
(w/w) polyethylene glycol 1600 (Fis 'njections were done according to 
Nepean, Ontario, Canada) for 60 cil for Animal Care guidelines, after 
were rinsed three cimes ,vith seru e lVlcGiIJ University Animal Care 
1640, and complete medium (RPMI 1 ale nude mice (ml/11ft; 6-8 weeks of 
FBS) was added to the flask and incu 0 age; Cha River Laboratory, St-Constant, Que-
night .. The rcsulting microcell hybrids ( ',q:!" ... b~e, ) were injected with PCa ce Ils. One 
and LN4B ... ; 'Thble 1) were selected in RPMti((j4'fYi&jïg~W~ ls in 200 ~tI ofHanks balanced saline solu-
medium eontaining + 80 1 hygrom- tlO ; Invitrogen, Burli , Ontario, Canada) 
yein B + 800 Ilg/ml ;l'~. w he upper backs of 
; .. nu when tumo.rs re-
Invasion Assay ~.' ae thotopic injections, 
We used a Bayden chamber as say (Albi ni et al., 1 million ceUs were resuspended in 16.6 J.tI of HBSS 
1987) to assess invasive potentia!. Briefly, 25,000 and injeeted with a push-button-controlled dispens-
cells were added to a chamber coated with Matri- ing device (Hamilton Syringe Company; Reno, NY) 
gel (Fisher Scientific, Nepean, Ontario, Canada), into the dorsal lobe of the prosr:ate. The mice were 
and RPl'vU 1640 medium supplemented \vith 5% sacrificed when they bccame moribund .. 
FBS \Vas added to the bottom ehamber to. serve as 
a chemoattractant. The chambers were incubated 
at 37"C for 22 he, and fiIters were stained witha 
Diff-Quick staining kit (Dade Behring, Newark, 
DE). Filte.rs were then put ooto microscope slides 
(Fisher Scientific, Nepean, Ontario., Canada), and 
invasive ceUs from five random fields were counted 
under a contrast phase microscope at 200X. Ali 
invasion expe.riments were performed t\vice in 
Tumol'$ in Culture 
Tumors were excised and digested two times for 
15 min at 37°C with 350 Ulml of type 1 eollagenase 
(Invitrogen, Burlington, Ontario, Canada), and cell 
suspensions \Vere seeded into culture ftasks contain-
iog RPMI 1640 supplemented with 10% FBS and 
1% penicillin (5,000 IU/ml)/streptomycin (5,000 J.tg/ml) 
(Invitrogen, Burlington, Ontario, Canada). Two days 
GemiS, ChrollltlSlJmes & Cllfll:er DOlto. lOO:!:/gcc 
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TABLE 1. Phenotypic Changes Associated Human Chromosome Transfer in PC-3M-Pro4GPI and PC-3M-LN4GP2 Prostate Cancer Cell Lines 
Mouse/human parental 
hybrid (transferred 
chromosome) 
B78MC75 (chr 10p) 
B78MC77 (chr 10) 
B78MC9 (chr 12) 
B78MCS7 [chr t(3; 17)] 
B78MCI56 (chr 18) 
B78MC77 (chr 10) 
B78MC9 (chr 12) 
B78MC57 (chr t(3; 17» 
B78MCI56 (chr 18) 
Invasion assay 
(Parental = 100%) 
nIa 
nIa 
Pro4B9-4: 88% (P = 
Pro4B9-8: 217% (P 
Pro4B9-17: 568% (P 
Pro4B9-41: 107% (P 
nIa 
LN4B77-9: 35% (P = 0007) 
LN4B77-50: 73% (P 
LN4B77-60: 63% (P 
LN4B77-80: 22% (P 
LN4B9-34: 2% (P = 
LN4B9-35: 10% (P = 
LN4B57-4: 250% (P 
LN4B57-5: 142% (P 
LN4B57-6: 26S% (P 
LN4B57-7: 281 % 9P = 
LN4B 156-1: 58% (P = 0.98) 
LN4BI56-2: 75% (P = 0.16) 
LN4B 156-6: 42% (P = 0.0002) 
LN4B 156-14: 19% (P = 0.0000009) 
Properties of hybrids 
Soft-agar assay 
(Parental = +++ or 100%) 
Pr04B75-2 ++ 
Pro4B75-3 ++ 1/2 
Pro4B7S-11 +++ 
Pro4B75-12 + 
Pro4B75-14 + 
Pro4B77-2: + 1/2 
Pro4B77-10: + 1/2 
Pro4B77-IS: + 
Pro4B9-11: +++ 
Pro4B9-17: ++ 
Pro4B9-18: ++ 
Pro4B9-21: ++ 1/2 
LN4B9-34: +1/2 
LN4B9-35: ++ 
LN4B9-36: +++ 
LN4B57-4: ++ 
LN4B57-5: +1/2 
LN4B57-6: ++ 
LN4B57-7: ++ 
LN4B IS6-1: ++++. 289% (P = O.OOS) 
LN4BI56-2: +++.91% (P = 0.45) 
LN4B 156-3: ++++. 227% (P = 0.0003) 
LN4BI56-14: ++++. 396% (P = 0.00000001) 
LN4B 156-6: +. 4%(P = 0.00001) 
LN4B 156-13:+. 23% (P = 0.00002) 
LN4B 156-16: ++. 58% (P = 0.0002) 
LN4B 156-20: ++. 58% (P = 0.0006) 
'In subcutaneous injections. PC-3M-Pro4GP 1 formed tumors in 9 of 10 micel and PC-3M-LN4GP2 formed tumors in 2 of 5 mice. 
Tumor formation" 
(subcutaneous) 
Pro4B75-12: 3/10 (P = 0.002) 
nIa 
nIa 
Pro4B 156-1 0: 3/5 (P = 0.07) 
LN4B77-44: 2/5 (P = 0.54) 
nia 
LN4B57-5: 2/10 (P = 0.04) 
LN4B 156-2: 5/5 (P = 0.08) 
LN4B 156-6: 2/1 0 (P = 0.05) 
"In orthotopic inje.ctions into the prostate. PC-3M-Pro4GP 1 formed tumors ln 3 of 3 mice. and PC-3M-LN4GP2 formed tumors in 9 of 13 mice. 
Turnor forrnationb 
(orthotopic) 
Pro4B75-12: 2/5 (P == 0.14) 
nia 
nia 
nIa 
nia 
nia 
nIa 
LN4B 156-6: 2/3 (P = 0.03) 
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TABlE 2. Genotyping of Chromosome f8 in Parental Celfs and LN4BIS6 Hybrids and Tu mors 
Position TLN 1 56-6·3 
Marker Cytoband (kbp) B78 B78MCI56 PC3MLN4GP2 LN4B156.2 TLN 1 56.2·2 LN4B 1 56.6 and TLN 1 56-6-6 
018559 18pl!.3 634 0 2 
018S63 18pll.3 3426 0 2.3 
0/85976 18pll.2 5238 0 2,3 
Of8S42 IBpll.2 5991 0 2 
0185843 18pll.1 8603 0 2,3,4 
018S542 18pll.! 11550 0 2.3 
018544 18'1 11 .1 19875 0 2 
0/8S877 18'11 LI 26613 0 2,3 
0/85847 18'1 11 .2 27591 0 2,3 
0/8S/133 18'1 12 31986 0 2 
0/8567 18'1 12 l58S5 0 2 
01851/57 18ql2 37751 0 2,3.4,5 
0/85535 18'1 12 38036 0 2 
0/8S65 ISql2 40425 0 2,3 
0/8S1f45 18'1 12 40435 0 2 
0/8S46 ISq21 48376 0 2,3 
0/85487 18'121 51673 0 1.2 
018SII09 ISq21 57430 0 2, 3,4 
0/8S39 18q21 54001 0 1,2 
018SIf55 18q21 56848 0 2.3 
01855/ 18'121 60734 0 2.3 
DI8S1270 18q21 61178 0 2,3 
0/85382 18'122 63354 0 2,3 
018S541 ISq22 69959 0 
018558 18'123 72125 0 
0/8550 18'123 75252 0 
0/8S1141 ISq23 76658 0 
l '" For-each rmrker. Allele ln the mouselhuman hy 
PC.3M.LN4GP2; 0 = absence of this marker. 
1,2 1,2 1,2 1,2 
2,3 2,3 2,3 2.3 
1,2,3 1,2,3 1,2,3 1,2,3 
1,2 1,2 1.2 1.2 
2, 3,4- 2, 3, 4 2,3,4 2,3,4-
1,2,3 1,2,3 1.2,3 1,2,3 
1,2 1,2 1,2 1,2 
J, 2, 3 1,2,3 1,2,3 1,2,3 
1,2,3 1,2,3 1,2,3 1,2,3 
1,2 1,2 1,2 1,2 
1,2 1,2 1,2 1.2 
2 .• 3 .• 4.5 2, 3. 4,5 2.3.4,5 2.3,4.5 
1,2 
1.2,3 
1.2 
1.2.3 
1,2 
2, 3.4-
1,2 
1.2.3 
1,2,3 
1.2,3 
2,3 
2 
1,2 1,2 1.2 
1.2,3 1,2,3 1.2.3 
1,2 1,2 1,2 
1.2,3 1.2,3 1.2,3 
1,2 1,2 1,2 
2, 3, 4 2,3,4 2.3,4 
1,2 1,2 1,2 
1,2,3 1,2,3 1.2.3 
1,2,3 1,1A,2,3 1,2,3 
1.2.3 1.2,3 1.2,3 
2,3 2,3 2.3 
1,2 1.2 1,2 
1,2 1,2 1,2 
1,2 1,2 1.2 
1 1 1 
le alleles derlved from the prostate cancer cell Une 
described previously (Bérubé et al., 
cterize LN4B156 hybrids further, we 
man chromosome 18 microsatellite 
ble 2). The polymorphie markeTS (heter-
> 0.8) used were: DI8S59, D18S63, 
D18S42, D18S843, D18S542, D18S44, Genotyping ofHybrid$ 
Th identify B78. 
selected tagged hu r .. ".;,Dl 18867. D. 1881157, , ... Dl D18S46, D188487, ':. Dl, 18851, D18S1270, 
PCR by using polymorp. lC rosate. s. 
We used DJOS196, DI0SJ692, and DI0S169 for c1lfo-
mOSOHle 10; Di2S43, D12S90, D128325, and D128368 
for chromosome 12; DI7S1850, D17S1853, and 
D17S1154 for chromosome 17; aswell as D18S66, 
D18S1148, and D18S554 for chromosQme 18. Sub-
sequent analysis by fluorescent in situ hybridiza-
tion (FISH) of B78MC57 revealed that this hybrid 
contains a translocation between chromosomes 3 
and 17; however, the breakpoints were not deter-
mined. We thus selected five hybrids chat contained 
human cllfomasomes 10, 10p, 12, translocated 3;17, 
and 18 (B78MC77, B78MC75, B78MC9, B78MCS7, 
and B78MC156, respectively). The presence of 
the desired chromosome "'ilS a1so confirmed by Alu-
D18S382, D18S541, D18S58, D18S50, and D18S1141 
6:vww.invitrogen.com). MarkeTS D18S847, D18S39, 
D18S58, D18S50, and D18S1141 were noninforma-
tive, whereas markets D18S63, D18S843, D18S1157, 
D18S1109, and D18S382 were not transferred. 
RESULTS 
Introduction ofHuman Chromosome 18 into 
PC~3M~LN4GP2 Cells Interferes with Their 
, ln Vitro Tumorigenic Properties 
From our mouse/human microcell hybrid panel 
(Speevak et aL, 1995), we have identified B78MC 
hybrids (Table 1) containing tagged human cllfO-
mosomes (hat have been implicated in PCa pro-
G(mes:, ChromOS:Ollles: & CancM' DOl IO.I002{gcc 
T2 
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gression (chromosomes 10, 12, 17, and 18). These did the parental ceUs (P < 0.001; Table 1). Al-
tagged chromosomes were transfer.red into highly though clonaI variation is often seen in soft-agar 
tumorigenic PC-3M-Pr04GP1 and highly meta- assays, these highly significant results contrast with 
static PC-3M-LN4GP2 cell Hnes to generate the the anchorage-independent growth obtained with 
Pr04B- and LN4B-derived hybrids (Table O. We another geneticin-resistant PC-3M-LN4 clone, 
compared the anchorage dependence and invasive- PC-31tf-LN4GPl, which formed 74% as many 
ness of our hybrids ta their parental human PCa colonies as did PC-3lvl-LN4GP2. Thus, the intro-
ceUs by usinggrm>Vth in soft agar and a Boyden duction of human chromosome 18 into PC-3M-
chamber assay. LN4GP2 cens suppresses the ability of sorne 
Although transfer of the translocated chromosome LN4B 156 hybrids to invade through Matrigel and 
(3;17) into PC-3M-LN4GP2cells could significantly to form anchorage-independent colonies. Although 
decrease lts tumorigenic potential (see tumor forma- LN4B156-14 ceUs were not able ta invade through 
tion of LN4B57-5 in Table 1), this translocated Matrigel, they formed four times as many colonies 
chromosome did not significandy reduce the in vitro in soft aga.r as did the parental PC-3M-LN4GP2 
tumorigenic properties of the two parental cell Iines cens (P < 0.00001; Table O. Such important clonai 
(see invasion and soft-agar assays for Pro4B57 and variation is sîmilar to what was observed in cluo-
LN4B57 hybrids; Table 1). Similarly, the in vitro mosome 18 hybrids generated by Padalecki et al. 
and .in vivo properties of the PC-3M-Pro4GP1 ceUs (2003) and could indicate that the integrity of the 
were not affected when chromosome 8 was trans- transferred chromosome 18 was not the same in aU 
ferred into them (data not shown), confirming that hybrids, a characteristic often seen in microcell 
chromosome transfer per se. is 110t sufficient to in'" hybrids. Moreover, the properties of the LN4B156-
hibit the malignant properties of these cells. 14 hybrid could argue that invasiveness and anchor-
In contrast, the introduction of human chromo- age-independent growt:h are controlled by different 
some 10 or chromosome 18 into PC-3M eP'1;'!<Wiffll'lènes'kpnchromosome 18. 
ceUs .was accompanied by reduction 
tumorigenic properties of sorne 
compared to their respective pa 
Pr04B77-15 and LN4B7'7-44 hybrids 
tluee times fewer colonies in soft 
. LN4B77-9 and LN4B77-80 were 
invasivethan PC-3M-LN4GP2 (P < 
SimiIarly, LN4B156-6 and LN4Bl 
showcd significantly decreased in"·"~i,.r"'n,,,,,., 
pared to PC-3.M-LN4GP2 cells (P = O. 
0.0001, respecrively; Table 1). However, 
crease in invasiveness \Vas not seen in other 
or LN~B156 hybrids as LN4B~, ~: LN4B77-
60, LN4B156-1, an ! . 
over, wc noticed ri, 
cells couId not be di ute mor t an'm:. n co 
son, parental PC-3M-LN4GP2 celIs could easily sus-
tain a 1:15 dilution. Furthermo.re, LN4B156-6 ceUs 
could not surVive in medium containing less than 
10% FBS, whereas parental PC-3M-LN4GP2 ceUs 
and LN4B 156-2 hybrid ceUs could easily grow in 
medium supplemented with only 1 % FBS. This fur-
cher suggestèd that the introduction of human chro-
mosome 18 into PC-3M·LN4GP2 celIs couId inter-
fere with their growth properties. 
We then quantitative!y measured the ability of 
eight LN4B156 hybrids (LN4B156-1, -2, -3, -6, -13, 
-14, -16, and -ZO) to grow in an anchorage-inde-
pendent manner. Four hybrids (LN4B156-6, -13, -16, 
and -20) fo.rmed statistically fcwer colonies than 
m<;lruuu",.~ .. !. ofHuman Chromosome 18 into 
r"'-~1"1-L."""''''''·'' Cells Interferes with Their 
vivo. tumorigenic properties of our 
ceUs from the selected hybrids 
PC-3M-Pro4GPl and PC-3M-
were injected subcutaneously into 
tested LN4B77-44 and Pro4B75-12 
contained an introduced chromosome 
fragment, respectively. A statistically sig-
ifference in tumor fomlatÏon ,vas ob-
th the Pr04B75-1 Tybrid .(P = 0.002; 
d opposite pheno-
gar assays, wc also. 
injected • i4B 156-6 hybrids. 
Indeed, LN4B156-2 hybrid ceUs were 75% as inva-
sive as the parental cell line and formed as many 
colonies (91%) in soft agar (Table 1). In contrast, 
LN4B156-6 cens were 42% as invasive as PC-3M-
LN4GP2 cells and formed 25 rimes fewer colonies 
(3.8%; Table 1). The few tumors (2 of 10) obtained 
on injection of LN4B 156-6 ceUs grew much more 
slowly than those obtained by either PC-3M-
LN4GPZ or LN4B156-2 celIs (Fig. lA). lndeed, Ft 
mice injected \Vith PC-3M-LN4GPZ or LN4B156-
2 ceUs becamè mo.ribund much earlier (an average 
of 31 and 50 days earlier, respectively) than did 
micc injected with LN4B156-6 ceUs (Fig. 1C, P = 
0.05). 
l 
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A 600..,-----__________ _ B 
- ~ ~O E 500 +-----~~-----~------~~-
P=O.08 
g 
o 7 11 20 29 36 43 60 
Days post-subcutaneous injection 
C P=O.05 
LN4B156-6 
PC-3M-LN4GP2 
o 25 60 15 100 125 160 17$ zOo 
Days post-subcutaneous injection 
. li 
Figure 1. Subcutaneous and orthotapic injections Hf'p 
cells inta nude mice. (A) Graphic representation of su1!"çu 
growth following injections of 1 X 10· PC-3M-LNip 
and LN46 156-6 cells (tumor growth was measured ti7 (6) Kaplan-Meier curves comparing survival rate (.il til 
moribund) of mice upon subcutaneous injection of P ,',M 
Furthermore, there was no statlstlca 
cant difference in tumor growth between 
cells and the LN4B156-2 (Fig. lB; P = 0.0 
LN4B77-44 hybrid 
chromosome 10 (P 
ence in tumor for 
LN4B156-6 cells were InJec e Hect y Into t·· e 
dorsal lobe of the prostate of nu de mice. Indeed, 
there was a significant difference between 
LN4B156-6 and PC-3M-LN4GP2 cells in delay 
(Fig. 10; P = 0.03) in orthotopic tumor growth. 
Taken together, these experiments demonstrate 
that the chromosome 18 introduced into the 
LN4B156-6 cells was responsible for the suppres-
sion of their tumorigenic phenotype. However, 
once orthotopic tumor growth was established, 
both hybrid and parental cells formed regional 
lymph node metastases. Thus, even if LN4B156-6 
cells showed delayed tumor growth, they still 
escaped the primary tumor mass to form metasta-
ses in retroperitoneallymph nodes. 
77 
D 
C-3M-LN4GP2 
LN4B156-2 
10 20 30 40 50 60 70 80 90 
Days post-subcutaneous injection 
P=O.03 
LN4B156-6 
o D 50 15 100 1D 150 115 
Days post-orthotopic injection 
(q Kaplan-Meier curves comparing survival rate 
oribund) of mice upon subcutaneous injection of 
) Kaplan-Meier curve comparin~ survival rate of 
ic prostatic injections of 1 X 10 PC-3M-LN4GP2 
. Mice were sacrificed as they became moribund. 
ficing the mice, we excised and cul-
umors from both subcutaneous and ortho-
PAf~I5:'-;"roups. Ali cultured tumor cells were still 
. th~. green fluores~9I! protein ~ene (data ) l'.' G allolymorphlC markers 
rio tre 18 (TLN156 hy-
bri s; a le ':b. co r t at tumors were derived 
from the injected hybrid cells. 
Region of Human Chromosome 18 15 Associated 
with Reduced Tumorigenicity of LN4B 1 56-6 cells 
FISH with a chromosome l~specific painting 
probe did not reveaI any major differences in the 
chromosome 18 introduced in LN4B156 hybrids 
(dara not shown). We complemented this analysis 
by genotyping the hybrids using 27 polymorphie 
markers (Fig. 2 and Table 2). To identify which F2 
allele was present in the parental celllines, we tested 
each marker with DNA from the B78MC156 mouse/ 
human hybrid and from the PC-3M-LN4GP2 
Glfoes, Chromosomes & Coocer DOl IO.l002/gcc 
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D1851133 at 18q12 
rlgUre 2. Genotype of 01851/33 and 01855/ markers in prostate 
cancer cells and hybrids. The left panel shows a representative autora-
diogram of PCP. analysis of microsaœllite polymorphie marker 
018SI/33 for DNA extracted From cell cultures of mouse/human 
hybrld B78MC156 (a1lele 1), human prostate cancer cell Une PC-3M-
lN4GP2 (anele 2). and microcell hybrlds lN4B 156-2 and LN4B 1 56-6 
and Ii'om tumor derived From nude-mouse injection of mese two 
mlcrocell hybrids Qndicated by TLN 1 56-2-2 and TlN 156-6-3). The 
right panel shows a representative autoramogram of PCP. analysis of 
mlcrosateflite polymorphie marker 0/855 / for DNA extracted From 
human prostate cancer cell Hne. Five markers 
(D18S487, D18S39, D18S58, D18S50, and 
"l 
co 
Il) 
..... 
al 
Z 
....1 
CI) '<t co 0 ~ CI) ~ ~ ~ .... .- ~ ~ • cb ~ co ID co Il) Il) Il) Il) Il) (0 .... .... .... .... ..... .... Il) CC CC CC CC al al 2 .... "Of" 
"'" "'" 
.., z "'" z Z Z Z Z Z ..J ..J 
....1 ....1 ....1 ....1 ....1 ....1 ... ... 
~ ~ 
D18551 at 18q21 
cell cultures of mOllSe/human hybrid B78MC 156 (alleles 1 and 2). 
human prostate cancer cell line PC-3M-LN4GP2 (alleles 2 and 3), and 
microcell hybrlds LN4B 156-1, -2. -3. -S, -6, -13, -14, -16, and -20 and 
from tumor derived From nude-mouse injection [both subcutaneous 
(TlN) and orthotoplc (OLN)] of LN4BI56-2 and lN4BIS6-6 microcell 
hybrids (TlN156-2-2. TLNIS6-6.3, TLNI56-6-6, OLNIS6-6-I, and 
OLN 1 56-6-5). For eath marker. peR amplification ms performed 
three limes. An asœrisk identifJeS hybrlds and tumorsthat contain the 
lA allele that is linked ta the tumor-suppressor locus. 
revealed chat this 0011 !ine contains two D18S51 
alleles. 
D18S1141; Table 2) could not distinguish theMiiiifi!fiiJlll'l%J\l"JW&\0',k'", 
DISCUSSION leles in B78MCl56 from those in PC-3l\'[-
eeUs, whereas five markets (D18S63,1 
D18S1157, D18S1109, and D18S382; Tlble 2 
not transferred inta PC-3M-LN4GP2 blb' 
We then tested ail 27 polymorphit', 
LN4B156 hybrids to determine whiJl\ 
chromosome 18 had been ~an~ferre4 
Table 2 (see alsoD18S1133 lU Fig. 2),' st mar 
l1ad been transferred into bath LN 56-2 an 
LN4B 156-6 hybrids. However, an addi le 
of D18S51 was present in the LN4B156 
(dlele lA; Fig. 2 and Table 2). This additiona 
was a1so present in 56-13 anocher 
hybrid chat 
(Table 1).lnterestin~ 
one of che 1:\'\"0 tumors 
from subcutaneous injections (TLNI56-6-3; Fig. 2) 
and in one of the two tumors occurring afeer ortho-
topic injections of LN4B156-6 cells (OLN156-6-5; 
Fig. 2). AUde lA ,"vas ruso seen faindy in B78MC156 
DNA, whieh could indicate chat a subpopulation of 
these cells contained either allele lA only or both 1 
and lA aBoies. Indeed, FISH experiments with a 
human chromasome 18-specmc painting probe 
showed chat a small portion of chromosome 18 was 
present in 23% of the B78?vIC156 ooll spreads exam-
Încd. This result could explain why che àllele lA 
band was hardly detecrable in B78MC156 cells. 
Moreover, direct sequencing of the D18S51 amplifi-
cation products obtained from B78MC156 DNA 
GGlUS, Chrol/lD.fttmes &CatlœrDOI 10.1002/gcc 
of chromosame 18 regions have been 
1 many cancers, including colorectal 
1., 2002), pancreatic (Lefter et al., 
(Lassus et al., 2001), head and neck 
carCÎnoma (Blons et al., 2002), lung 
al., 2001), and prostate carcinoma 
999; Padalecki et al., 2000; Padalecki 
et a, 2001; et al., ZOOl; Chu et al., 2003). Func-
e~ ence of tumor-supp.ressor genes on 
'hromosome 18 was demonstrated when 
ion of this chromosome into pancreatic 
Is resulted in suppr . on of their tumori-
1., 2002). Similar 
Ilines DU 145 and 
a a ec. 1 e 03). As compared to 
DU 145 ceUs, PC-3 and its derivatives likely repre-
sent a more appropriate model for study of prostate 
cancer. Indeed, PC-3 ceUs ,"vere derived from bone 
metastasis, a common [cature seen in patients at an 
advanced stage of the disease. In contrast, the DU 
145 ceU line W'aS derived from a brain metastasis, 
which rarely occurs in patients. Although PC-3 
ceUs [onn metastases upon injection into the 1eft 
cardiac ventricle (Padalecki et aL, 2003), che use of 
a more aggressive PC-3-derived cell line (PC-3M-
LN4) allows the study of metastatic cancer pro-
gression as it appears in human patients. Indeed, 
PC-3M-LN4 cells formed lymph node metastases 
upon orthotopic injection into the prostates of 
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nude mice (Pettaway et aI., 1996). Thus, injecting The characterization ofLN4B156 hybrids (Table 1 
cancer and hybrid ceIls orthotopically more appro~ and Fig. 1) revealed that sorne hybrids had re-
priatdy mimics clIe conditions in PCa patients and duced tumorigenicity in vitro and in vivo (see, for 
furcher confirms that chromosome 18 is implicated example, LN4B156-6 and LN4B.156-13), whereas 
in PCa progression. othees (like LN4B156-1 and LN4B156-2) were 
The introduction of human chromosome 18 into at leasc as tumorigenie as the parental PC-3.M-
the metastatic PC-3M-LN4GP2 œIl Hne had a con- LN4GP2 ceUs. Such differences eould he a result 
siderable effect on its tumorigenic properties. Both of hybrids like LN4B156-2 ha,,·ing an introduced 
LN4B156-6 and LN4B156-14 hybrids had reduœd chromosome 18 whose suppressor gene is already 
capacity ID invade througb Matrigel, ,vhereas L.'\l4Bl56.6, inactivated or deleted. A1though FISH analysis did 
LN4B156-13, LN4B156-16, and LN4B156-20 hybrids not show any chromosomal differences between 
had reduced ability to grow in an anchorage-inde- LN4B156-2 and LN4B156-6 hyb.rid ceUs (data not 
pendent manner, a fcature also observed by Pada- shown), genotype analysis of these hybrids pointed 
lecki et aL (2003) in their PC-3-derived hybrids. ta the 18q21 region. Indeed, when compared ta 
Furthennoee, the LN4B156-6 hybrid also showed tumorigenic hybrids, many hybrids having a re-
significantly deIayed tumor growth upon subcutane~ duced tumorigenic phenotype (either in vitro. or 
ous (P= 0.05) and orthotopic (P = 0.03) injections in vivo) carried an extra D18S51 allcle (allele lA). 
into nude mico. Howeve.r, in the prostate environ- That this alle1e is often lost in cancer ceUs de.rived 
ment, LN4B156-6 cells did fonn proportionally from LN4B156-6 subcutaneoliS or orthotopic in-
nl0re tumors (2 of 4 mice; 50%) than when injected jections further validates the impo.rtance of chis 
subcutaneously (2 of 10 mice; 20%). Such results region in PCa. 
could indicace that the natural prostatic environ- Chrûmûsome band 18q21 encodes few idemified 
ment is a more appropriate site than under the tllmor-suppressor genes. Among those identified, 
derma (subcutaneous) for the estabIishment,,,4tlÏd);!'lt' "t1:~fd,f,1'(.; gene has been associated with colorectal 
growth of turnorigenic ceUs. Moreover, 0,0'~ ession, whereas the SjJfAD2 and 
lished in the prostate, aU tumoes were able sare inactivated in pancreatic cancer. 
metastasize to Iymph nodes. Upon or ause these genes are rarely mutated 
tion, allmice became moribund beca rûgan et al, 1997; Ueda et aL, 1997; 
and had to bé sacrificed. As seen in Fi ; Yin et al., 2001), the involvement 
aIl mice orthotûpically injected with enes in this disease is probably lim-
3M-LN4GP2 celIs became moribund Iy, a preliminary analysis using clIe 
75 days, whereas it took up to 13 ray, which contains 19,200 human 
LN4B156-6 orthotopic injections for mi genes .microarrays.ca/products/types.html}, 
moribund. did not.", 'eal any variation between PC-3.M-
Thus, our results confirm and complem LN4GR4!"'cells and LN4B156-6 cells in the exp res-
of Padalecki et al. (2003) and, in addition, T;;;S'i\:l:lfI'~r the ,siJtAD4 gene (data not shown). This 
sorne 18 Imetasca- fu ests that Sl1fAD4fJj not implicated in 
sis~suppressor genes 
pressar genes are 
the cime it takes the tu mors orm man anl 
Within the framework of this hypothesis, it is 
worth noting that LN4B156-6-tumor-derived cells 
(TLN156-6-3) displayed a significancly increased 
capability to fOIDl colonies in sûft aga.r (409%; P = 
1 X 10-7) compared to that of PC-3M-LN4GP2 
(data not shown). As reported for nonpapillary 
renal eeU carcinoma, such inactivation could result 
from chromosomal rearrangement (Yang et aL, 
2001). In renal œIl carcinoma-derived microcell 
hybdds, sueh rear.rangements often not only occur 
in the introduced chromosome but also affect 
endogenous homologous chromosomes and other 
polysomic chromosomes (Kost-Alimova et al., 
2004). 
r'. ".' the . . otype observed in . the at a not-yet-identi-
. fie suppressor g éln the 18q21 region. 
Moreover, these three genes are more than 10 
megabases (Mb) (DCC, 49 .Mb; SM.4.D2, 43.5 Mb; 
and SilfAD4, 47 :Mb away) from the D18S51 locus, 
59 Mb (wW\v.ncbLnlm.nih.gûv/mapview/maps.cgi? 
taxid=9606&chr=18). Thus, it is very unlikely that 
these genes are implicated in the less tumûrigeruc 
phenotype of our LN4B156-6 hybrid. 
Whatever lts inactivation mechanism, the chro-
mosome 18-encoded suppressor gene is likely to 
be implicated (directly or indirectly) in cell-cell 
adhesion or cell-matrix interaction because some 
of our LN4B156 hybcids had a deceeased ability co 
grow in an anchorage-independent manner and to 
invade thraugh Matrigel. Inactivation of the sup-
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pressor gene is unlikely to occur over 22 hr 
required ta perforro the invasion assay or even dur-
ingthe 21 days ta perform the soft-agar assay. Such 
suppressive in vltm properties are siroilae ta those 
reported for the CD82 metastasis-suppressor gene 
(Kauffroan et al., 2003) in both prostate and breast 
cancer cells. However, the suppressor gene in the 
LN4B156-6 hybrid was unable ta inhibit lymph 
node metastasis formation once tumors had devel-
oped after orthotopic injections in the pmstate. 
Nevertheless, at this point, we cannot mie out Chat 
this suppressor gene could also affect roetastatic 
development because the suppressor gene is Iikely 
to be inactivated by the time the ceUs form tumoes 
in mice. Such inactivation could also interfere with 
hs putative metastasis-suppressing properties. 
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